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to report the conventional trial findings. Baseline 
characteristics of the sample from data gathered 
from both  postal self-completion questionnaires 
and face-to-face interviews suggest that our sample 
experienced very few symptoms of constipation 
(PAC-SYM) and that the condition itself did not 
have a major impact upon their quality of life (PAC-
QOL). The low level of symptoms of constipation is 
most likely explained by 90% of the sample using a 
laxative in the previous week. Most participants in 
our sample were satisfied with the performance of 
their laxatives, and levels of anxiety and depression 
were low. Their fibre consumption was classified as 
‘moderate’ but their average water consumption fell 
below the recommended guidelines. Daily diaries, 
completed each day for a period of 6 months, were 
analysed primarily in terms of overall response 
rate and item response rates, and the participants 
accepted this method of data collection. For the 
economic evaluation, all of the trial arms experienced 
a reduction in utility, as measured by EQ-5D. There 
was no statistical evidence to suggest that either the 
personalised intervention arm or the standardised 
intervention arm was associated with significant 
changes in utility at 3 months compared with the 
control arm. Data on related health-care costs show 
a cost saving of £13.34 for those in the personalised 
arm, compared with the control arm, and a smaller 
cost saving for the standardised arm. These savings 
Objectives: To investigate the clinical effectiveness 
and cost-effectiveness of laxatives versus dietary and 
lifestyle advice, and standardised versus personalised 
dietary and lifestyle advice.
Design: A prospective, pragmatic, three-armed 
cluster randomised trial with an economic evaluation.
Setting: General practices in England and Scotland, 
UK.
Participants: People aged ≥ 55 years with chronic 
constipation, living in private households. Participants 
were identified as those who had been prescribed 
laxatives three or more times in the previous 
12 months, or with a recorded diagnosis of chronic 
functional constipation.
Interventions: Prescription of laxatives, with class 
of laxative and dose at the discretion of the GP and 
patient (standard care control arm); standardised, 
non-personalised dietary and lifestyle advice; and, 
personalised dietary and lifestyle advice, with 
reinforcement.
Outcome measures: The primary outcome 
was the constipation-specific Patient Assessment 
of Constipation-Symptoms (PAC-SYM)/Patient 
Assessment of Constipation-Quality of Life (PAC-
QOL). 
Results: The trial planned to recruit and retain 1425 
patients from 57 practices (19 per arm); however, only 
154 patients were recruited from 19 practices. Due 
to these low recruitment rates it was not possible 
Abstract
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primarily occurred because of reduced hospital costs. 
There was no significant change measured in utility, 
so the personalised arm appeared to be the preferred 
course, producing the greatest cost savings.
Conclusions: Due to the low number of participants 
in the trial, no firm conclusions could be drawn about 
the effectiveness of the interventions. However, a 
number of factors that contributed to the conduct 
and progress of the trial are highlighted, which may be 
relevant to others conducting research on a similar 
topic or population.
Trial registration: ISRCTN73881345.
Funding: This project was funded by the NIHR Health 
Technology Assessment programme and will be 
published in full in Health Technology Assessment; 
Vol. 14, No. 52. See the HTA programme website for 
further project information.
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Preface
Running simultaneously with LIFELAX was 
another HTA-commissioned complex randomised 
controlled trial (RCT) investigating the cost-
effectiveness of the stepped treatment of older 
adults on laxatives [Stepped Treatment Of Older 
adults on Laxatives (STOOL) – ISRCTN11557289]. 
The HTA Commissioning Board funded a small 
qualitative study alongside the STOOL and 
LIFELAX trials to investigate the definition and 
meaning of constipation among older people and 
health professionals. The results of this pilot work 
were used to inform a number of decisions made 
by the LIFELAX trial team while developing 
the interventions, the data collection tools and 
preparing patient information sheets.
Set-up and preparation for the LIFELAX trial (the 
development of the interventions, data collection 
tools – questionnaire and diaries, the production 
of the trial protocols, the production of practice 
training resources, and applications for regulatory, 
ethics and research governance approval) started 
in June 2003. Major changes to the Ethics and 
Research Governance structure and process 
during the life of the trial, challenges in practice 
recruitment and the lower than anticipated levels 
of patients’ participation meant that recruitment 
targets were not met in the time agreed with 
the HTA. Towards the end of the recruitment 
period available to LIFELAX, the infrastructure 
to support research activities in the primary care 
setting was in place [initiatives such as the UK 
Primary Care Research Networks (PCRNs), the 
UK Local Comprehensive Research Networks]. 
However, these networks were still very much in 
their infancy, and the LIFELAX Trial Steering 
Committee made the decision in September 
2007 to close recruitment and follow up the small 
number of participants in the trial rather than 
recommend approaching the HTA for a further 
extension.
In conjunction with LIFELAX, the HTA 
programme funded an integrated qualitative 
process evaluation study. The aim of the process 
evaluation was to develop a critical understanding 
of the social processes and practices implicated 
in the development, implementation and 
dissemination of a RCT within the field of HTA. 
In 2001, the Health Technology Assessment (HTA) programme produced the commissioning 
brief (HTA 01/10/04) for a trial on the use of a 
diet and lifestyle intervention versus laxatives 
to manage chronic constipation in older adults. 
The commissioning brief specified the key 
research question: ‘What is the comparative 
cost-effectiveness of laxatives compared with 
dietary and lifestyle changes in the treatment of 
elderly patients with chronic constipation?’ The 
brief was based on recommendations of a HTA-
commissioned systematic review, which had found 
only weak evidence that laxatives can improve stool 
frequency and consistency, and related symptoms. 
Dietary and lifestyle interventions (increase in 
consumption of dietary fibre and fluid, moderate 
exercise, obeying the call to stool) had been 
shown to alleviate constipation. More generally, 
in studies aimed at the modification of dietary 
behaviour, brief interventions had been shown to 
have limited effect, while intensive, patient-tailored 
interventions had been more effective, though 
costly.
In response to the commissioning brief, the 
research team designed a pragmatic three-
armed trial [diet and LIFEstyle versus LAXatives 
in the management of chronic constipation 
in older people (LIFELAX) – International 
Standard Randomised Controlled Trial Number 
(ISRCTN)73881345] to compare laxative treatment 
of chronic constipation in older people with 
both standardised, non-personalised dietary 
and lifestyle advice (delivered in a single, short 
consultation) and personalised dietary and lifestyle 
advice (delivered in a long consultation, with 
telephone reinforcement). Through this study 
design the trial team was able to address the 
following key questions, derived from the research 
brief:
•	 What is the comparative clinical effectiveness 
and cost-effectiveness of laxatives versus a 
combination of dietary and lifestyle advice?
•	 What is the comparative clinical effectiveness 
and cost-effectiveness of brief, standardised, 
non-personalised dietary and lifestyle advice 
versus personalised dietary and lifestyle advice, 
including reinforcement?
Preface
x
Because the process evaluation was ethnographic, 
qualitative research techniques were used, and it 
was therefore not appropriate to set out research 
questions in hypothetical form.
Methodologically, the approach taken by the 
process evaluation was a shift away from the 
conventional, with the relationship between 
the quantitative (LIFELAX) and qualitative 
(process evaluation) being integral rather 
than complementary. In this respect the 
process evaluation was concerned primarily 
with documenting HTA in action through 
implementation of an RCT, rather than the 
provision of supplementary qualitative data to 
support the key LIFELAX outcome measures.
Due to the lower than necessary levels of patient 
recruitment it has not been possible to conduct 
a full evaluation of the interventions, therefore 
this report has a slightly different emphasis to 
the model HTA monograph. We describe the 
background to, and rationale for, the study. We 
describe the development of the interventions and 
the various training resources. We present the 
design of the trial and detail the various strategies 
and techniques used in its implementation to 
optimise practice and patient participation. 
We examine the various barriers to successful 
implementation of LIFELAX at a practical level. 
We present the findings of the process evaluation 
and discuss the contribution it makes to our 
understanding of a complex intervention at work 
using the Normalisation Process Theory and the 
implications for future complex interventions in 
primary care.
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Executive summary
Setting
General practices in England and Scotland, UK.
Participants
People aged ≥ 55 years (lowered to 50 years during 
the course of the trial) with chronic constipation, 
living in private households. Participants were 
identified as those who had been prescribed 
laxatives three or more times in the previous 
12 months, or with a recorded diagnosis of chronic 
functional constipation.
Outcome measures
The primary outcome was the constipation-specific 
Patient Assessment of Constipation-Symptoms 
(PAC-SYM)/Patient Assessment of Constipation-
Quality of Life (PAC-QOL). Secondary outcomes 
comprised: European Quality of Life-5 Dimensions 
(EQ-5D), reported number of bowel movements 
per week; the presence/absence of the other Rome 
II criteria for constipation; and adverse effects of 
treatment; and relapse rates.
Intervention development
The content and mode of delivery of the two 
intervention arms was developed by working 
closely with patients and practice staff from two 
GP practices. The patient information underwent 
a series of revisions following extensive patient 
feedback using a range of cognitive interview 
techniques.
Results
Baseline data
The trial planned to recruit and retain 1425 
patients from 57 practices (19 per arm); ultimately, 
154 patients were recruited from 19 practices. Due 
to the low recruitment rates, we are not able to 
report the conventional trial findings. We report 
the baseline characteristics of our sample from 
data gathered from both the postal self-completion 
questionnaire and the face-to-face interview. These 
data suggest that our sample experienced very 
Background
The management of constipation in the over-
55s is costly, generating far in excess of 450,000 
general practitioner (GP) consultations per year in 
the UK, at an estimated cost of more than £4.5M 
per year. In older adults living in the community, 
approximately 20–25% have symptoms of 
constipation. The propensity to consult increases 
with age – for a GP with an average list size of 
2000, approximately 16 patients aged 55 and 
over will consult about constipation each year 
(McCormick A, Fleming DF, Charlton J. Morbidity 
statistics from general practice: fourth national study. 
OPCS: London; 1995).
Though often trivialised as a medical problem, for 
people with chronic constipation the impact on 
quality of life (QoL) is considerable and the burden 
on health-care resources is substantial.
Objectives
To investigate the clinical effectiveness and cost-
effectiveness of:
1. laxatives versus dietary and lifestyle advice
2. standardised versus personalised dietary and 
lifestyle advice.
Methods
Design
A prospective, pragmatic, three-armed cluster 
randomised trial with an economic evaluation.
Health technologies being 
assessed
1. Prescription of laxatives, with class of laxative 
and dose at the discretion of the GP and 
patient (standard care control arm).
2. Standardised, non-personalised dietary and 
lifestyle advice.
3. Personalised dietary and lifestyle advice, with 
reinforcement.
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few symptoms of constipation (PAC-SYM – Frank 
L, et al. Psychometric validation of a constipation 
symptom assessment questionnaire. Scand 
J Gastroenterol 1999;34:870–7) and the condition 
itself does not have a major impact upon their QoL 
(PAC-QOL – Marquis P, et al. Development and 
validation of patient assessment of constipation 
quality of life questionnaire. Scand J Gastroenterol 
2005;40:540–51). The low level of symptoms of 
constipation is most likely explained by the fact 
that 90% of the sample had used a laxative in 
the previous week and thus were asymptomatic 
for constipation. Most people in our sample were 
satisfied with their laxatives in terms of the time 
they took to work and the effect they had on their 
stools. Levels of anxiety and depression were low in 
this group.
Fibre consumption can be classified as ‘moderate’ 
(Roe L, et al. Dietary intervention in primary 
care: validity of the DINE method for diet 
assessment. Fam Pract 1994;11:375–81). There 
was therefore scope for an intervention that 
focused on increasing dietary fibre to be effective. 
Characteristically in a sample of this age, average 
water consumption fell below the recommended 
guidelines.
Diary data
The daily diaries were analysed primarily in 
terms of overall response rate and item response 
rates. The diary was completed each day for a 
period of 6 months. The results show that the 
daily diary developed for the diet and LIFEstyle 
versus LAXatives in the management of chronic 
constipation in older people (LIFELAX) trial 
was an acceptable method of data collection for 
participants.
Economic data
With regard to the economic evaluation, all of 
the trial arms experienced a reduction in utility, 
as measured by EQ-5D. There was no statistical 
evidence to suggest that either the personalised 
intervention arm or the standardised intervention 
arm was associated with significant changes in 
utility at 3 months compared with the control 
arm. Data on related health-care costs show a cost 
saving of £13.34 for those in the personalised arm, 
compared with the control arm, and a smaller cost 
saving for the standardised arm. These savings 
primarily occurred because of reduced hospital 
costs, offset by a smaller increase in costs incurred 
through additional telephone consultations. As 
there was no significant change measured in 
utility, cost minimisation would suggest that the 
personalised arm would be the preferred course, 
as it produced the greatest cost savings. This 
finding is qualified by the fact that the statistically 
significant reduction in health-care costs was 
due to a relative small number of cases in this 
relatively small sample; confidence limits around 
all estimates are large.
Integrated qualitative 
process evaluation
Background
The randomised controlled trial (RCT) is the 
primary means by which clinically reliable 
knowledge and ‘evidence’ is constructed within 
the field of health technology assessment (HTA). 
The importance of the RCT lies not simply in 
its apparent methodological security, but in the 
social and political uses to which its results might 
be put. Evidence is a vital element of the politics 
of health care at the beginning of the twenty-
first century: its production and application are 
politically contested both within the NHS and by 
specific interest groups, ranging from political 
parties to advocacy groups for particular groups 
of service users. Given the importance of the 
RCT in contemporary health care it is surprising 
that this crucial means of the social organisation 
and production of knowledge about health care 
has not been subject to sustained empirical 
attention in depth – but has instead been mainly 
the focus of macro-level analyses, such as that 
by Faulkner (Faulkner A. Strange bedfellows’ in 
the laboratory of the NHS? An analysis of the 
new science of health technology assessment in 
the United Kingdom. In Elston MA, editor. The 
sociology of medical science and technology. Oxford: 
Blackwell; 1997. pp. 183–207). The process 
evaluation embedded within the LIFELAX 
RCT contributed toward addressing this gap, 
through the application of ethnographic research 
techniques to the empirical investigation of the 
social organisation, production, and effects, of the 
RCT in practice.
Objectives
The process evaluation addressed the following 
specific questions:
1. Formation How are ideas about the 
appropriateness of health technologies 
and their clinical applications formed and 
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mobilised in practice; and how are the interests 
of consumers and other users defined and 
incorporated in the organisation of the trial?
2. Integration How are specific clinical and 
methodological problems within an RCT 
identified and resolved within professional 
groups and networks; how is the trial 
integrated into the existing organisation 
of clinical service provision, and what 
professional and organisational dynamics 
are involved in this integration; and how 
is participation in the RCT negotiated and 
understood by subjects?
3. Implementation How is the production of 
results negotiated and organised within 
networks of researchers; how are its results 
mediated to the wider community and how is 
this negotiated and organised, both formally 
(through report writing and presentation); 
and, informally, how are the mechanisms and 
results of the trial understood by subjects?
4. What lessons can be learned that will improve the 
organisation and conduct of HTA RCTs in the UK 
– and further afield? This study has important 
implications for the organisation and conduct 
of HTA. It is important that its results can 
inform and develop both policy and practice.
Methods
Study group
Purposive sampling from three specific groups of 
participants in the trial: (1) project management 
and steering group (n = 11); (2) general 
practitioners (GPs), practice managers (n = 6) 
and nurses (n = 9) working to recruit and deliver 
patients to the trial and conduct the interventions; 
and (3) patients (n = 23) participating in the trial.
Data collection and analysis
A combination of qualitative research techniques 
were used, broadly following the precepts of Glaser 
and Strauss’ (1967) model of constant comparison 
to develop first order analyses of the data. 
Throughout the contact period with each group 
a programme of semistructured interviews was 
undertaken. Some members of the trial team were 
interviewed iteratively across the life of the trial 
as new issues arose. All semistructured interviews 
were audio-taped with the respondent’s consent, 
and transcripts formed the data subjected to 
formal analysis. The constant comparative method 
of qualitative analysis was carried out. Emerging 
themes were applied to the Normalisation Process 
Model (NPM) (May C. A rational model for 
assessing and evaluating complex interventions in 
health care. BMC Health Serv Res 2006;6:86).
Fieldwork commenced with initial mapping of the 
technical and social components of the trial. This 
mapping identified both the stakeholders and 
key structures of the system, from which a sample 
of both intervention situations and interviewees 
were chosen. Where observation was possible 
(e.g. at meetings or presentations), it involved 
the production of contemporaneous field notes 
from which analytic themes and categories were 
identified. It was important to observe routine 
and problematic applications of the trial, such 
as negotiations regarding the implementation 
of the protocol in busy primary care practices. 
Local documentary materials (e.g. protocols, 
correspondence, minutes of meetings, notices, 
leaflets, entries in newsletters) in which the trial 
was explained to professionals and subjects were 
analysed for comparison with themes emergent in 
the interview data, and with the wider literature 
concerning the particular form of intervention, 
and with HTA as a discrete field.
Results
The trial team followed the guidelines set out 
by the Research Management and Governance 
framework (RM&G – Central Services Agency, 
2008) for clinical trials in the UK. However, certain 
milestones proved difficult to attain. In particular, 
the experience of the trial team was that RM&G 
guidelines were subject to localised, and sometimes 
inflexible, interpretation by governance bodies 
implicated in the research, whereas the Multi-
Centre Research Ethics Committee (MREC) 
stipulations were also difficult to negotiate in 
practice. As an example, observation of the trial 
team revealed that they had significant difficulty 
in implementing the multicentre RCT when a 
shared understanding of what constituted ‘risk 
to patients’ was lacking across sites. A great deal 
of the trial team’s resources were therefore spent 
in developing creative and workable solutions to 
emerging practical problems of implementation. 
As demonstrated by a growing number of reports 
in the literature (e.g. Wald DS. Bureaucracy of 
ethics applications. BMJ 2004;329:282–4), the 
LIFELAX trial was not alone in experiencing these 
difficulties.
The LIFELAX trial depended on cooperation 
between the trial team and key individuals from 
a number of external organisations. To facilitate 
administrative work, the trial manager actively 
identified key contacts and developed working 
relationships with them through a sequence of 
telephone calls and/or written communication. In 
this regard the trial relied heavily upon the ‘social 
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aptitude’ of the trial manager and his tactful 
approach in requesting additional resources. 
Social skills are infrequently identified as a key 
component of a trial manager’s repertoire, yet they 
proved to be pivotal in the development of the 
LIFELAX trial, despite its early closure.
In following the research brief to assess the cost-
effectiveness of diet and lifestyle interventions for 
the treatment of chronic constipation, the trial 
team developed nurse training packages based on 
Behaviour Change Counselling (BCC) techniques. 
Despite the time, expertise and financial resources 
spent on these interventions, the feedback from 
the interviewed primary care staff was that chronic 
constipation was a comparatively low priority issue 
for general practices. The perspective of practice 
staff can be summarised in three key points:
1. Chronic constipation was regarded as being 
successfully managed via laxatives.
2. Patients with chronic constipation typically saw 
their GP or a community nurse, therefore the 
practice nurses viewed the issue of constipation 
management as falling outside their remit of 
work
3. Some practice nurses described the BCC 
approaches as part of their current skill set, 
and therefore reported that the training 
interventions had little practical benefit for 
their routine patterns of work.
In this respect, the trial was perceived by 
some staff as giving nurses additional work, 
for a condition of low priority, and offering an 
intervention that, at best, was seen as relatively 
elementary to professional nursing practice. The 
participants interviewed through the process 
evaluation struggled to articulate whether they had 
benefitted from taking part in the research, while 
most of those attending practices randomised to 
the BCC arm did not view their consultation as 
differing from a routine nurse-led interaction.
Recommendations for 
research
A number of issues regarding the development 
and implementation of RCTs have been identified 
through the conduct of the process evaluation. 
The problem of the trial’s topic, setting and 
training packages may have been identified had 
a prior feasibility study been conducted. At the 
time of the LIFELAX trial the HTA programme 
did not fund pilot studies of this nature, although 
the HTA have now changed their policy in this 
regard. However, numerous system-wide problems 
– such as the changing RM&G guidelines and 
research briefs that did not match General Medical 
Services contracts – also taxed the capacity of the 
trial to be successful. Following the results of the 
process evaluation, and the input of several of the 
reviewers of this report, we suggest the following:
1. Improved means and methods of communication 
are required between governance bodies, 
MRECs and researchers regarding the 
best way to conduct RCTs that are ethically, 
methodologically and practically sound.
2. There is a need for a clear and consistent 
means of applying for RM&G approval across 
Primary Care Trusts.
3. There is a clear need for pilot studies prior to 
the design and implementation of HTA RCTs:
i. Pilot studies should assess the feasibility of 
all aspects of the intended research but, 
specifically, ensure that the assumptions 
underpinning the study are correct. These 
assumptions may be multiple but should 
ensure that: (1) there is an identified need 
for a technological intervention; (2) the 
intended beneficiaries also perceive a 
need for intervention and are in equipoise 
between the proposed interventions and 
control; and (3) the definition of the need 
or problem is commensurate between 
researchers, users and beneficiaries.
ii. Pilot studies should assess whether the 
interventions will enable the intended 
users and/or beneficiaries to achieve 
relevant goals (such as disposal of 
symptoms).
iii. Pilot studies should assess whether the 
intended interventions fit within existing 
patterns of work, and where they do 
not, assess the likely disruption and 
acceptability to intended users.
iv. Pilot studies designed to assess the 
feasibility of the research should be 
conducted prior to any significant 
investment in the development of an RCT.
Trial registration
This trial is registered as ISRCTN73881345.
Funding
The National Institute for Health Research Health 
Technology Assessment programme.
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Chapter 1  
Background
means different things to different people.16,17 
Even to health-care professionals constipation 
remains a largely subjective diagnosis.18 As the 
experiences of the STOOL (Stepped Treatment Of 
Older adults on Laxatives) trial and its associated 
qualitative study show, both constipation and 
normal bowel function are so difficult to define 
that it is entirely understandable that there is often 
a mismatch between what patients and health-
care professionals mean when they use the term 
‘constipation’ (p. 67).19
Clinical definitions
It is not surprising that constipation is subjectively 
diagnosed when one considers the lack of an 
accepted definition of constipation in clinical 
practice. Attempts to define it have been made 
and the following working definition has been 
proposed:18 ‘straining at passing stools for 
more than 25% of bowel movements’. Others 
attempts at a definition have used the frequency 
of bowel movements: passing a stool ‘less than 
three times per week’ has been offered as an 
operational definition of constipation in clinical 
and epidemiological research.20,21 According to the 
Rome II criteria for functional constipation,22 the 
‘gold standard’ criteria at the time of designing the 
LIFELAX (diet and LIFEstyle versus LAXatives 
in the management of chronic constipation in 
older people) trial, for a diagnosis of constipation, 
individuals are required to have two or more 
of the following symptoms present for at least 
12 consecutive weeks in the previous 12 months:
•	 straining in more than one in four defecations
•	 lumpy or hard stools in more than one in four 
defecations
•	 sensation of incomplete evacuation in more 
than one in four defecations
•	 manual procedures (e.g. digital evacuation or 
support of the pelvic floor) in more than one in 
four defecations
•	 fewer than three defecations per week.
In the more recent Rome III criteria, a less 
restrictive time frame is introduced. Symptoms 
must have begun 6 months prior to diagnosis and 
be active for 3 months. Thus, onset of symptoms 
Introduction
As a medical problem, constipation is often 
trivialised.1 However, chronic constipation has 
a considerable impact upon the individual 
and all of the health-care resources associated 
with managing the condition. The effect of 
chronic constipation on quality of life (QoL) 
is considerable,2,3 and the burden on health-
care resources, in terms of visits to health-care 
practitioners, and medications, is substantial.4 In 
England and Wales, constipation generated some 
450,000 general practitioner (GP) consultations 
per year in 1991–2,5 at an estimated cost of £4.5M 
per year.6 The net ingredient cost in 2005 of 
prescriptions for laxatives was approximately £50M 
per year in England alone.7
Defining constipation and 
‘normal’ bowels
Constipation is ‘variably defined’8 by patients 
and medical professionals and is a common 
complaint of industrialised societies.9 Patients 
perceive ‘regularity’ to be an important variable in 
determining good health.10 In Scouting for Boys,11 
Baden Powell declared that in order ‘to make 
yourself strong and healthy it is necessary to begin 
with your inside’, and recommendations for this 
included ‘making the stomach work to feed the 
blood’ with exercises such as the ‘cone’, or ‘body 
bending’, and ‘twisting’. In order to ‘make the 
bowels active to remove the remains of food and 
dirt from the body’ he suggested ‘body bending’ 
and ‘kneading the abdomen’, and suggested his 
scouts ‘drink plenty of good water’ and had, what 
he referred to as, a ‘regular daily rear’.
The frequency and consistency of stools are 
important in defining constipation and ‘normal 
bowels’, both in lay and clinical definitions. 
Regarding ‘frequency’, clinicians consider passing 
a stool anywhere from three times a day to three 
times a week as being ‘normal bowel function’.12 
Regarding ‘consistency’, as this is linked to 
transit time through the gut it is considered by 
clinicians to be a useful indicator of normal bowel 
function.13–15 In everyday life, however, constipation 
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should begin at least 6 months before clinical 
presentation and the diagnostic criteria must be 
fulfilled for the last 3 months (rather than 1 year 
for Rome II).23
Considering the complexity of the above, it is 
entirely understandable that there is so little 
agreement between a patient’s self-perceived 
constipation and assessments based on the Rome 
II criteria.14,19 With the Rome II criteria for 
constipation being so far removed from the patient 
definition,19 underestimation of the prevalence of 
condition could be expected. In a systematic review 
of studies of the epidemiology of constipation 
in North America,24 the authors reported that 
the prevalence of self-reported constipation was 
consistently higher than that defined by the Rome 
II criteria.22 Figures from a North American review 
paper estimate that, in addition to the 63 million 
people meeting the Rome II criteria for functional 
constipation, a further 50 million reported that 
they had constipation. The authors of the review 
suggest that these differences may reflect the lay 
perceptions and expectations of normal bowel 
function, in particular frequency.24 In line with 
the STOOL report findings,19 it was the absence of 
a daily bowel movement that people described as 
‘being constipated’. Evidence from the literature 
surrounding irritable bowel syndrome suggests 
that the Rome criteria are not used to any great 
extent within routine clinical practice in primary 
care, with estimates of between 12% and 20% of 
GPs knowing the criteria and only 3–4% using 
them.25,26
Lay definitions
Frequency of bowel movements is an often-
used lay criterion, with most people associating 
constipation with decreases in normal frequency 
of bowel movements. Within ‘frequency of bowel 
movements’ there are at least three distinctive 
experiences:
1. those who are unable to pass a stool despite 
having an urge to go (‘can’t go’)
2. those for whom there is an infrequent passing 
of stools (‘not going to the toilet’)
3. those who miss a day without a bowel 
movement (‘not going as often’).19
In a UK-based study of hospital outpatients, 
almost one-half of the participants thought of 
constipation purely in terms of frequency of bowel 
action, without considering difficulty or pain on 
defecation.27 The importance attached to the 
frequency of bowel movements is not just a UK 
finding, with both Japanese28 and Australian17 
studies finding it to be of the highest importance28 
to older people, and the most often cited 
description of constipation.17
The STOOL report highlights the range of 
factors taken into account when people define 
constipation.19 In addition to frequency, when 
defining constipation lay people place emphasis 
on a range of other symptoms, such as straining,29 
bloating30 and unsatisfactory defecation.31 To 
further add to the complexity of the lay definition 
of constipation, the importance, or implicit 
weighting, attached to different symptoms, or 
combinations of symptoms, varies from patient to 
patient.17,19,28
Prevalence rates of 
constipation among older 
people
Given the lack of consensus on the definition of 
constipation in the clinical world, and the variation 
in definition and perceptions of constipation 
among lay people, it is not surprising that there 
is little agreement on the prevalence rates of the 
condition. UK estimates of prevalence rates of 
constipation in the general population range from 
2% to 51.5%.13,15,32–34 In the epidemiological study 
in North America mentioned earlier, prevalence 
rate estimates range from 1.9% to 27.2%.24
Regardless of this lack of consensus over actual 
prevalence rates, there is agreement that the rates 
do increase with age5,35,36 (Table 1). In the HTA-
commissioned systematic review of the effectiveness 
of laxatives in the elderly, the authors assert that 
approximately one-fifth of older people living in 
the community have symptoms of constipation.1
TABLE 1 Consultation rates in primary care for constipation in 
the over-45s
Consultation rates/10,000
Age range of 
patients (years)
75 45–64
200 65–74
400 77–84
600 85+
Adapted from McCormick et al.37
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Impact of constipation on 
QoL in older people
Given the prevalence and burdensome nature of 
chronic constipation, the literature surrounding 
the impact it has upon QoL and standardised 
assessments to measure this is surprisingly sparse.38 
Many of the early studies attempting to investigate 
the overall burden of chronic constipation on 
QoL made use of general assessments such as 
the Gastrointestinal Symptom Rating Scale and 
the Psychological General Well-Being Index.3 
These assessments have been limited, however, 
to observational studies and cross-sectional 
comparisons.
Psychological General Well-Being Index scores 
(which assess anxiety and depression, perceived 
health, vitality, and overall well-being) were 
significantly lower (poorer) for people with 
constipation than the published scores for a 
general population sample.3 In a cross-sectional, 
population-based survey of individuals of at least 
65 years of age completing the Medical Outcomes 
Study Short Form General Health Survey, those 
with chronic constipation reported poorer role 
functioning and pain scores compared with those 
without constipation.2 A similar pattern was shown 
in a mailed survey that assessed health-related QoL 
(HRQoL) (using the Short Form questionnaire-36 
and Short Form questionnaire-12 items) among a 
Canadian population with self-reported functional 
constipation (Rome II criteria), when compared 
with Canadian norms.39 In interviews with frail 
older people living at home, constipation was 
considered by 11% to be a major problem adversely 
affecting their QoL.21 Although there is a paucity 
of them, studies that report the relationship 
between QoL and constipation show that people 
with constipation generally have impaired QoL 
compared with the general population.
Management of 
constipation in older people
The most common method to treat constipation 
in older people (> 50 years) is to use laxatives. 
However, there is little evidence to support either 
their clinical effectiveness or cost-effectiveness.1 
Readers interested in the evidence (or lack thereof) 
for the use of laxatives in the management of 
constipation in older people are encouraged to 
read the Health Technology Assessment (HTA)-
commissioned review,1 Gallagher, O’Mahony and 
Quigley’s recent review40 and the STOOL trial 
report.19
While there is little evidence supporting the use of 
laxatives in the treatment of constipation in older 
people, there is also little evidence-based guidance 
on what constitutes effective management of 
constipation in older people more generally.1,41 The 
HTA review concludes that laxatives may not be 
an appropriate method for treating constipation 
for all people, and that change in general diet may 
be sufficient to treat and/or prevent the condition. 
However, the authors concede that there is a lack 
of good-quality evidence showing that dietary 
interventions are effective.
Petticrew et al.1 proposed a stepped approach 
to the management of constipation, which first 
considered dietary and lifestyle changes then (if 
unsuccessful) considered dietary supplements, and 
then (if both of the previous interventions failed) 
considered the use of a prescribed cost-effective 
laxative treatment.
Taking into account the findings of the review, the 
advisory panel to the HTA proposed a further step 
in the constipation management strategy. This step 
involved prescribing a single class of laxative (bulk, 
stimulant or osmotic laxative) in the first instance 
and then, if this failed to resolve the constipation, 
adding in a second laxative from another class 
(e.g. stimulant plus bulk). In light of this, the 
HTA commissioned two independent randomised 
controlled trials (RCTs) – STOOL and LIFELAX.
The STOOL trial19 was commissioned to 
investigate the clinical effectiveness and cost-
effectiveness of laxatives prescribed for older 
people from the three classes (bulk, stimulant or 
osmotic laxative) and for different management 
strategies of combining the classes.
LIFELAX was commissioned to compare the 
clinical effectiveness and cost-effectiveness of 
practice-based educational interventions to change 
the diets of older people who have constipation 
with traditional medical management using 
laxatives.
Impact of diet and lifestyle 
on constipation
Interest in the role of dietary fibre has existed 
from the Victorians, who believed that bran 
stimulated colonic movements. By the 1900s, fibre 
had received some attention for its role in relieving 
constipation, and in the 1930s dietary fibre was 
being investigated for its laxative properties.42
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Epidemiological evidence suggests that diseases of 
the large bowel, commonly seen in industrialised 
countries, are linked with decreasing fibre intake.43 
Findings from the recent European Prospective 
Investigation into Cancer and Nutrition study have 
suggested that where there is a low average fibre 
intake, doubling total fibre intake from foods could 
reduce the risk of colorectal cancer by 40%.44
Intake of dietary fibre is just one of a number of 
factors that influence bowel frequency.45 The most 
common causes of constipation in primary care 
are related to diet, fluid intake and psychological 
factors.8 Although there is ‘no compelling medical 
evidence that inadequate fluid intake results 
in constipation’, it is generally agreed, both by 
the medical profession and the general public, 
that low levels of fluid intake are associated with 
constipation.10
Constipation is more common in women than 
men and its prevalence increases with age.46 
In constipated older people, a lifetime of 
environmental risk factors, such as poor intake 
of dietary fibre, chronic use of laxatives and 
ignoring periods of high motility, rural living 
and colder temperatures are likely to have been 
causes of constipation.45,47 Others have found 
evidence for gender (female), ageing, low energy 
intake, inactivity, number of medications taken, 
low income and low education level, as well as 
depression, physical and sexual abuse being factors 
associated with constipation.48
Constipation is rarely seen in developing countries 
and it has been related to the low-fibre diet 
consumed in the typical industrialised society.43 
From this brief introduction it is apparent that 
the impact of diet and lifestyle on constipation is 
multifactorial. A more detailed consideration of 
the evidence of these factors and summary of the 
evidence, as was incorporated into the LIFELAX 
diet and lifestyle advice, follows.
Fibre and constipation
‘Fibre supplementation is generally the cornerstone 
of prophylaxis against constipation.’29 Increasing 
stool weight and improving bowel movement are 
two of the primary physiological functions of the 
large bowel49 in which dietary fibre has a role 
to play. Dietary fibre can be defined as a ‘plant-
derived material’ that is ‘resistant to digestion by 
human alimentary enzymes’;50 it affects the large 
bowel more than any other dietary component.51 
Dietary fibre’s relationship with the gastrointestinal 
(GI) tract includes roles of being a substrate for 
bacterial fermentation, water holding, cation 
exchange and adsorptive functions.50 These 
mechanisms cause an increase in stool output and 
dilute the colon’s contents.51 The increase in faecal 
bulk depends upon the type of fibre ingested (e.g. 
wheat produces high faecal bulk compared with 
pectin).52
Adding sources of insoluble fibre to the diet 
significantly increases stool weight.49 Wheat bran 
and oat bran, which are composed of differing 
amounts of insoluble fibre (> 90% and 50–60%, 
respectively), have similar effects on daily 
stool output, although they work by a different 
mechanism. Oat bran, which consists of more 
soluble fibre, results in greater bacterial growth 
than wheat bran, whereas the insoluble fibre of 
wheat bran provides more slowly fermentable 
polysaccharides to maintain the microbial 
population during transit through the large 
intestine. Neither oat bran nor wheat bran should 
be thought of as the superior ‘treatment’ for 
constipation, as both have important (if different) 
roles to play.
Results from a double-blind controlled trial to 
measure the effects of wheat bran in the treatment 
of constipation suggest that bran was effective 
in improving bowel frequency and large bowel 
transit time, and that a daily dose of 20 g of bran in 
addition to a high-fibre diet is beneficial to patients 
with chronic non-organic constipation.53 Gear et 
al.54 also concluded that a high intake of dietary 
fibre is associated with more rapid transit times.
Non-starch polysaccharides (NSPs) refers to all 
fibre in the diet. Recommendations as to the 
amount of NSP the average adult diet should 
contain suggest at least 18 g per day.55 The Dietary 
and Nutritional Survey of British Adults56 found 
that fibre intake was significantly greater in 
individuals from higher social classes, higher in 
men who did not smoke or drink and higher in 
older women. The National Diet and Nutrition 
Survey (NDNS)57 of people aged ≥ 65 years 
reported, nonetheless, that the mean NSP intakes 
for free-living men and women (13.5 g for men 
and 11.0 g for women) were significantly below the 
dietary reference value, with intake decreasing 
with age. There was a positive association between 
the number of bowel movements and NSP intake 
in free-living men and women in the NDNS;57 
for women, this increased bowel movement with 
increased NSP intake was regardless of laxative 
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use. Analysis from the Nurses’ Health Study58 
found a higher dietary fibre intake to be associated 
with a decreased prevalence of constipation.
Though a systematic review concluded that 
neither strong nor consistent evidence existed 
regarding the effectiveness of using dietary fibre 
for constipation in older adults, this, the authors 
conceded, was due, in part, to weak study design.59
Fluid and constipation
Whether or not fluid relieves constipation is a 
disputed fact. Health practitioners regularly 
recommend increased fluid intake to alleviate 
constipation, but the role of fluid has been 
challenged. Lindeman et al.60 found no association 
between fluid intake and frequency of chronic 
constipation in the elderly, while Chung et al.61 
did not observe any significant increase in stool 
output by healthy volunteers when fluid intake 
was increased. There is, however, evidence 
which does suggest that increased fluid intake 
has a role in alleviating constipation. Klauser 
et al.62 found that a relatively short period of 
fluid deprivation decreased stool frequency and 
stool weight in young healthy male volunteers. 
Positive associations between fluid intake and 
bowel movements were reported for women aged 
≥ 65 years in the NDNS,57 while no relationship 
between fluid intake and bowel movement 
frequency was seen in men and women living in 
institutions. It is important that when individuals 
are advised to increase their fibre intake they are 
also advised to increase their fluid intake.63
Probiotics, prebiotics and 
constipation
Probiotics and prebiotics both have a beneficial 
impact on gut microflora.64 Prebiotics have an 
osmotic effect on the gut, as long as they are 
not fermented; when they are fermented by the 
endogenous flora they increase gas production.64
Gut bacteria, of which 400–500 species exist in 
the human large intestine, carry out fermentation, 
which metabolises endogenously produced and 
dietary residues.65 Dietary carbohydrates that 
have not been digested in the upper GI tract are 
the main substrates for gut bacterial growth, in 
addition to amino acids, bacterial secretions, lysis 
products, sloughed epithelial cells and mucins, 
which are metabolised to produce short-chain 
fatty acids (SCFAs).65 In summary, the positive 
influences of gut microflora is that they prevent 
colonisation by harmful bacteria, have roles such 
as improving lactose tolerance, providing SCFAs as 
energy substrates, neutralising toxins, stimulating 
the intestinal immune system and having a role in 
reducing blood lipid levels.
Probiotics, defined as viable non-pathogenic 
microorganisms, which, on ingestion, exert a 
positive influence on host health or physiology,66 
are either bacteria or yeast.67 In a recent study,68 
350 healthy elderly subjects consuming one, two 
and three 125-g servings per day of Bifidobacterium 
SP/DN-173010, had marked reduced transit time 
(22%, 40% and 47% reduction of initial values). 
This effect was still present for 2–6 weeks after the 
end of the product consumption.
Constipation was explored in a recent review of 
probiotics in human studies;69 the authors reported 
that few studies were of double-blind design and 
had adequate washout periods. Sample size was 
often limited and outcome markers were non-
comparable, including both bowel frequency 
and transit time. They concluded, however, 
that probiotics do have a probable effect on gut 
transit time and on stool frequency, although this 
is species and strain specific rather than genus 
dependent.
Described as non-digestible food ingredients, 
prebiotics stimulate selectively the growth and 
activity of bifidobacteria and lactobacilli, which 
benefit health.70 Non-digestible oligosaccharides 
are found in plant cells naturally and are also 
manufactured food components, they are 
non-digestible (in the upper GI tract) and are 
prebiotics; two well-studied and well-established 
prebiotics are inulin and oligofructose, which are 
fermented by the beneficial flora (bifidobacteria 
and also lactobacilli) The major food sources 
of both inulin and oligofructose in the typical 
Western diet are wheat (70%) and onions (25%).71 
Evidence indicates that these fructans are digested 
in the large intestine, increasing microbial mass 
and producing SCFAs,72 which also increases the 
stool mass, beneficial for bowel health.51
The laxative effect of prebiotics was shown by 
Gibson et al.,73 in whose study oligofructose and 
inulin significantly increased stool output, possibly 
due to an increase in biomass. In constipated 
patients, low-digestible carbohydrates, with a 
low molecular weight, had a positive effect on 
intestinal transit time in constipated patients.74 
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An earlier study75 examined the effect of fructo-
oligosaccharides – found naturally in onion, 
asparagus root, artichokes and wheat – on gut 
health. Increases in bifidobacteria – believed 
to be beneficial to the host – following fructo-
oligosaccharide ingestion, were found to relieve 
both constipation and loose stools, as well as 
improving blood lipid profiles.
The definition of dietary fibre alludes to the fact 
that it consists of ‘remnants of edible plant cell 
polysaccharides and associated substances resistant 
to hydrolysis by human alimentary enzymes’.76 
Dietary fibre improves laxation by increasing 
stool weight from the fibre in the stools and also 
by bacterial cells (which have high water content). 
Higher faecal water content increases the ease of 
stool passing. Cherbut76 described how inulin and 
oligofructose, found in a number of vegetables, 
fruits and whole grains, both fit into the current 
concept of dietary fibre and contribute to a well-
balanced diet.
Kleessen et al.77 observed that inulin and lactose 
improved the clinical signs of constipation on 
elderly constipated individuals whose bowel 
movements increased from one or two per week to 
7.5 times per week with a 40 g/day intake of lactose 
and eight to nine stools per week with either a 
20 g/day or 40 g/day dose of inulin. The elderly 
tend to experience an increase in bifidobacteria 
and a decrease in enterococci and enterobacteria 
numbers with inulin, which had a better laxative 
effect than lactose. Use of prebiotics that change 
the elderly patient’s intestinal microflora, as seen 
in Kleessen et al.’s77 elderly population, may be of 
benefit to the wider elderly population.
Exercise and constipation
There is perceived to be a lack of convincing data 
relating physical activity (or a lack thereof) to 
constipation.29 Propulsive movements in the large 
intestine are increased by exercise.78 Although it 
is thus assumed that increased activity stimulates 
bowel motility, an investigation on healthy young 
men failed to confirm this;79 however, mild exercise 
accelerated mouth–caecum transit time for a 
liquid-based meal by 20–25%.80
In patients with chronic idiopathic constipation, 
4 weeks of regular moderate physical activity 
did not alleviate slow transit constipation.81 The 
authors of this study suggested that more vigorous 
activity, for a longer time period, might have 
shown more positive results, but compliance in an 
elderly population may have been reduced with a 
requirement for increased vigour.
In women aged 36–61 years, increased physical 
activity was related to a reduced prevalence of 
constipation;58 taking part in physical activity daily 
was independently associated with a 44% lower 
risk of constipation, while physical activity two to 
six times per week was associated with a 36% lower 
risk when compared with less than once daily.58
A daily walking programme, within 30 minutes 
after a meal has been recommended, with 
stationary exercises for those who cannot walk.29 
The authors29 suggested that abdominal and pelvic 
floor strengthening exercises may be useful.
Position for defecation
In industrialised societies the preferred position 
for defecation is seated, while in Asia and Africa 
the main position is squatting. In a study carried 
out in individuals with normal bowel habits, the 
squatting position required less time and less 
straining for faeces depletion than any other 
sitting position.82 In the squatting position the 
rectoanal junction is straightened, whereas in the 
seated position more straining is required to push 
the faeces through the right rectoanal junction.82 
The strain required to defecate in a seated 
position may lead to repeated Valsalva manoeuvres 
(forcibly exhaling against the closed airway) and 
may result in defecation syncope and death, while 
the squatting position is associated with reduced 
amounts of straining.83
Summary of diet and 
lifestyle advice for the 
LIFELAX trial
•	 Most people experience constipation at some 
point.
•	 ‘Normal’ bowel movement frequency is from 
three times/day to three times/week.
•	 Signs of constipation include:
 – hard stools that are difficult to pass
 – frequency of stools decreasing
 – cramp-like pains in lower abdomen.
•	 Constipation may be caused by:
 – not eating enough fibre (fruit, vegetables 
and cereals)
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 – not drinking enough fluid
 – poor bowel habits (ignoring the ‘call to 
stool’)
 – medicines (antacids, codeine, iron tablets, 
some antidepressants).
•	 Constipation is made worse by:
 – dehydration
 – inactivity
 – painful anal conditions (e.g. haemorrhoids).
•	 Constipation can be eased by:
 – eating regularly
 – eating more fibre-rich foods (fruit, 
vegetables and cereals)
 – drinking eight to ten cups of water/juice/
soft drinks per day
 – keeping active/regular exercise.
•	 Toileting:
 – sitting in a comfortable position
 – spreading your legs slightly apart and 
leaning forward
 – relaxing and taking your time.
Behaviour change
The nutritional evidence-based guidelines 
that underpinned both the standardised and 
personalised intervention arms were the same, 
and it was in the style and mode of delivery that 
the arms varied. Not all of the findings of the 
studies we used to inform the intervention were 
appropriate for both arms. Full discussion of the 
literature reviewed, and the theoretical approaches 
and models used to inform the behaviour change 
interventions used in LIFELAX, can be found in 
Chapter 3, which details the development of the 
intervention.
We were seeking to develop two notionally different 
interventions in LIFELAX. One of the arms 
(standardised) needed to sit firmly within the 
current nursing model in the UK84 and be suitable 
for delivery within a routine appointment time. 
The other arm (personalised) was informed by 
techniques that had been shown to be effective in 
interventions of behaviour change in similar topic 
areas with similar samples to ours.
In studies of individual behaviour change strategies, 
particularly those relating to dietary change and 
exercise,85–87 personalised interventions have been 
shown to be more effective than standard, non-
customised approaches. Personalised interventions, 
however, are typically more resource intensive than 
non-individualised approaches.88
Summary
Although it is often viewed as a trivial complaint, 
constipation is undoubtedly a major concern to 
both patients and the health-care system. For an 
intuitively simple condition, defining constipation 
continues to prove difficult. Among health 
professionals, there is little consensus on a formal 
definition of constipation. The Rome II (and more 
recently the Rome III) criteria were an attempt to 
formalise the assessment of constipation yet as we 
have seen, they are complex and few practitioners 
use them in practice. Rather, in clinical practice, 
constipation tends to be a subjective diagnosis. 
Frequency of bowel movement is an important 
factor in the assessment of constipation yet there 
is no consensus on how often the ‘normal’ bowel 
opens. Clinicians do agree, however, that there is a 
wide variation between individuals in the ‘normal’ 
frequency of bowel movements, ranging from 
three times per day to three times per week but 
many patients have expectations of a daily bowel 
movement.
Lay perceptions of constipation are far removed 
from the Rome II criteria though, as with health-
care professionals, frequency of bowel movements 
is a key component of the definition of constipation 
for the majority of older people.
The Petticrew et al.1 review found that there is little 
known about the clinical effectiveness and cost 
effectiveness of laxative treatment for constipation, 
although dietary and lifestyle changes may help 
in the prevention and treatment of constipation, 
there is also little clear evidence about the cost 
effectiveness of such management strategies.
Collectively the STOOL19 and LIFELAX trials 
were designed to provide such evidence. It is sad 
to report that given the recruitment difficulties in 
both trials, clinical trials to evaluate the clinical 
effectiveness and cost effectiveness of these 
treatments remain to be done in the UK.
Embedded qualitative 
process evaluation
Randomised controlled trials and process 
evaluation studies are complementary research 
methodologies.89 Although the former excel in 
producing outcomes data, the latter provide 
procedural information, such as the fit between the 
study protocol and how the research is practically 
carried out.89,90 Oakley90 describes the typical 
Background
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functions of embedded process evaluations in 
detail:90
Process evaluations within trials explore the 
implementation, receipt, and setting of an 
intervention and help in the interpretation of 
the outcome results. They may aim to examine 
the views of participants on the intervention; 
study how the intervention is implemented; 
distinguish between components of the 
intervention [and] investigate contextual 
factors that affect an intervention. Process 
evaluation can help to distinguish between 
interventions that are inherently faulty (failure 
of intervention concept or theory) and those 
that are badly delivered (implementation 
failure).
(p. 413)
Process evaluations are therefore particularly 
useful within RCTs of complex interventions, when 
it may be difficult to identify the active components 
of the interventions from contextual ‘noise’.91 
Examples of RCTs incorporating qualitative 
process evaluations include the Southampton 
Heart Integrated care Project (SHIP) in which 
the evaluation contributed towards interpretation 
of the research findings, and the Birmingham 
Rehabilitation Uptake Maximisation Study 
(BRUM), in which the evaluation provided insights 
regarding reasons for non-adherence.92–94
Within the LIFELAX RCT, a qualitative process 
evaluation was used to collect data on the 
development and implementation of both the 
RCT and its interventions. Whereas in previous 
studies, process evaluations have largely functioned 
as auxiliary studies, supplementing the research 
findings of their host trials, in LIFELAX the 
process evaluation took a subtly, yet fundamentally 
broader, role by examining the process of HTA 
in action, through the medium of an RCT. In 
this respect the research questions were designed 
not to ask ‘how closely does implementation of 
the interventions fit the protocol?’ but ‘how is 
the protocol constructed and practically enacted, 
and what are the implications for the types of 
knowledge produced?’ The process evaluation 
was thus fully integrated into the RCT, rather 
than playing a complementary role; its results 
contributed information about the process of 
evaluation, the barriers faced by the trial team, 
the manner in which some of these barriers were 
circumvented, and the overarching structural 
problems that eventually prevented the trial’s 
completion.
Understanding the process of evaluation is 
important, for we actually know little about the 
practical conduct of HTA through RCTs, although 
there is a large and expanding body of literature 
that details either the RCT’s methods or the results 
of their application. In one specific field of HTA – 
the development and evaluation of ‘telehealthcare’ 
systems – May et al. have undertaken a series of 
studies95–98 that have examined the evaluation 
of a relatively unstable health technology using 
RCTs and other methods, and have developed a 
model of the social and technical process of HTA 
that defines the contingent points on the journey 
between ideation (i.e. the emergence of ideas about 
the value of a new technology) and normalisation 
(i.e. the point at which it becomes possible for it 
to be embedded in clinical practice).99 Of specific 
interest here is the way that evaluation acts as 
a mediating set of practices between these two 
points on the ‘innovation journey’: specifically, the 
production of evidence supports – or hinders – the 
uptake of a new technology.
Evaluation is not a discrete asocial activity, nor 
is it self-evident. At the very outset, we place the 
kinds of evaluations that define the specific utility 
of health technologies within the frame of the 
larger ‘proto-discipline’ of HTA. HTA is one of 
the major research enterprises of our time. Broad 
in scope, and defined by its emphasis on formal 
– mainly quantitative – methods and its focus on 
clinical effectiveness and cost-effectiveness, HTA 
is directed at the production of evidence about the 
efficacy and utility of techniques and technologies 
of health-care delivery treatment modalities and 
ways of working. As a field of practice, HTA is 
orientated around the production of evidence 
that meets particular criteria of adequacy100,101 – 
its formal proof, as it were, is to be found in the 
outcomes of the RCT, systematic review and meta-
analysis. The questions that inform it tend to arise 
directly from the thrust of health-care policy, 
and the outcomes of HTA practitioners’ work are 
specifically intended to mediate between policy 
and practice. So within the field of HTA, it is 
method that is prioritised either in the production 
of primary outcomes data or in the synthesis of 
existing knowledge.102 The expository literature 
of HTA reflects the priority given to methods, 
not theories, by locating them in a rhetoric of 
political and social neutrality, and emphasising 
applied investigatory technique over broader 
political questions. None of this is intended to 
imply that practitioners of HTA are unaware of 
the political implications of their work or the wider 
social implications of their practice – the reverse is 
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certainly the case. But HTA emulates the neutral 
rhetorical form of the wider field biomedical 
science, constructing apparently methodologically 
secure quantitative facts. So it has, at the outset, a 
first line of defence against wider political critique 
– it is given as quantitative science rather than 
politics.
In this broad context, HTA can be seen as the 
development of a field of research practice that 
accords well with contemporary notions of the 
place of ‘research’ in the complex political and 
social contexts of the advanced economies. For 
example, it fits well with the model of Gibbons 
et al. of ‘mode 2’ knowledge production through 
its connectedness with ‘user’ communities, its 
multidisciplinarity and because of the permeability 
of the institutional structures in which it is 
located.103 Certainly the evaluation of new systems 
of working and of the delivery of treatments is 
not simply directed at establishing their fitness 
for specific tasks, but about adjudicating on 
their superiority over others. More than this, it 
is focused on evidence production: HTA is thus 
one of a number of regulatory systems of practice 
available to governments and others in the 
advanced economies to constrain the conduct of 
health professionals and health-care institutions. 
It can be understood as a form of institutional 
surveillance that governs the conduct of practice, 
defines the directions of innovation, and defines 
potential new fields of clinical organisation and 
practice. As Tanenbaum104 has observed, the thrust 
towards outcomes studies within the field of HTA 
(and across biomedicine more generally) can also 
be seen to represent a powerful and authoritative 
social movement.
Relevant work to conceptualise HTA to date 
has mainly been directed either at practical 
problems of recruitment into trials,105–111 or at 
macrolevel analyses of the relationship between 
policy formation and evidence production.104,112 
More localised critiques have investigated the 
assumptions that underpin outcomes themselves 
or the methods by which they are reached.95 Much 
less work has investigated the specifics of HTA 
as a field of practice, the sociotechnical networks 
in which knowledge about efficacy is defined 
and generated, negotiations about criteria for its 
adequacy or the procedures through which these 
are enacted in concrete practices. The paucity 
of literature in this field is surprising, given the 
importance of the RCT as an HTA method. The 
process evaluation was necessary to provide a more 
detailed understanding of the organisation of 
RCTs, and to assist in the development of a robust 
theoretical model of HTA practice.
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Chapter 2  
Trial design
Health technologies being 
assessed
Treatment strategies at the 
patient level
LIFELAX was a cluster randomised trial. Practices 
were randomly assigned to one of the three 
treatment strategies, with all patients in the 
practice then getting their practice’s allocated 
strategy. Within the laxatives arm, free choice 
of class and dose of laxatives were allowed as 
there was insufficient evidence10,114 of the relative 
superiority of one class of laxatives over another 
or of combination therapies as opposed to single 
preparations. Free choice of laxative therapy more 
closely replicated the situation in routine clinical 
practice, therefore participant adherence to 
treatment protocol was expected to be better than 
should a change in drug have been required. For 
similar reasons, leeway in dosage was permitted 
within dose ranges commonly used in clinical 
practice. To minimise the risk of prescribing 
subtherapeutic doses, the practice training/
initiation reminded participating health-care 
professionals of the therapeutic dose ranges for the 
available laxative preparations.
The dietary and lifestyle interventions were 
informed by findings from previous trials of diet 
and lifestyle interventions.85,87,115,116 They drew upon 
theories of individual behaviour change, including 
the concept of self-efficacy117 and the stages-of-
change model.118
For the personalised intervention arm, a series 
of information leaflets on a range of topics were 
developed and tested.119 These comprised eight 
patient information leaflets (PILs) on constipation, 
activity, bowel health, fruit and vegetables, fibre, 
fluid, alternative therapies and laxatives (see 
Appendix 3). In the standardised arm, participants 
were given a general constipation PIL. Copies of 
the materials produced can be obtained from the 
lead author.
In both of the diet and lifestyle intervention arms, 
the training package was designed to be delivered 
by practice nurses, community nurses or other 
Overview
LIFELAX was designed as a pragmatic113 
three-armed cluster (randomisation at the 
level of the individual general practice) RCT to 
compare laxative treatment (current practice) 
of chronic constipation in older people with 
both standardised, non-personalised dietary 
and lifestyle advice (delivered in a single, short 
consultation) and personalised dietary and 
lifestyle advice (delivered in one long consultation 
– or two shorter consultations – with telephone 
reinforcement) in the management of chronic 
constipation in older people. LIFELAX was to 
be conducted in north-east England and was 
to recruit patients aged ≥ 55 years, registered 
with practices participating in the trial, with 
a current diagnosis of functional constipation 
(operationalised as either having a recorded 
diagnosis of functional constipation or having 
received three or more prescriptions for laxatives 
in the preceding year). Due to poor levels of 
practice uptake and lower than expected levels of 
patient recruitment, it was necessary to approach 
the HTA for an extension to the LIFELAX trial 
and these eligibility criteria were revised in the 
subsequent protocol amendments. In Chapter 4, 
which details the implementation of the LIFELAX 
trial, we describe the protocol revisions in depth. 
Here we will describe the design of the trial as it 
was in the original protocol, agreed with the HTA 
and submitted to the Multi-Centre Research Ethics 
Committee (MREC). The original protocol (version 
2, 4 October 2004) and the final version (version 5, 
24 July 2006) can be found in Appendix 1.
Objectives
The primary objectives for the study were to 
investigate the clinical effectiveness and cost-
effectiveness of:
1. laxatives versus dietary and lifestyle advice
2. standardised versus personalised dietary and 
lifestyle advice.
Trial design
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appropriate health-care professionals (according 
to local custom). Appointments were generally 
offered at the surgery, although home visits were 
an option where appropriate. In the standardised, 
non-personalised arm, there was a single short 
(approximately 10 minutes) appointment, with 
delivery of a standard pack of information and 
brief and general explanation of the information 
leaflet. In the personalised arm, there was 
an initial long (30–45 minutes) appointment 
(though this could be undertaken in two shorter 
appointments should clinic time so dictate) and 
the technique of ‘motivational interviewing’ – 
‘a directive client-centred counselling style for 
eliciting behaviour change by helping clients 
to explore and resolve ambivalence’88 – was 
undertaken. The personalised approach included 
a patient-specific assessment of barriers to and 
facilitators of change and delivery of a personalised 
pack of information with individual targets (tools 
were developed to assist nurses with setting 
personalised goals and plans). Patients in this arm 
received a follow-up motivational telephone call 
from the nurse at 1 week and 1 month after initial 
appointment.
A potential threat to patient recruitment and 
retention in this trial was patients’ unwillingness 
to forgo medication. For this reason, although diet 
and lifestyle was the first-line treatment for patients 
allocated to those arms, the option of continuing 
laxative use [either prescribed or over the counter 
(OTC)] was available if required; the need for and 
use of such medication was captured as part of the 
evaluation process.
Although a ‘washout period’ is recommended in 
trials in functional GI disorders120 the clinicians 
and dietitians involved in the design and 
management of LIFELAX took the decision not 
to implement this. There was a concern that 
patients would be reluctant to withdraw from any 
laxative regimen that was currently effective before 
embarking on any diet and lifestyle changes, 
and that this would have a negative impact upon 
recruitment. There was also a concern that even 
without a ‘washout’ period – as diet and lifestyle 
alterations typically take time to show change in 
bowel function – participants may see this as a 
failure of the intervention and not adhere to the 
protocol or withdraw. In light of this, participants 
in the diet and lifestyle intervention arms of 
the LIFELAX trial were able to continue to use 
laxatives (prescription or OTC) should they or 
their GP feel it appropriate, while those in the 
laxative arm continued to take their usual laxatives 
as prescribed.
Training strategies for 
health professionals
An orientation and training programme was 
developed for the practices recruited to the study. 
All practices had an on-site training visit to discuss 
aspects of the treatment protocol and how it was to 
be delivered in the practice. In addition, a dietitian 
with experience in health promotion delivered in-
practice training on how to deliver the dietary and 
lifestyle intervention to patients, as follows:
•	 Standardised dietary and lifestyle intervention All 
primary health-care professionals (GPs, 
practice and district nurses, and health visitors) 
in the practice were invited to a single 1-hour 
session to introduce the programme and the 
patient resource pack.
•	 Personalised dietary and lifestyle intervention All 
primary health-care professionals in the 
practice were invited to an initial 1-hour 
session to introduce the programme and 
the patient pack. Practice staff involved in 
delivering the intervention to patients were 
invited to take part in two further 45-minute 
sessions on the delivery of a personalised pack 
and motivational interviewing techniques.
The choice of number and duration of training 
sessions was based on experience in other 
similar studies, and represented a balance 
between minimising the demands on busy health 
professionals’ resources, while having sufficient 
time to motivate doctors and nurses and to equip 
them with the knowledge and skills required 
to deliver the interventions to patients. Our 
personal experience, reinforced by the literature,121 
suggested that in-practice delivery of training of 
this nature is more cost-effective than delivery at a 
single central location.
Study participants
Target population
The target population for the study was people 
aged ≥ 55 years (reduced to 50 years after protocol 
amendment) with chronic functional constipation, 
living at home. This ‘age’ choice was made after 
due consideration of the morbidity statistics 
from general practice,5 which indicated that GP 
consultation rates for constipation rise rapidly in 
the 45- to 64-year age group and continue to rise 
steadily with age. The exclusion of residents in 
long-term care reflected the different morbidity 
and the lack of autonomy over decisions pertaining 
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to diet and lifestyle changes and lifestyle 
experience of long-term care residents. LIFELAX 
focused on a predominantly ambulant population 
able to attend independently a primary care clinic.
Inclusion criteria
The complexity of the Rome II criteria for 
functional constipation122 militates against 
their use in screening for chronic constipation. 
Moreover, newly incident cases of constipation, 
especially among older adults, should be 
investigated to determine the underlying cause 
of the constipation and to eliminate more serious 
problems123 before laxatives are prescribed. 
LIFELAX therefore identified and recruited only 
‘prevalent’ cases, defined primarily in terms of 
those prescribed laxatives three or more times 
in the previous 12 months, or with a recorded 
diagnosis of functional constipation (although it 
was unusual to find such a diagnosis consistently 
recorded and coded). Participants meeting this 
criterion were identified from general practice 
computerised patient records using an electronic 
‘query’ (the electronic query was designed to 
work with the EMIS practice computer system to 
interrogate repeat prescribing databases). It was 
recognised that the relapsing and remitting nature 
of constipation meant that not all patients thus 
identified would be constipated (by objective or 
subjective criteria) at any given time.
Patients who fitted one or more of the following 
criteria were therefore eligible for the trial:
1. a recorded diagnosis of chronic functional 
constipation
2. prescribed laxatives three or more times in the 
previous 12 months
3. prescribed a laxative (or combination thereof) 
continuously for the previous 12 months.
Exclusion criteria
1. Patients resident in long-term care.
2. Patients with inflammatory bowel disease, 
intestinal obstruction/bowel strictures, 
known colonic carcinoma, and conditions 
contraindicative to the prescription of laxative 
preparations.124
3. Inability to read and understand written 
treatment plans and educational material.
4. Inability to complete outcome assessments, 
even with assistance (e.g. major cognitive 
impairment, lack of understanding of English).
5. Patients using opioid analgesics.
Consent
Favourable opinion from MREC was granted, 
although the request from the chief investigator 
(CI) for ‘no local investigator status’ was not 
approved. (For a full account of the trial’s status 
as ‘site-specific exempt’ see Chapter 4.) The 
implication of this was the need for a favourable 
opinion to a site-specific assessment (SSA) for 
each individual primary care practice (site) from 
appropriate Local Research Ethics Committees 
(LREC). Written informed consent was obtained 
for all participants recruited to the trial. All the 
patient recruitment materials followed Central 
Office of Research Ethics Committees (COREC) 
guidelines. The trial team used its experience 
from previous studies, where it had been felt that 
the COREC guidelines for information sheets led 
to a large, burdensome and often-intimidating 
document, and produced a short, succinct version 
to accompany the full version. A full patient 
information sheet (PIS) (version 6, 24 July 2006) 
(see Appendix 2) and a brief information leaflet 
(version 5, 26 May 2006) (see Appendix 2) were 
provided to send to patients via their GP. Patients 
were given time to consider the trial fully and ask 
any questions about the implications of the trial as 
part of the consent process.
Sampling design and 
implementation
Sample size
Participating practices were randomised to one of 
three arms. In calculating sample size for cluster 
randomised trials,125 it was necessary to take into 
account within-cluster variance, measured by an 
intraclass correlation (ICC). Our experience in 
previous studies suggested that ICCs of 0.05 for 
QoL outcomes were typical.
Preliminary analysis of data from the average-
sized practices of one of the applicants suggested 
that there would be approximately 40 patients 
in such a practice meeting eligibility criteria. We 
recognised that patients in practices allocated to 
the diet and lifestyle arms of the trial might be 
reluctant to undertake a change to their diet or 
lifestyle and might therefore withhold consent to 
participate. It was in anticipation of this risk that 
we made the assumption that only 30 out of 40 
patients identified (75%) would agree to participate 
and that only 25 would provide follow-up data for 
12 months.
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Our primary outcome was a continuous variable 
score on a QoL scale. In the absence of detailed 
data on the distribution of QoL scores in our 
population, we were able to specify, nonetheless, 
the effect size that we wished to detect. We 
arbitrarily set this at 0.3 standard deviations on 
the condition-specific QoL scale.38 Within the 
literature on QoL assessment, there has been 
a growing consensus126 that an effect size (i.e. 
change over time divided by standard deviation at 
baseline) of < 0.2 represents a ‘negligible’ change, 
an effect size of 0.2–0.5 represents a ‘small’ effect, 
an effect size of 0.5–0.8 represents a ‘moderate’ 
change and an effect size of in excess of 0.8 
represents a ‘large’ change. These criterion values, 
which have been shown to be stable across a range 
of settings, have been established by reference 
to what clinicians and patients consider to be an 
‘important’ difference – the emphasis is therefore 
on clinical rather than statistical significance. Our 
proposed effect size of 0.3 therefore represented 
the difference between the threshold values for 
‘small’, ‘moderate’ and ‘large’ changes (0.5 – 0.2; 
0.8 – 0.5).
It is important to note that the LIFELAX trial was 
not a comparison of an intervention with placebo 
or with normal practice. Instead, there were three 
active treatment groups. It is not unreasonable 
to assume that we might have observed at least a 
small change over time in symptom-related and 
QoL outcomes in all of these treatment groups. 
What we were primarily interested in was whether 
one intervention offers a relative advantage 
over the others. For example, if the changes 
over time for the laxative and standardised diet 
and lifestyle interventions were ‘small’ by the 
established criteria set out above, but a ‘moderate’ 
improvement was observed in the individualised 
diet and lifestyle arms, we might reasonably 
conclude that this intervention offered a relative 
advantage.
For an effect size of 0.3, 90% power, a significance 
level of 5%, an ICC of 0.05, and the ability to 
recruit and retain 25 patients per practice, we 
therefore needed a total of 57 practices (19 per 
arm).
Recruitment
Practices
General practices in England and Scotland, UK, 
were invited by letter to participate. As the STOOL 
Trial19 was recruiting practices in the north-
east of England at the same time as LIFELAX, 
we were careful to divide up the Primary Care 
Trusts (PCTs) so that the same practices were 
not approached by the two studies. When the 
STOOL Trial closed, personal approaches were 
made to the practices that had expressed interest 
in STOOL by the STOOL trial manager in a bid 
to ‘convert’ them to LIFELAX. The remaining 
(non-recruited) practices in the PCTs eligible for 
the STOOL trial were then approached by the 
LIFELAX team. It was felt that LIFELAX would 
be more appealing than STOOL to practices 
as there was a range of relevant training that 
accompanied the interventions, and therefore that 
practices which had not been willing to participate 
in STOOL might nonetheless be agreeable to 
take part in LIFELAX. All practices that wished 
to join LIFELAX were then randomised into 
one of the three trial arms. As each practice was 
recruited to the study it was allocated a study 
identification number by the research team. 
This together with a measure of the practice 
size (number of partners) was then passed to an 
independent statistician who then generated the 
treatment allocation using electronically generated 
random numbers. The research team were kept 
blind to the randomisation algorithm that was 
used (the probability that a practice was allocated 
to a particular treatment depended on the size 
and number of practices previously allocated to 
each of the treatment arms). We recognised that 
practices may have had preferences with respect 
to allocation of intervention arm. We made it 
clear to the practices approached to participate in 
LIFELAX that allocation to intervention arm was 
completely at random and that practice preferences 
could not be taken into account.
Note: details on rounds of recruitment and Trusts 
approached can be found in Chapter 4.
Participants
LIFELAX recruited only prevalent cases that were 
retrospectively identified through computerised 
records of laxative prescriptions, as described 
above. The electronic query was offered to all 
practices. However, many surgeries did not use 
the EMIS system and others preferred to run the 
searches manually. Patients were initially screened 
by practice staff to remove those identified as 
ineligible for the study by reference to exclusion 
criteria. Eligible participants were then invited 
to attend a practice nurse-led research clinic to 
discuss entry into the study. Following informed 
consent, a baseline assessment (a face-to-face 
interview and self-completion questionnaire) was 
completed. A copy of the signed consent form was 
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posted back to the study team. The completed 
baseline assessments were posted back in a separate 
envelope. Following consent, the practice nurse 
contacted the study team and released the personal 
details of recruited patients. (This model of patient 
recruitment was the one used by the STOOL trial 
after several iterations of their approach to MREC 
to gain a favourable opinion. It proved to be rather 
time-consuming and burdensome to practices. 
As such, a different model was introduced after 
a major protocol amendment. This is covered in 
Chapter 4.)
Minimising bias and improving 
compliance
The commitment of GPs and practice staff was 
known to be crucial to the success of the study. 
Educational events were used to introduce the 
study protocol to health professionals from the 
participating practices. Regular updates on the 
study were included in Trust newsletters and also 
in the Northern Primary Care Research Network 
(NoReN)/Northern and Yorkshire Primary Care 
Research Network (NYReN) newsletter. Financial 
support was provided to practices to identify and 
recruit patients. Service support costs and excess 
treatment costs secured through the Support 
for Science (SfS) funding stream meant that 
there was be no financial ‘cost’ to practices for 
participating in the study. All study-related tasks 
were reimbursed at a generous level. Though a 
practice would not be able to look upon LIFELAX 
as a money-making activity, it would not be a drain 
on its resources.
The risk of recruitment bias (i.e. patients being 
unwilling to enter the trial because they may have 
to forgo their laxative treatment) was recognised. 
We believed that the availability of ‘rescue’ 
medication for patients randomised to the diet 
and lifestyle arms would reduce the risk of non-
consent or loss to follow-up, due to anxieties about 
not being able to use medication. Likewise, the 
provision for continuing with an established and 
preferred laxative regimen in the laxatives arm 
was felt to increase the likelihood of participation 
and compliance.
Both at the point of recruitment and intervention 
initiation, the importance of adherence to 
the course of treatment, and of completion 
of questionnaires and diaries, was stressed to 
participants. Up to two written reminders were 
used for participants who failed to return postal 
questionnaires.
For LIFELAX, an intention-to-treat analysis 
was adopted, as it was important that we were 
able to estimate the extent of non-adherence by 
participants. We addressed this issue by collecting 
data about laxative use (both prescription and 
OTC) as part of the participants’ daily diary and in 
follow-up questionnaires.
Baseline and outcome 
measurement
Participants were followed up for 12 months 
from the date of intervention initiation. Follow-
up data were captured through a daily self-
completed structured diary (for 6 months), and 
telephone interviews and self-completed postal 
questionnaires at 3-, 6- and 12-month time points 
(Tables 2 and 3).
QoL and clinical outcomes
The primary outcome, and the criterion upon 
which the sample size calculations were based, 
was patient-reported condition-specific QoL at 
3 months post recruitment. Our preferred measure 
of QoL was the constipation-specific Patient 
Assessment of Constipation-Symptoms (PAC-SYM)/ 
Patient Assessment of Constipation-Quality of 
Life (PAC-QOL),127 which had been demonstrated 
to have good validity and reliability. Permission 
to use this instrument was granted by the owners 
of the scale (Janssen Pharmaceuticals, Titusville, 
NJ, USA) after agreement that anonymised 
patient data (i.e. questionnaire responses) would 
be submitted to them for the purposes of further 
refinement of their scales and development of 
population norms. However, this measure is not 
utility based. For the purposes of the economic 
evaluation, a measure of the utility placed by 
patients on their health state was required. 
The condition-specific measure of QoL was 
therefore supplemented by the generic utility-
based European Quality of Life-5 Dimensions 
(EQ-5D).128,129 Secondary outcomes included 
bowel movement frequency, the presence/absence 
of the other Rome II criteria for constipation, 
patients’ own perceptions of whether or not they 
were constipated, patient satisfaction with bowel 
function, adverse effects of treatment; relapse/
reconsultation rates, and fluid and fibre intake. In 
addition, the cost implications of the condition and 
its treatment (e.g. GP consultations, purchase of 
prescribed and OTC medication) was assessed, as 
part of the economic evaluation.
Trial design
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TABLE 2 Baseline and outcome measures
Outcomes Measurement method When Where
Primary outcome
HRQoL Postal questionnaire At 3 months post 
recruitment
Participant’s home
Secondary outcomes
HRQoL Postal questionnaire At 6 and 12 months post 
recruitment
Participant’s home
No. of bowel movements 
per week
Self-completed structured 
diary + postal questionnaire
Daily for 6 months
At 12 months
Other Rome criteria: 
straining at defecation, 
stool consistency, perceived 
incomplete evacuation
Self-completed structured 
diary + postal questionnaire
Daily for 6 months and for  
1 week at 12 months
At 12 months
Subjective perception 
of whether constipated; 
satisfaction with bowel 
function
Telephone interview + postal 
questionnaire
At 3 months
At 6 months and 12 months
Adverse events: abdominal 
pain, nausea, bloating, 
flatulence, diarrhoea
Self-completed structured 
diary + postal questionnaire
Daily for 6 months and for  
1 week at 12 months
At 12 months
Use of prescribed and OTC 
laxatives
Self-completed structured 
diary + postal questionnaire
Daily for 6 months and for  
1 week at 12 months
At 12 months
Fluid and fibre intake Self-completed structured 
diary + postal questionnaire
1 day per month for  
6 months
At 12 months
Relapse rates, including 
repeat consultations
Self-completed structured 
diary, GP records
Daily for 6 months;  
12 months post recruitment
Participant’s home (diary); 
general practices (GP 
records)
Personal measures 
of success with the 
management of constipation
Telephone interview At 3 months and 6 months Participant’s home
TABLE 3 Measuring treatment impact
Impact Measure When Where
Costs to participants 
of the condition and its 
management
Telephone interview At 3 months Participant’s home
At 6 and 12 months
Consultation rates and 
laxative prescriptions
GP records End of 12-month follow-up 
period
General practices
Adherence to drug 
treatment
Health diary; telephone 
interview
Using different methods, at 
3 months
Participant’s home
At 6 and 12 months
Patient satisfaction Postal questionnaire At 3 months
At 6 and 12 months
HRQoL, including utility-
based assessment of health 
state
Postal questionnaire At 3 months
At 6 and 12 months
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Methods of data collection
Table 4 shows participants’ pathways through the 
trial in the original recruitment protocol, the 
clinical assessments completed and data collection 
methods used at different points on the pathway.
Baseline assessment (T0)
Prior to any assessments being conducted, each 
participant was able to speak on the telephone 
with a member of the research team and was 
invited to discuss any aspect of participation in 
the study they wish. An appointment was made at 
the practice for patients to meet a practice nurse, 
who took informed consent and undertook the 
baseline assessment. This assessment included a 
short, structured face-to-face interview and a self- 
completion questionnaire. Current bowel function, 
fluid and fibre intake, patients’ self-perceptions 
of whether they were currently constipated, and 
levels of anxiety and depression130 were elicited, 
and data on activities of daily living,131 condition-
specific QoL, laxative use (both prescribed and 
OTC) and personal criteria for successful outcomes 
(‘how would you define “successfully managed 
constipation” ’?) were collected. A weekly structured 
self-completed diary was left with the participant 
and details on how to complete it were given. 
After the consent and baseline assessment visit 
was complete, a second appointment was made 
for participants to start the intervention. Should 
patients decide to withdraw when they returned to 
collect either their laxative prescription or for their 
diet and lifestyle appointment, the practice notified 
the research team and all baseline assessment data 
and patient identification data were destroyed or 
deleted from the study database.
Daily diary
To minimise recall bias, data on bowel habits 
and symptoms based on the Rome II criteria122 
were gathered by a structured diary (tick box 
format), completed daily and returned each month 
for 6 months. This diary was developed and 
piloted in parallel with the qualitative study that 
accompanied the STOOL study. It was designed 
to capture information on the number of bowel 
movements, other Rome II criteria, adverse 
events, relapse rates, use of laxative, costs of food 
purchased or activities undertaken as part of any 
diet or lifestyle changes made, and any out-of-
pocket expenses associated with constipation and 
its management. Based on previous experiences 
of similar diaries in studies with older people, we 
expected that 90% of diaries would be returned 
completed.132,133
Postal questionnaires
Follow-up self-completion questionnaires, with up 
to two reminders for initial non-respondents, were 
TABLE 4 Participants’ pathways through triala
Activity
Potential participants identified from computerised practice databases using simple electronic query to flag individuals 
receiving prescriptions for constipation (three or more in previous 12 months)
Initial screen by practice to identify clear exclusions
Written invitation sent by practice; appointment date to give consent at practice set with patient
Consent given at practice; baseline assessments conducted. ‘Intervention start’ appointment made
Appointment at practice – laxative prescription issued or diet and lifestyle intervention initiated; all patient information 
and baseline data destroyed by research team if patient notifies practice of their wish to withdraw from study
1-week reinforcement telephone call from nurse to patients randomised to personalised diet and lifestyle advice
Intervention fidelity measure – a small sample of patients in the standardised and personalised intervention arms of the 
trial receive a short postal questionnaire to ask about the diet and lifestyle advice
1-month reinforcement telephone call from nurse to patients randomised to personalised diet and lifestyle advice
3-month follow-up outcome assessment (postal questionnaire) and collection of cost data and personal levels of success 
(telephone interview)
6-month follow-up outcome assessment (postal questionnaire) and collection of cost data and personal levels of success 
(telephone interview)
12-month follow-up outcome assessment (postal questionnaire and 1-week symptom diary); review of practice notes to 
abstract data on consultation rates and prescription patterns
a This pathway reflects the original protocol. The changes to it are described in detail in Chapter 4.
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sent by post to arrive at T+3 months, T+6 months 
and T+12 months. These questionnaires contained 
the same items as the baseline self-completion 
questionnaire.
Follow-up telephone interviews
The follow-up telephone interviews were also 
administered at 3 months and at 6 months. They 
focused on (a) the participant’s perceptions of the 
outcome/success of treatment and (b) the use of 
health-care resources, and out-of-pocket expenses 
associated with the use of those resources, 
including purchase of OTC medication to manage 
constipation. The interviews were conducted by a 
trained member of the research team.
Medical records
Previous experience suggested that data on 
consultation rates and prescribed medication could 
be gathered most accurately and reliably from 
medical records. Our intention, therefore, was to 
collect such data about all study participants from 
practice-based medical records at the end of the 
follow-up period. Based on experiences in previous 
primary care trials,134,135 for efficiency in data 
capture, we proposed that this be done practice by 
practice at the end of the data-collection period. 
However this activity was not completed due to the 
premature closure of the trial.
Methods of data analysis
Analysis was to be on an intention-to-treat basis. 
No subgroup analyses were pre-planned. The data 
were to be analysed using mixed effects models, 
accepted practice for the analysis of data from 
cluster randomised trials.125 Variation between 
practices and variation between patients nested 
within practices were to be fitted as random effects. 
The difference between treatment strategies (i.e. 
the three arms of the trial) was to be fitted as 
fixed effects. Most of the outcome variables [e.g. 
QoL scores, number of days with (or without) 
symptoms] were continuous and were to be 
analysed assuming a normal error structure. The 
dependent variable in each model was point of 
follow-up (3-, 6- and 12-month outcomes for QoL, 
symptoms and perceptions of bowel function, 
12 months for consultation and prescription rates). 
For each patient, baseline data were to be included 
as covariates. The mixed models were to be used 
to generate interval estimates for the differences 
between alternative treatment strategies.
(Due to the poor recruitment rates, the planned 
analysis and economic evaluation described 
here did not take place. Chapter 5 describes the 
analyses agreed with the HTA after the decision 
was taken to close recruitment.)
Economic evaluation
Perspective of the evaluation
We planned to conduct a cost-effectiveness analysis, 
placing particular emphasis on the subset of costs 
and effects relevant to address the health service 
perspective at a macro level. We had hoped to 
supplement this by an individual participant 
perspective. Our selected outcome measures 
included condition- and treatment-specific QoL 
and a generic utility-based measure of health state, 
measured at the individual level. We also recorded 
the costs of the condition and its management, 
which were met directly by the patients themselves.
Measure of benefits used and 
type of study
Considering all of the measures of effectiveness 
estimated within the clinical trial, a cost-
consequence analysis136 was outlined alongside the 
cost-effectiveness analysis. In the cost-consequence 
analysis, clinical and QoL profile scores, resources 
used for the implementation of the intervention 
strategies and related costs, were to be presented 
in a disaggregated way. For each arm of the trial, 
the breakdown of costs and outcomes was to be 
listed in a tabular format; no summary measures 
were to be presented. This type of evaluation 
and presentation provides readers with a more 
transparent interpretation of the results and allows 
them to make a more selective application of the 
findings to specific decision-making contexts.
Although QoL is an important indicator of 
benefit in the treatment of constipation, and 
was the primary outcome measure in this study, 
none of the currently available condition-specific 
measures yield a unique QoL score. A comparison/
synthesis of costs and outcomes based on each 
of the separate QoL dimensions in our chosen 
profile measures would be methodologically 
invalid. For this reason, a utility-based, index 
measure – the EQ-5D128,129 – was also to be used, to 
facilitate calculation of quality-adjusted life-years 
(QALYs). We were, however, aware of the concerns 
about the use of QALYs in devising resource 
allocation strategies between different age cohorts. 
Therefore, we aimed to apply already existing 
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‘corrective’ measures to the results we obtained, 
so that our findings would not have unfavourable 
implications for the funding of health technologies 
for older people.
Furthermore, we anticipated that the EQ-5D might 
not be sensitive enough to detect differences in the 
population being studied. Therefore, alongside 
this utility-based measure, we aimed to calculate 
discomfort-free days (DFDs) as a new measure of 
outcome. This measure included the impact on 
patients’ well-being of unwanted symptoms due to 
both constipation and treatment side effects. It is 
a crude but meaningful measure of the patients’ 
perceived effectiveness of treatment. DFDs 
were to be derived through the self-completed 
structured diaries. Severity of impact was to be 
graded in levels, and the number of days spent 
in each level of discomfort was to be calculated. 
This information was to be used to assess 
correlation with DFDs responses. We believed 
that the comparison of DFDs with EQ-5D utilities 
would represent a useful addition to the body of 
knowledge on the assessment of cost-effectiveness 
in trials where the main impact is expected to be 
on palliation of symptoms and improvement of the 
QoL, rather than on extension of life.
Design of the integrated 
qualitative process 
evaluation
Introduction
The aim of the integrated qualitative process 
evaluation was to develop a critical understanding 
of the social processes and practices implicated 
in the development, implementation and 
dissemination of a RCT within the field of HTA. 
Because the study was ethnographic, qualitative 
research techniques were used, and it was therefore 
not appropriate to set out our research questions 
in hypothetical form. However, at the outset, we 
addressed the following specific questions:
•	 Formation How are ideas about the 
appropriateness of health technologies 
and their clinical applications formed and 
mobilised in practice; how are the interests 
of consumers and other users defined and 
incorporated in the organisation of the trial?
•	 Integration How are specific clinical and 
methodological problems within an RCT 
identified and resolved within professional 
groups and networks; how is the trial 
integrated into the existing organisation 
of clinical service provision, and what 
professional and organisational dynamics 
are involved in this integration; how is 
participation in the RCT negotiated and 
understood by subjects?
•	 Implementation How are the production of 
results negotiated and organised within 
networks of researchers; how are its results 
mediated to the wider community and how is 
this negotiated and organised, both formally 
(through report writing and presentation), 
and informally; how are the mechanisms and 
results of the trial understood by subjects?
What lessons can be learned that will improve the 
organisation and conduct of HTA RCTs in the UK 
– and further afield? The study holds important 
implications for the organisation and conduct of 
HTA. It is important that its results can inform 
and develop both policy and practice.
Methods
The study design used the Normalisation Process 
Model (NPM), which had been developed through 
empirical work in the evaluation of telehealthcare 
systems in the UK.137 The NPM is a useful means 
of identifying and explaining the socially-mediated 
factors that affect the implementation of new 
technologies in health-care settings.
Four primary groups of actors involved in the 
deployment of the RCT were targeted. These were 
(1) the trial team (n = 11), (2) senior clinical staff 
and practice managers at each site (n = 6), (3) the 
practice nurses enrolled in the trial to deliver the 
intervention (n = 9), and (4) recruited participants 
(n = 23). Collectively, we describe these groups as 
trial contributors.
Due to the concerns of the MREC that repeated 
multiple interviews of recruited participants or 
enrolled NHS staff might constitute harassment, 
we conducted multiple (follow-up) interviews with 
members of the trial team and single interviews 
with practice staff and participants. Data from the 
research team comprised transcriptions of project 
meetings and audio-recorded semistructured 
interviews, field notes written during periods of 
observation, internal and external correspondence, 
and formal and informal documentation. Audio-
recorded semistructured interviews were used to 
provide data from primary care staff and trial 
participants. Table 5 presents the types of data 
collected through the process evaluation.
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The data collected through the process evaluation 
were pooled and analysed as a complete data set. 
In this report we have drawn primarily on the 
interview data, as this facilitates a more concise 
account. However, in the analysis underpinning 
this report, all forms of data were utilised.
Recruitment strategy
Practices enrolled in LIFELAX were recruited 
to the process evaluation by a three-step process. 
Initially, information relating to the process 
evaluation was included in LIFELAX recruitment 
packs distributed by the trial team. When a 
practice had been identified as suitable for 
inclusion, a letter was sent to the practice manager 
or senior partner in accordance with previous 
methods of contact with that practice. The letter 
included a brief summary of the process evaluation 
and forewarned the staff that a researcher (BH) 
would contact the practice by telephone within 
several days. In addition, senior staff were asked 
to cascade the content of the letter to the practice 
nurses as per local custom. The final step in this 
recruitment strategy was to telephone the relevant 
member of senior staff and/or practice nurses to 
arrange an interview. In some instances it was not 
possible to speak to relevant members of staff on 
any given occasion, and repeated telephone calls 
were necessary. However, the availability of staff 
was hard to predict, and even when a time and 
date for a return telephone call had been made in 
advance, staff were not always available to speak 
on the telephone or asked to reschedule the call. 
Consequently, if staff had not expressed an interest 
in participating in the process evaluation after 
approximately four telephone calls to a practice, it 
was decided not to pursue the recruitment further 
at that site. The rationale for this decision was to 
both maximise the productive use of research time, 
and avoid undermining relationships between the 
practice and the trial team, and thus jeopardising 
the RCT.
During the opening phases of the RCT, the 
recruitment of practices ran behind intended 
targets. Consequently, at this point in the process 
evaluation, staff from all recruited practices were 
approached to take part in an interview. Towards 
the end of the trial, when recruited practices were 
distributed across the country, we purposively 
sampled practices according to their randomised 
allocation status and geographical location. 
Practices situated more than approximately 
60 minutes drive from Newcastle, UK, were offered 
only a telephone interview rather than the option 
of a telephone or face-to-face encounter. Practices 
randomised to either of the two diet and lifestyle 
arms of the trial [behaviour change counselling 
(BCC) or brief intervention] were specifically 
targeted, as these conditions required the most 
input from practice staff. Unfortunately, relatively 
few practice staff were recruited to the process 
evaluation.
TABLE 5 Data collected through the process evaluation
Interviews with trial ‘contributors’ 
(trial team, enrolled NHS staff and trial 
participants)
Trial team N = 11
Practice nurses N = 9: personalised (BCC), n = 6; brief 
intervention, n = 3; control, n = 0
GP/practice managers N = 6: personalised (BCC), n = 1; brief 
intervention, n = 4; control, n = 1
Trial participants N = 23: personalised (BCC), n = 6; brief 
intervention, n = 11; control n = 6
Steering group meetings Each lasting approx. 
80–100 min
N = 4
Trial team meetings Each lasting approx. 
150 min
N = 16
Working group meetings Each lasting approx. 
90 min
N = 8
Field notes A
B
2003–4
2005–7)
Additional meetings Press release N = 1
Additional materials Numerous e-mails, protocol documents, letters, etc.
BCC, behaviour change counselling.
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In following the research strategy outlined above 
it became apparent that in many practices the 
practice manager rather than a senior partner 
mediated between the trial team and the practice. 
While senior partners ultimately made the decision 
for their practice to participate in the RCT, their 
general involvement in the trial was limited, 
although possibly also included the screening of 
patients for contraindications and comorbidity. 
Only two senior clinicians were recruited to the 
process evaluation. With regard to senior practice 
staff, including practice managers, we observed 
that during interviews these staff usually struggled 
to discuss the research beyond the reason for 
the inclusion of their practice in the RCT. While 
these explanations were of interest to the research 
team, the senior staff viewed their lack of practical 
involvement in the trial as a limit for the scope 
and value of the interview. Therefore, we found 
it difficult to reach many senior staff and after a 
period of time questioned the value of pursuing 
interviews with this group. It would be inaccurate 
to claim therefore that saturation of data occurred 
within the sample, although meaningful data were 
nevertheless collected.
At their recruitment to the RCT, participants 
were informed about the purpose of the process 
evaluation, and the possibility that they might be 
asked to partake in an interview. All participants 
were given the opportunity to have their preferences 
recorded if they preferred not to be contacted. 
At the initial stages of the LIFELAX trial all 
participating patients who had not objected to being 
contacted were sent a recruitment pack for the 
process evaluation. This included an information 
sheet and a response slip. Once response slips 
had been obtained from the participants, those 
willing to be contacted by the research team were 
telephoned to arrange a time and place for an 
interview. In the latter stages of the trial, due to 
the over-representation of participants within 
the brief intervention arm, we approached all 
participants recruited to the trial with the exclusion 
of those randomised to this condition. As it was 
not possible to conduct repeat interviews with 
individual participants – due to concerns by the 
ethics committee of potential harassment – we 
recorded the stage of participation in the trial for 
each individual. The rationale for this approach was 
that different phases of the research might present 
new issues for participants, and that the meaning of 
the research might also vary along the continuum 
of involvement. Participants were interviewed from 
5 weeks post recruitment to the trial, through to the 
time of completing a final 12-month questionnaire. 
Nevertheless, retrospective analysis of the data set 
did not reveal notable thematic differences across 
the participants’ stage of participation. Appendix 
5 contains a consolidated standards of reporting 
trials (CONSORT) checklist for the process 
evaluation and an adapted flow chart of participant 
recruitment.
Role of the qualitative 
researcher in the trial team: 
ethnography
The ethnographer worked closely with the trial 
team on a daily basis. This proximity had clear 
advantages with regard to accessing materials, 
and attending/observing everyday events in the 
construction and deployment of the trial. All 
members of the trial team were accommodating 
of requests for interviews and recorded meetings; 
however, it took time for both parties to 
understand the role of the other. For the trial 
team it was initially disconcerting having their 
activities routinely observed and recorded, and for 
the ethnographer it was initially difficult to decide 
what was useful data from the vast quantity of 
information collected.
The status of the process evaluation as an integral 
component of the LIFELAX trial ensured that 
all team members gave their formal consent 
to participate in the ethnography, and, in this 
regard, access to some forms of data was assured. 
Formal consent was obtained from all individuals 
attending audio-recorded meetings, and additional 
consent was obtained for interview data. Formal 
and informal consent was obtained before 
reporting data contained in field notes.
The ethnographer was offered a significant 
level of disclosure and cooperation by the trial 
manager and the dietitian tasked with developing 
the training packages. In addition to offering 
personal friendship, the trial manager became a 
key informant and confidant during the conduct 
of the trial, facilitating the ethnographer’s 
understanding of the activities at hand. Both 
contacts facilitated initial attempts to understand 
and map the terminology of the RCT, the 
intricacies of its design, including the basis of 
the interventions, and, perhaps most usefully, 
the broader administrative and bureaucratic 
networks in which the RCT was embedded. 
Moreover, the ethnographer was occasionally 
given small tasks within the RCT. This role, 
however small, facilitated the ethnographer’s 
integration with other trial team members. 
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Through observation, participation and personal 
contacts the ethnographer was therefore able to 
map interactions that would have been problematic 
topics within an interview setting.
Analysis
The process evaluation used a combination of 
qualitative research techniques. In broad terms, 
we followed the precepts of Glaser and Strauss’s 
model138 of constant comparison to develop first-
order analyses of the data. The NPM137 was applied 
to emergent categories in a cyclical process, 
whereby the model’s constructs were partially 
redefined to fit the nature of the data. Because 
of the relatively large body of data collected we 
used nvivo 7 collation and management software. 
Analysis occurred through application of the 
model’s four constructs, as illustrated in Table 6.
TABLE 6 The four constructs of the NPM
Interactional workability
How a complex intervention is practically enacted by 
the people using it
Q. How does the work get done?
(e.g. In LIFELAX, how did the trial team practically 
implement the trial? What did practice staff report 
regarding implementation of training materials and 
contact with participants?)
Skill-set workability
The distribution and conduct of work associated with a 
complex intervention in a division of labour
Q. How is the work distributed?
(e.g. In LIFELAX, which groups of NHS staff were 
targeted by the training interventions, and how did they 
configure the work alongside ongoing responsibilities?)
Relational integration
How knowledge and work about a complex intervention 
is mediated and understood within networks
Q. How is the work understood by the people doing it?
(e.g. In LIFELAX, how do the trial team reconcile 
differences in the implementation of RM&G guidance 
across PCT sites? How do practice nurses make sense of 
the training sessions based on BCC?)
Contextual integration
The incorporation of a complex intervention within an 
organisational domain
Q. How is the work supported?
(e.g. In LIFELAX, what work needs to be performed in 
order to implement an RCT in primary care practices?)
RM&G, Research Management and Governance.
Initial field work consisted of mapping both the 
stakeholders and structures of the system, from 
which a sample of both intervention situations 
and interviewees were chosen. It was particularly 
important to observe routine and problematic 
applications of each arm of the trial, especially the 
negotiations over treatment modalities and how 
the boundaries between these were agreed.
Local documentary materials (e.g. protocols, 
correspondence, minutes of meetings, notices, 
leaflets, entries in newsletters), in which the trial 
was explained to professionals and subjects, were 
analysed for comparison, with themes emergent 
in the interview data and with the wider literature 
concerning HTA as a discrete field.
Due to recruitment difficulties in both the 
LIFELAX trial and process evaluation, it is not 
possible to claim that we finished data collection at 
a point of ‘category saturation’ in thematic analysis 
(i.e. no new forms of data were emerging) for all 
of the categories of contributors (such as senior 
partners and practice managers). Nevertheless, 
data collected across the larger categories of 
‘primary health-care staff ’ and ‘participants’ was 
thematically consistent bar several ‘deviant cases’, 
as described in Chapter 7.
The nature of the process evaluation posed 
important ethical and practical problems. It 
was particularly important that the contributors 
at every level felt safe to report on difficulties 
and disagreements about the focus, design 
and implementation of the RCT. At the outset, 
therefore, we needed to be able to promise the 
contributors that ‘data’ would be treated in a way 
that was ‘non-attributable’, and that it would be 
protected in the same way that we would wish to 
protect, for example patients in a study using these 
techniques. To ensure that this was accomplished, 
we do not identify individuals or specific PCTs 
or practice sites in this report or in any other 
presentation or publication that was made as a 
result of this study. Our previous experience in 
such work has demonstrated to us that this is the 
only way to ensure openness and candour on the 
part of participants, and so effectively achieve the 
objectives of the study.
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professionals; it was therefore important for the 
diet and lifestyle interventions to map on to these 
aspects of routine practice. The standardised 
intervention arm followed the Pendleton et al.84 
model. The Pendleton model has two main 
components. The first component is to do with the 
nature of the consultation – the aim is to produce 
an effective consultation between practitioner and 
patient in which they work together, both to define 
the problem and decide the solution. The second 
component of the model is to do with the teaching 
method used during the consultation – Pendleton 
et al.84 describe a teaching method by which both 
the teacher and the learner enable the learner 
to build on his/her strengths and ability to be 
effective.
In the consultation there are a number of tasks:
•	 Understanding the problem:
 – the nature and history of the problem and 
its effects.
•	 Understanding the patient:
 – look at the problem from the patient’s 
perspective.
•	 Sharing the understanding:
 – consider other problems
 – consider options and implications.
•	 Sharing decision and responsibility:
 – enable the patient to manage the problem
 – choose the most appropriate course of 
action
 – practitioner and patient both have 
responsibility
 – agree goals.
Maintaining the relationship
It is by understanding the problem and the patient, 
and by sharing this understanding, that the 
health-care professional will be working towards 
fulfilling the aim of the first component one of 
the model: effective consultation. It is by using 
an educational style that allows the patient to 
build upon their existing abilities to manage the 
problem, rather than by telling the patient what 
to do, that the spirit of the Pendleton approach 
is upheld. The standardised intervention focused 
In this chapter we will look at the evidence that supported the design of the two diet 
and lifestyle intervention arms in LIFELAX. In 
essence, the lifestyle and nutritional guidelines 
that underpinned both the standardised and 
personalised intervention arms were the same and 
it was in the style and mode of delivery that the 
arms varied.
In LIFELAX, the model we adopted was one in 
which health-care professionals (usually practice 
nurses) were trained to deliver the diet and lifestyle 
interventions. The models of delivery of both 
the standardised and personalised interventions 
were informed both by theories of behaviour 
change and by considerations of the practicalities 
of implementing these interventions in the 
primary care settings. We invested a great deal 
of time, effort and resources in the intervention 
development phase, working closely with practice 
staff and patients in two local surgeries to inform 
the design of interventions that health-care 
professionals could deliver and wanted to deliver. 
During this pilot phase, patients were consulted 
and this feedback was used to inform the content, 
language and layout of the information booklets 
we developed.
Not all of the findings of the studies on behaviour 
change that we used to inform the intervention 
were appropriate for both arms. We were seeking 
to develop two notionally different interventions. 
One of the arms (standardised diet and lifestyle 
advice) needed to sit firmly within the current 
nursing model in the UK84 and be suitable for 
delivery within a routine appointment time 
(10 minutes). The other arm (personalised diet and 
lifestyle advice) would be informed by techniques 
and skills that had been shown to be effective 
in interventions of behaviour change in similar 
topic areas and similar populations to ours. (The 
contents of both the standardised and personalised 
manuals, along with the information leaflets, can 
be found in Appendix 3. Copies of the manuals 
and patient literature are available for purchase 
from the LIFELAX team.)
Motivating patients and facilitating health 
behaviour change are key roles for health-care 
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on enabling the practitioners to have the most 
up-to-date knowledge and information on 
constipation. One general PIL was developed for 
the standardised arm of the trial. The aim was 
to enable the practitioner to understand what 
constipation meant to their patient and to explore 
the options for management. The practitioner had 
10 minutes in which to see patients and to set goals 
for changes to their diet and lifestyle.
The personalised intervention arm drew on a 
range of models of behaviour change. It is the 
development of the resources, training and 
materials for the personalised intervention arm 
that is the main focus of the remainder of this 
chapter.
Theories and models of 
behaviour change
There is a wide range of conceptual models 
of behaviour change, such as Bandura’s Social 
Cognitive Learning Theory, Becker’s Health 
Belief Model, Azjen and Fishbein’s Theory of 
Reasoned Action, Prochaska and DiClemente’s 
Stages of Change Theory (discussed in greater 
depth in the section entitled Motivational 
interviewing, below) that can be applied to the 
primary health-care setting.139–141 When designing 
the interventions for LIFELAX we reviewed 
evidence from interventions, theories, techniques 
and counselling styles that had been used to 
encourage individual (patient) behaviour change. 
From the outset we were minded to produce 
interventions that would use techniques and skills 
already familiar to health-care professionals and 
that would be easily communicable to them so 
as to reduce any potential barriers and patient 
dissatisfaction that are documented to arise from 
poor communication.142
Interventions for behaviour 
change in healthy eating
From a review of literature indexed in MEDLINE, 
Web of Science and CSA Illumina on the 
effectiveness of interventions to promote healthy 
eating in the general population, it was apparent 
that there was a number of specific characteristics 
common to the successful interventions.140 
According to the review, any intervention, 
whether the focus was on diet alone or on diet 
and exercise, should be based on a model of 
behaviour change (i.e. it should be theory and 
goal driven) rather than simply on the provision 
of information. Successful interventions tended 
to be the ones that emphasised personal contact 
and were related to specific behavioural change 
strategies. Tailoring the intervention to the patient 
by using individualised personalised materials 
or using trained personnel to deliver a case by 
case intervention was also shown to be beneficial. 
Opening a dialogue between the health-care 
professional and patient that allowed for feedback 
on changes in behaviour (i.e. multiple contacts 
over an extended time period) was also found to be 
advantageous.
Physical activity 
interventions in primary 
care
In a review of primary prevention and secondary 
prevention interventions (12 and 24 studies, 
respectively),143 the authors identified several 
components of an intervention to promote physical 
activity that are likely to improve success (some of 
which had also been identified as being associated 
with successful interventions for dietary change), 
these include:
1. using behavioural approaches (individualised 
goal setting and problem-solving, self-
monitoring, feedback and reinforcement)
2. supervised exercise
3. provision of exercise equipment.
The concept of ‘self-efficacy’ was highlighted and 
shown to be closely linked to a stage of self-change 
in physical activity. Individuals at the different 
stages of preparedness to change have different 
‘degrees of exercise specific self-efficacy’.144 
Individually tailored reports and self-help manuals 
matched to the patient’s stage of motivational 
readiness to start physical activity were found to 
increase physical activity significantly more than 
standard self-help materials.145 A brief negotiation 
intervention, based on motivational interviewing, 
was found to be more effective than attempts to 
persuade or coerce.146
Interventions for elderly 
people living in the 
community
The decision to exclude non-community dwelling 
older adults from the LIFELAX study had been 
taken at the design stage as it was felt in residential 
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care people would have less control over what 
they ate, and therefore that there would be less 
opportunity for them to make lifestyle changes. 
As elderly people living alone in the community 
account for 80% of the lowest single household 
income groups147 it was important that the diet and 
lifestyle changes promoted by the interventions 
were not costly to the individual. There is a paucity 
of literature on interventions that are focused on 
community-based nutrition. From a review of 23 
such studies, none of which was from the UK (21 
from the USA, one in Australia and one in France), 
we concluded that there was limited evidence for 
the effectiveness of healthy eating interventions in 
the elderly.147 However, the review did find that the 
strategies of individual feedback and goal-setting 
highlighted previously142 were beneficial and were 
associated with a positive intervention.147 The 
review restated the fact that the elderly community 
dwelling population is a heterogeneous group and 
that more research is required to identify suitable 
approaches at different age groups, social class and 
health status.147
Primary care as a setting
Promotion of behaviour change 
in general practice
General practitioners have very little time with 
a patient to embark upon any programme of 
individual behaviour change. In the UK, people 
see a GP on average five times a year for an average 
consultation time of 9.4 minutes, which equates to 
47 minutes of contact time per year per patient.148 
This lack of contact time with the GP and the 
belief that the practice nurse was more likely to 
deal with patients with constipation added strength 
to the argument that it should be members of 
the nursing staff who were trained to deliver the 
intervention. Other studies149–151 have found that, 
although patients report high levels of satisfaction 
with both GP and nurse encounters, patients report 
greater levels of satisfaction with nurse consultation 
than with GP consultations. These studies found 
that there was no significant difference in other 
health outcomes and most found that consultations 
with nurses tended to be slightly longer than 
with GPs, that nurses gave more information to 
patients and that they offered more advice on 
self-care and disease self-management. These 
findings reinforced the choice of the practice 
nurse as the lead in delivering the diet and lifestyle 
interventions.
Based upon the knowledge that health-care 
professionals may not give advice during a 
consultation unless they understand and believe 
the information themselves,152 we decided to 
involve health-care professionals in the planning 
of the interventions and the production of the 
materials used.
There is good evidence for the use of counselling-
style interventions in promoting dietary change in 
primary care.153 Face-to-face dietary counselling 
either in small groups (two to three members) or 
individual sessions of 5 minutes (or less), which 
provided self-help material and interactive 
health communications, were viewed as being 
‘promising’.153 This review found that effective 
interventions are those that combine nutrition 
education with behaviour-orientated counselling 
to provide patients with the skills, motivation and 
support they require to make lifestyle adjustments. 
Examples include:
•	 teaching self-monitoring
•	 training individuals to overcome common 
barriers to eating a healthy diet
•	 goal-setting
•	 shopping and food preparation guidance
•	 intratreatment social support.
The above recommendations were incorporated 
into the interventions.
A systematic review of 37 trials (10 dietary and 
six exercise behaviours) concluded that primary 
care-based health programmes do have a modest 
and variable effect on lifestyle change.154 From 
this review, it was, however, difficult to draw 
any meaningful conclusions from the dietary 
trials as the interventions varied widely. Exercise 
interventions showed promising evidence of their 
effectiveness.
Though the importance of nutrition is not disputed 
by primary health-care professionals, there are 
a number of barriers that are known to restrict 
their provision of nutritional counselling. These 
include lack of time, lack of training in behaviour 
change,155 a belief that patients will not follow their 
advice, a lack of reimbursement for counselling 
and inadequate teaching materials.156 As described 
in Chapter 4, despite our best efforts to address 
all of these in the interventions we designed and 
the support we provided, these barriers are highly 
resistant to change.
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The practitioner, patient and 
concordance with regimens
Only about one-half of patients comply with 
long-term drug regimens and even fewer comply 
with changes in lifestyle, especially when an 
advice giving approach is used.157 The dominant 
paternalistic style of a physician (or other health-
care professional) giving their patient advice is 
often not a suitable model for chronic disease 
management or health promotion. The model 
of a ‘meeting between experts’, where both the 
patient and health-care professional are considered 
to be experts on the patient’s problem, and 
changes are negotiated to enhance the patient’s 
well-being, is a more successful approach.157 
Motivational interviewing is one such negotiation-
based strategy; it is very much a ‘client’-centred 
approach (discussed below) and enables health-
care professionals to share information and offer 
suggestions.
Delivery methods for behaviour 
change
With the absence of standardised definitions of 
the techniques included in behaviour change 
interventions, it is difficult to both replicate 
effective interventions and identify the techniques 
contributing to effectiveness across interventions.158 
At the outset we need to make it clear that the 
approaches or methods described below are not 
mutually exclusive. Many of the techniques and 
practitioner skills are common to several or all of 
the techniques, and are those shown to be effective 
in previous studies of interventions designed to 
promote individual behaviour change in diet, 
physical activity, etc. as described above. They also 
have a theoretical underpinning in models and 
theories of behaviour change. LIFELAX made 
use of a combination of the approaches outlined 
below to develop the most practical approach to 
the development and delivery of personalised diet 
and lifestyle advice by nurses in the primary care 
environment.
Tailored information
There are two main forms of health 
communication – targeted generic and tailored 
communications.159 ‘Targeted generic’ information 
is defined as material intended to reach a specific 
subgroup of the general population, based 
on one or more demographic characteristics, 
while tailored information is designed to reach 
one individual, and is derived from individual 
assessment and is unique to that individual. 
Generic information is less costly to produce than 
tailored information, although there is evidence 
of the success of the use of tailored information 
disseminated using a variety of communication 
methods including the telephone, audio, video, 
internet or other electronic media.159 A review of 
eight tailored/generic comparisons found evidence 
that tailored personalised communications 
were more effective than generic, non-tailored 
communications;160 therefore, in the personalised 
arm of LIFELAX all communications were suitably 
personalised (targeted to the individual).
Motivational interviewing
While motivational interviewing holds ‘substantial 
promise for health behaviour change’, is patient 
centred, can be tailored to the patients degree for 
readiness of change and is an effective means for 
working with patients who are ambivalent or not 
ready for change, it should be added as a note of 
caution that few controlled studies measuring the 
efficacy of motivational interviewing exist, and 
little is known about how to structure sessions.161
Motivational interviewing is ‘a directive, client 
centred counselling style for eliciting behaviour 
change by helping clients to explore and resolve 
ambivalence’.162 Motivational interviewing has four 
principles:163
1. expressing empathy
2. developing discrepancy
3. rolling with resistance
4. supporting self-efficacy.
Table 7 shows the characteristics of what is and 
what is not a characteristic of motivational 
interviewing.
Motivational interviewing is not defined as a 
technique per se but rather by ‘its spirit as a 
facilitative style for interpersonal relationship(s)’.162 
This ‘spirit’ involves collaboration between health-
care professional and patient. The health-care 
professional elicits the motivation to change 
from the patient, through drawing on their 
patient’s own perceptions, goals and values, while 
the responsibility for change remains with the 
patient.163 The focus of the motivational interview 
is to examine and resolve ambivalence, defined as 
a key obstacle to change, in a patient-centred and 
directive manner.162
Although not explicitly based on any specific 
theory of behaviour change, motivational 
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interviewing has been linked with the 
Transtheoretical Model of Change,164 which assists 
by ‘providing a framework for understanding 
the change process itself ’, whereas motivational 
interviewing provides ‘a means of facilitating 
this change’.161 The combination of motivational 
interviewing with the Transtheoretical Model has 
been described as an ‘optimal patient encounter’.142
Because the notion of a readiness to change 
is important in all motivational interviewing 
approaches, including ‘brief motivational 
interviewing’, it is necessary to have a working 
understanding of the Transtheoretical Model 
(Figure 1).165
Debate as to the merits of the Transtheoretical 
Model as a predictive or descriptive model is 
beyond the scope of this report; suffice to say that 
this is a model with which health-care professionals 
are familiar, and it provides a useful lexicon to 
describe people as they undergo a behaviour 
change intervention. The rationale behind this 
model is that behaviour change does not happen in 
one step. People tend to progress through different 
stages on their way to successful behaviour change. 
People also progress through the stages at different 
rates. Expecting behaviour change from someone 
who is still in the ‘pre-contemplation’ stage is 
unlikely because, when in this stage, the individual 
is not ready to change. Decisions as to when to 
move through the stages (i.e. when a stage is 
complete) must be made by the patient, as opposed 
to being imposed by the health-care professional. 
In each of the stages there is a different set of 
issues and tasks that relate to changing behaviour. 
The health-care professional can use different 
tools and techniques at each stage.
The focus of traditional medical consultations 
regarding behaviour change is ‘advice giving’. 
As discussed above, this paternalistic approach 
is not always the most effective mechanism and 
may be met with resistance and disagreement 
between patient and practitioner.166 In behaviour 
change interventions, ambivalence to change is 
an often encountered problem. Ambivalence to 
change can be characterised as a conflict between 
two courses of action (patient and counsellor). It 
is difficult to resolve as each party has benefits 
and costs associated with the behaviour change.166 
This is particularly true when a directional 
(e.g. advice giving) approach, with unequal 
partners, is adopted, rather than a negotiated 
strategy. Motivational interviewing, although it 
uses a non-directive counselling approach, is a 
negotiated approach and does focus explicitly 
on ambivalence and the resolution of it.167 The 
practitioner can positively or negatively influence 
their patient’s resistance to change and the 
outcome of the consultation. Negotiations in which 
the patient expresses his/her perceptions of the 
costs and benefits of change have been shown to 
promote the patient’s motivation to change.166 
Behaviour change interventions that tailor 
advice to the patient’s readiness to change should 
ensure closer agreement between patient and 
practitioner, encounter less resistance and improve 
the effectiveness of the intervention.166 The most 
successful use of motivational interviewing is 
when the patient is given individual, personalised 
feedback.168
While we knew that some of the practice staff 
involved in the LIFELAX intervention delivery 
would have a specific interest or experience in 
constipation or GI conditions, there was good 
evidence to suggest that motivational interviewing 
could also be successfully used by health-care 
professionals that were non-specialist in a specific 
field.169
TABLE 7 The characteristics of motivational interviewing
Motivational interviewing Opposite to motivational interviewing
Collaboration
Partnership conducive to change
Confrontation
Ignoring patient’s perspective
Evocation
Intrinsic motivation to change is drawn from patient’s own goals
Education
Aim of the practitioner is to educate the patient for change to 
occur
Autonomy
Patient-led self-direction
Authority
Practitioner tells patient what to do
Adapted from Miller and Rollnick.163
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Despite these theoretical benefits of motivational 
interviewing, we were aware that the most limiting 
factor in using motivational interviewing in a 
medical or public health setting is time,170 in 
particular the length of time available in the 
‘normal’ appointment slot for either GPs or 
practice nurses. For LIFELAX, therefore, we 
recognised that a briefer format of motivational 
interviewing would be required. Within the time 
constraints of the normal encounter with a practice 
nurse, we felt that there might not be sufficient 
time to fully explore the patient’s ambivalence. 
We were also aware that asking health-care 
professionals to adopt the LIFELAX intervention 
protocols may require some adjustment from 
the traditional prescriptive methods of patient 
education (i.e. provision of advice) to becoming 
more facilitative and collaborative.170 Health-care 
professionals delivering the interventions in the 
trial would be required to leave their traditional 
‘expert’ role and allow the patient to become the 
expert.167
Brief motivational interviewing
Brief motivational interviewing techniques have 
been used with success in brief interventions in 
primary care in a range of topics, for example 
perinatal drug use,171 to improve dietary 
adherence in adolescents172 and psychiatric 
patients’ attitudes to their care, motivation to 
change, compliance and outcome.173 There are 
a number of key elements that characterise a 
successful brief intervention and these should be 
apparent to anyone observing such a consultation. 
Contemplation
Decision
Action
‘I’m doing something about it now’
Maintenance
Long-term change
Relapse
Precontemplation
‘What problem?’
FIGURE 1 The Transtheoretical Model. Adapted from Prochaska and DiClemente.165
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These elements are represented by the acronym 
FRAMES.174
•	 Feedback Systematic assessment and feedback 
of individual findings.
•	 Responsibility Emphasising the individual’s 
personal responsibility for change, that this 
change is a free choice and a personal decision
•	 Advice Advice giving consists of two negative 
factors: first, it provides the patient with 
information (usually using tactics of fear 
induction), and, second, it uses persuasion (why 
a patient should do what you tell them).
•	 Menu The variety of ways in which change 
could be accomplished.
•	 Empathy Style of counselling.
•	 Self-efficacy Intervention should contain 
elements to strengthen the individual’s self-
efficacy.
Despite ‘advice’ being a key element, it is important 
to recognise that ‘brief motivational interviewing’ 
consultations are not in the traditional advice-
giving mould; advice is not given without the 
patient’s permission, and when advice is given it 
needs to be accompanied by encouragement for 
patients to make their own decisions.161
Brief motivational interviewing was developed for 
use in a medical setting, where most patients do 
not enter in a state of readiness to change.175
An implication of the Transtheoretical Model is 
that, before attempting to give people the skills 
and resources needed to change their behaviour, it 
may be more effective to assess their readiness to 
change. A person’s preparedness to change can be 
assessed accurately by the use of a questionnaire;176 
however, this is likely to prove to be impractical 
in a routine clinical setting. Other useful tools to 
assess readiness to change, including an agenda 
setting chart (Figure 2), a ‘pros and cons’ chart 
(Figure 3) and a readiness-to-change ruler (Figure 
4), have also been developed.177 In LIFELAX we 
produced an agenda-setting chart that allowed 
patients to address constipation-specific factors 
(known to impact on bowel health), such as 
exercise, diet and fluid, as well as three open 
options where the patient could identify their own 
priority areas. In the intervention, patients were 
encouraged to identify their own priority items 
and set achievable goals when they were ready 
(Figure 5).178 We understood that patients might 
well have had a rigid mental picture as to the 
consultation that they should expect when they 
underwent the intervention. We were aware that 
changing the consultation process and associated 
behaviours might not be easy; however, we felt that 
the simplicity of the agenda-setting chart, and its 
ability to help patients express choice and take 
the lead in target-setting, would make it a useful 
instrument.178
In order for behaviour to change, a person needs 
be motivated to change their behaviour and feel 
confident to do so. Motivation can be defined 
as the individual’s expectations of the costs and 
benefits of change, whereas confidence may be 
described as their ability to master the demands 
of assistance. Bandura’s Self-Efficacy Model and 
the distinction between outcome and efficacy 
expectation provide a theoretical framework 
to use motivation and confidence.179 Exploring 
the importance of changing a behaviour with 
the patient is an important exercise. For this 
exploration, a ‘pros and cons’ chart was developed 
(see Figure 3). Using this chart it is possible to 
explore and record the positives of making a 
behaviour change and staying the same. Below is a 
worked example.
Confidence to change can be assessed simply by 
asking two questions:180
1. ‘If on a scale of 1–10, where 1 is not at all 
motivated to eat more fruit and 10 is 100% 
motivated to eat more fruit, what number 
would you give yourself at the moment?’
2. ‘If you were to decide to eat more fruit now, 
how confident are you that you would succeed? 
If, on a scale of 1–10, 1 means that you are not 
at all confident and 10 means you are totally 
confident that you could eat more fruit, what 
number would you give yourself now?’
After the topic (eating more fruit) had been raised, 
the aim of the next stage would be to identify 
arguments for change (motivation) and practical 
steps to make the change (confidence); this could 
be done through scaling questions
•	 First, by asking the patient why they scored as 
they did rather than a lower number:
 – ‘Why have you given yourself a score of 6 
and not 1?’
•	 Second, by asking the patient what would need 
to be in place for them to move to a higher 
number:
 – ‘What would have to happen for your 
motivation score to move up from 6–9?’ 
‘How could your confidence score move up 
from 5–8 or even 9?’
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This information would then be incorporated 
into the ‘setting aims and plans’ sheet (Figure 5) 
as part of the ‘contract’ between the patient and 
health-care professional during the LIFELAX 
personalised intervention counter between the 
patient and health-care professional. Patients 
would take a copy of this away and a copy would 
also be retained in the practice for future reference 
in terms of follow-up telephone calls and follow-up 
visits.
Counselling
Counselling is defined as a ‘cooperative mode of 
interaction between the patient and primary care 
Staying the same Changing
Pros I wouldn’t have to change a thing I could do without my laxatives
Cons I’d still need my laxatives every day I would have to change my diet
FIGURE 3 LIFELAX pros and cons chart.
FIGURE 2 LIFELAX agenda setting chart.
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1 2 3 4 5 6 7 8 9 10
Not motivated
Not confident Confident
Motivated
Motivation scaling ruler
1 2 3 4 5 6 7 8 9 10
FIGURE 4 Scaling tools.
FIGURE 5 Setting aims and plans.
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physician or related health-care staff members to 
assist patients in adopting behaviours associated 
with improved health outcomes’.181 Improved 
behavioural outcomes in dietary counselling are 
thought to be associated with a number of factors, 
including the use of dietary assessment, enlisting 
family involvement, providing social support, using 
group counselling, emphasising food interaction 
(tasting, testing and cooking), encouraging goal 
setting and using advice appropriate to the patient 
group.182
In a review of 21 studies, focusing on the 
counselling effect on changes in fat, fruit, 
vegetable and fibre intake, higher-intensity 
interventions, (more than one 30-minute contact) 
were found to be more effective than lower-
intensity interventions.181 Counselling interventions 
using self-help material and interactive 
communication alongside brief provider advice 
seemed to produce medium changes. Elsewhere, 
behavioural counselling to increase fruit and 
vegetables consumption have also been shown to 
be effective.183 The PILs were designed to enable 
respondents to think about their current practice 
and to compare this with recommendations. For 
example, the PIL on ‘Fluid and constipation’ 
contained a fluid counter, the ‘Fibre and 
constipation’ PIL contained a fibre counter, and the 
‘Activity and constipation’ PIL, an activity counter.
Behaviour change counselling
In addition to the principles of (brief) motivational 
interviewing, and the models and theories that 
underpin (brief) motivational interviewing (the 
Transtheoretical Model, and Bandura’s Self-
Efficacy model), the personalised diet and lifestyle 
arm of LIFELAX also drew heavily on the BCC 
model. BCC184 is a set of consulting strategies 
derived from the patient-centred method,185 
health behaviour change184 and motivational 
interviewing.163 See Table 8 for a summary of the 
characteristics of BCC. As we described above, 
motivational interviewing is a directive, patient-
centred counselling style for increasing intrinsic 
motivation by helping patients explore and resolve 
ambivalence. Being ‘patient-centred’ involves a 
number of factors:
•	 It is an active process that involves both patient 
and practitioner.
•	 There is a core partnership between patient 
and practitioner.
•	 It is not directional advice giving.
•	 Careful listening – listening to the patient to 
learn from them.
•	 The patient has greater control in decision-
making.
•	 The practitioner and the patient reach joint 
decisions together.
Behaviour change counselling, like motivational 
interviewing and brief motivational interviewing, 
has been developed for brief health-care 
consultations to help the individual talk through 
the ‘why’ and ‘how’ of change. The practitioner’s 
main task is to understand how the person is 
feeling and his/her plans for change.40
TABLE 8 The characteristics of BCC
Goals Establish rapport, identify goals, exchange 
information
Choose strategies/goals based on individual’s 
readiness
Build on motivation for change
Style Practitioner – patient both active
Seldom confrontational
Use of an empathic style, information is 
exchanged
Skills Ask open-ended questions
Summaries
Ask permission
Encourage patient choice and responsibility
Provide advice
Reflective listening
Adapted from Rollnick et al.184
As in motivational interviewing and brief 
motivational interviewing, establishing rapport 
is an essential component of BCC consultations. 
Once rapport is established, two-way information 
exchange tends to occur more readily. Establishing 
the patient’s readiness for change and what 
behaviour to focus on are also parts of the BCC 
approach. Establishing and agreeing goals and 
strategies for behaviour change should involve the 
patient setting realistic aims and plans that can be 
achieved. The consultation is an active process that 
involves both the patient and the practitioner; it 
should be collaborative, rather than prescriptive, 
and should be non-confrontational. By the 
professional asking permission to discuss a topic 
during a consultation, the patient will not feel it 
has been forced upon them.
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Empathy – which can be defined as: ‘the ability 
to share someone else’s feelings or experiences 
by imagining what it would be like to be in their 
situation’186 – is a further core skill of the BCC 
process. This includes empathic listening, an 
active listening process, and demonstration that 
the professional is indeed listening, by replying 
and reflecting to what the patient has just said. For 
example:
Patient: ‘Being constipated makes me 
feel lethargic, I can’t be bothered doing 
anything and I am scared of leaving the 
house.’
Practitioner: ‘Your constipation makes it 
difficult for you to be more active – that 
must be hard.’
The BCC interviewing style is one that ‘quiet and 
curious’ – allowing the patient to do more talking, 
using open-ended questions, rather than closed 
questions.184 Empathic listening, reflection and 
summaries are useful in rapport building and 
also ensure that aims are understood by both 
patient and practitioner. The practitioner provides 
structure to the consultation but decision-making 
should be shared184 (Figure 6 – suggested BCC 
consultation ‘flow’) and should be the patient’s 
choice as well as their responsibility. In BCC, 
as in motivational interviewing, it is vital that 
practitioners avoid falling into a paternalistic, 
directional advice-giving trap. Evidence suggests 
that this generally does not induce behaviour 
change.184 When advice needs to be given, a more 
positive form of advice giving is giving a number 
of options, with the patient choosing the most 
suitable one.
FIGURE 6  The BCC consultation ‘flow’.
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The key principles that 
underpinned the LIFELAX 
personalised intervention
•	 Individualised goal identification.
•	 Realistic goal setting.
•	 Practitioner listening to the patient.
•	 The intervention being directed by the patient.
•	 Setting and following up the patient’s 
individual goals, using a range of novel tools: 
the agenda-setting chart, the scaling tools, 
the ‘pros and cons’ sheet and the goal-setting 
sheet.
•	 Monitoring of patient’s progress using 
specifically developed PILs containing tools, 
such as a fluid counter, fibre counter, measures 
of physical activity.
•	 A user-friendly and accessible practitioners’ 
manual that had all necessary trial 
information, and set out clearly and concisely 
what was required in the intervention.
•	 Training materials and resources.
From visiting practices and speaking to 
practitioners, the study team established that 
there was a scarcity of independent constipation, 
diet and lifestyle PILs, with the majority being 
produced by drug companies and laxative 
producers. A comprehensive suite of materials 
and resources was developed to enhance the 
LIFELAX interventions. We worked closely 
with patients and health-care professionals to 
develop many of the tools and the information 
materials needed. For example, we used cognitive 
interviewing techniques to test the acceptability 
and comprehensibility of the PILs (from text to 
pictures) and thereby to ensure their relevance and 
acceptability to the target audience.119
High-quality training and reference manuals 
for health-care professionals were produced for 
both the standardised and personalised diet and 
lifestyle intervention arms. These contained the 
entire set of information (see Chapter 1, Impact of 
diet and lifestyle on constipation) that health-care 
professionals would need about constipation and 
bowel health, as well as full details of the delivery 
style and techniques for the appropriate arm.
Training of practice staff was envisaged to take 
place over a number of visits (one to two) for 
the standardised arm and (two to three) for the 
personalised arm. The training sessions were 
conducted by the project dietitian and nutritionist. 
As we were aware that we might be asking 
practitioners to change their consulting behaviour, 
this training drew heavily on the behaviour change 
techniques we were passing on for LIFELAX. 
However, after much discussion within the team 
it was agreed that there would be no formal 
assessment of the any health-care professional’s 
preparedness to change their own consulting 
behaviour.
The time available to train health-care 
professionals in the intervention techniques 
was always an issue in this trial; however, 
the importance of training cannot be over 
emphasised.167 We needed to be flexible and 
to tailor our training to fit in with the practice 
schedule. There is evidence that training based 
upon two or three 1- to 1.5-hour training sessions 
and role play demonstrations is successful.177 We 
were told by the practices involved in developing 
the interventions that practice nurses would not 
readily enter into or enjoy role play, especially if 
senior colleagues were to be involved or observing. 
As a result of this, we elected to produce training 
DVDs in place of the role play. Evidence suggests, 
too, that outside of the training sessions few of the 
health-care professionals were willing to practice 
the training and techniques.177 For this reason, we 
felt that the DVD would serve as a useful resource 
and aide-memoire.
Our experiences of practice training varied from 
practices that set aside the majority of a day for 
training to ones that required us to fit in with 
lunch breaks. Having project staff (a research 
dietitian) that were sympathetic to and understood 
the dynamics of working in a primary care 
environment was seen as an advantage.
We felt it important that staff should have a 
positive experience from the training, and worked 
to create sessions that were informative, interesting 
and with clear useable learning outcomes. We 
felt that our training DVD helped to avoid the 
embarrassment of role play and the unfeasibility of 
offering staff ‘refresher’ courses.
Novel ways for engaging practice staff and 
assessing their knowledge of the condition were 
used, for example we used the quiz show formats 
of ‘Who Wants to Be a Millionaire’ and ‘The Weakest 
Link’ rather than a more formal assessment or 
lecture. A lecture would imply they may not know 
how to deal with constipation, whereas the quiz 
format was a two-way process that facilitated 
discussions and information exchanges.
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Summary
In designing both the standardised and 
personalised diet and lifestyle interventions for 
LIFELAX there were a number of theoretical 
models that we could have potentially chosen 
on which to base our materials, methods and 
resources. The standardised approach made use 
of the existing nursing model in use in primary 
care as the basis for those appointments. For 
the personalised intervention arm, we reviewed 
a number of trials that had successfully used a 
number of different models and techniques to 
deliver behaviour change with respect to diet, 
physical activity and other aspects of lifestyle. We 
drew on the recommendations from those papers 
and from other practising health-care professionals 
to produce training, training materials and 
literature, the likes of which were not otherwise 
available to practitioners in the UK.
Copies of the resource packs, PILs and training 
DVD are available for purchase from the central 
trial team.

DOI: 10.3310/hta14520 Health Technology Assessment 2010; Vol. 14: No. 52
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
37
Chapter 4  
Implementation of the trial
secondary care. Added to this ‘standard’ challenge 
of primary care research, LIFELAX also coincided 
with a period of considerable change within the 
NHS, both in terms of the emergence of a new 
research governance and ethics framework and the 
implementation of new GP contracts.
Regulatory approval
Although LIFELAX began after the publication 
of the EU Clinical Trials Directive, it was prior to 
the Directive’s enactment into UK law. This meant 
that although the LIFELAX trial appeared to meet 
the criteria for a clinical trial of an investigative 
medicinal product (ctIMP) we were able to apply 
for a Doctors’ and Dentists’ Exemption (DDX) 
certificate when obtaining regulatory approval 
from the Medicines and Healthcare products 
Regulatory Agency (MHRA). This meant that 
we did not need to submit a full application for a 
Clinical Trial Authorisation (CTA) to the MHRA. 
In common with all other trials at the time, the 
DDX was issued and was then ‘rolled over’ into a 
CTA on 1 May 2004. (With hindsight it would seem 
that the study could have made the case to the 
MHRA that the study was a trial of management 
strategies, rather than specific drugs. However, the 
general advice we received was that if there was 
any possibility of a study being a ctIMP the DDX/
clinical trial exemption route should be followed 
to avoid the additional paperwork associated with 
obtaining a CTA.)
MREC approval
An overview of the time line for the trial is shown 
in Table 9. The initial ethics application was 
submitted to the allocated MREC in December 
2003, at which time the subsequent approval of 
the LREC associated with each participating 
site was required, unless a ‘no local investigator’ 
(NLI) status was agreed by the MREC. To reduce 
the burden on the multiple GPs who were to be 
recruited to this study, we asked the MREC to 
consider NLI status for LIFELAX. Unfortunately, 
NLI status was not granted. The MREC reviewed 
the application on 22 January 2004. A number 
Introduction
In this chapter we will describe the challenges 
encountered during the implementation of 
LIFELAX. These challenges arose both with the 
recruitment of practices and of patients. The 
planned recruitment model described in Chapter 
2 (which formed the original study protocol) and 
the account of the reality presented here differ 
widely. Various reasons for the challenges will be 
documented in this chapter and the embedded 
Process Evaluation Study (see Chapter 6) offers a 
further interpretation on this account.
In summary, some 1114 practices in total were 
approached and invited to participate. Of these, 
44 ( just under 4% – 13 short of our target of 
57) agreed to participate and were randomised. 
However, only 19 practices (43% of those 
randomised – 33% of the target of 57) recruited 
participants to the trial; 16 practices withdrew post 
randomisation and six practices were unable to 
recruit during the time frame available. Figure 7 
presents the CONSORT diagram for the trial.
A total of 154 participants were recruited to 
LIFELAX. Initial calculations showed that in order 
to recruit the required number of participants 
(approximately 1800) for the trial we would need 
to recruit 57 GP practices (31 patients per practice 
on average). This would seem now to be a vast 
underestimate, given the poor levels of participant 
uptake we experienced.
Preparation and 
implementation of the trial 
protocol
For the findings of clinical trials such as LIFELAX 
to be generalisable across primary care (i.e. to have 
external validity), it is important for the amount 
of research and the proportion of research-active 
primary care staff, in particular GPs, to increase.187 
Increased participation in primary care trials is 
a priority in the UK,188 even although such trials 
have always been more challenging to researchers 
than trials in alternative environments, such as 
the more controlled and more research-orientated 
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FIGURE 7 LIFELAX CONSORT diagram. a, Although not all consented participants received the allocated intervention they were 
eligible for a baseline assessment; therefore n = 154 is used in the analyses of baseline data. b, Not all withdrawals were complete 
withdrawal from all follow-up assessments; consequently, some participants supplied questionnaire data and not diary data, and 
some participants agreed to telephone follow-up only.
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of minor changes were requested in the patient 
information sheets. The MREC delegated authority 
to their ‘lead reviewers’ for this application 
to approve these amendments once they had 
been received. The formal letter conferring the 
favourable opinion of the MREC was issued on 12 
March 2004.
The LIFELAX trial team had concerns over the 
burdensome nature of the recruitment protocol 
submitted to MREC as part of the approval 
process. This method had been approved by 
another MREC for the STOOL trial.19 The 
approval process for STOOL had taken 15 months, 
and we were concerned that any deviation in 
LIFELAX from an already approved method 
might lead to unnecessary delay. [At this time 
there were many changes in the research ethics 
committee (REC) approval process. Many of the 
recruitment strategies that had been acceptable 
in earlier studies were deemed to be no longer 
so. It is in the context of this changing landscape 
and inconsistencies across RECs that LIFELAX 
operated.]
LREC approval
As LIFELAX was not able to operate as a NLI 
study, an extra level of approval was required 
before recruitment could begin. LRECs treated 
each general practice recruited into the study as 
a separate ‘site’ and required the submission of a 
separate SSA, accompanied by the CV of the GP 
taking on the role of principal investigator (PI) 
for that site, before they would consider that site 
for approval. The process was made additionally 
burdensome to GPs as it required that each local 
PI should apply for an LREC number, complete 
and sign the relevant form and send it to the 
appropriate LREC. These requirements created 
a number of difficulties: many GPs did not have 
readily available CVs of the type required; many 
GPs were unfamiliar with the new LREC forms 
and processes and did not have sufficient time to 
carry out these tasks; and others felt that they did 
not wish to be designated as responsible for a study 
that ‘wasn’t theirs’ and felt that responsibility for 
the study lay with the research team.
To facilitate this process we designed a short CV 
template that would allow GPs to provide us with 
the minimum amount of information required 
for LREC to carry out the SSA. Having heard 
anecdotal evidence/horror stories of trials that 
needed SSAs spending > 7 months on this part of 
the approval process alone, we made an approach 
to our MREC, the local COREC manager and 
the Director of NoReN (the local primary care 
research network) with an innovative solution.
The COREC guidelines at the time stated that 
if two or more GP practices had contracted to 
conduct research collaboratively, whether through 
a consortium or under the direct management 
of the PCT, they could be collectively identified 
as a single site and, in such cases, one of the 
investigators should be appointed as the PI for the 
site. Our solution to the local approvals dilemma 
proposed that NoReN (an inclusive organisation 
for all north-east general practices, not requiring 
any practice to ‘opt in’) should form the consortium 
with the other recruiting practices in the area, 
with the clinical director of NoReN (GR, already a 
coinvestigator on the study) acting as the PI for the 
purpose of the SSA.189 This solution was accepted, 
and notification that the various LRECs had 
approved LIFELAX to run in the ‘Area 1’ PCTs 
came via MREC on 10 November 2004.
Although LIFELAX pioneered this approach, 
allowing us to speed up the SSA process in the 
areas covered by NoReN, we were not entirely 
happy with it as a model outside the NoReN 
area. Although successful in Cumbria with the 
CumbReN network (again with the CumbReN 
director acting as PI for the consortium), there 
was a concern that should the trial seek to recruit 
further afield the directors of other GP research 
networks might not agree to take responsibility as 
PI for the sites within their network’s geographical 
area. In light of this concern we again approached 
MREC and asked them to reconsider the ‘NLI’ 
status of LIFELAX. At the time of this final 
approach, the ‘NLI’ status for trials had ceased 
to exist. By this time, the LREC approval process 
required site-specific information (SSI) to be 
submitted to LREC as part of the local approval 
process or, in certain circumstances, an SSI 
exemption could be claimed. After consultation 
with the local COREC manager and the agreement 
of the COREC policy officer to support the MREC 
decision to support the SSI exemption, should it be 
granted, an approach to MREC for SSI exemption 
was made in October 2005. We argued that the 
LIFELAX was a ‘low-risk’ study, the prescribing 
of laxatives was in line with normal practice (with 
no stipulation on class or dosage) and that the 
behaviour change techniques were often used in 
routine practice.
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After agreeing that LIFELAX was a ‘low-risk’ 
study, MREC considered that it could be an ‘SSI-
exempt’ trial (favourable opinion 12 October 
2005), which meant that sites no longer needed a 
GP to act as a PI and that no application to LREC 
for approval of sites (or consortia thereof) needed 
to be made.
TABLE 9 Timeline for the trial
Month (duration 
in months) Activity or comment
June 2003 (1) Trial manager begins work on LIFELAX (tasks include securing LREC and Trust R&D approval 
for pilot, preparing the pilot study materials, training in pilot study research methods, and 
preparation of the documentation and materials needed for the MREC approval application)
Dietitian appointed and begins work (full time)
July 2003 (2) Dietitian reduces hours to part-time for personal reasons (work continued on developing the 
materials for the intervention and dietitian is trained in cognitive interview techniques)
October 2003 (4) Dietitian returns to full time. Applications for NHS honorary contracts made
November 2003 (5) LREC approval for pilot study, R&D approval given for pilot
December 2003 (6) MREC application submitted
March 2004 (9) Favourable opinion from MREC received; work begins on various LREC applications (i.e. SSAs); 
ad hoc funding is sought from the DH to ‘pay per patient’ recruited via the SfS funding stream
April 2004 (10) Diet and lifestyle leaflets completed for the intervention
May 2004 (11) Pilot for nurse training begins; PCT/GP meetings attended by trial manager in order to promote 
LIFELAX and generate interest; ad hoc funding is secured
Negotiations with COREC re. practices being ‘research consortia’ with one PI begin
July 2004 (13) PCT/GP presentations continue; application made to LRECa and PCTs for R&D approval
August 2004 (14) Pilot of nurse training completed; printing of ‘packs’ and associated intervention materials; 
training DVD produced
October 2004 (16) COREC manager supports our attempt to gain SSA exemption
November 2004 (17) Practice recruitment and staff training begins (area 1); the electronic query is run to identify 
patients
February 2005 (19) Follow-up telephone calls begin to practices to discover why there was little interest in the 
study
March 2005 (20) Work continues on promoting the trial and looking at ways of making it less burdensome to 
practices
May 2005 (23) First training visits to practices arranged (area 1)
June 2005 (24) Application to MREC made to revise recruitment protocol. Favourable opinion given (20 June 
2006); application to revise the ad hoc funding in line with protocol revisions made
July 2005 (25) Application made to HTA for 22-month extension; six participants consented
August 2005 (26) 10 participants consented
September 2005 (27) Five participants consented
October 2005 (28) Three participants consented; SSA exemption given by MREC
November 2005 (29) Recruitment of practices begins (area 2)
Four participants consented
December 2005 (30) Eight participants consented
January 2005 (31) Eight participants consented
March 2006 (33) Three participants consented
April 2006 (34) Eight participants consented
May 2006 (25) Nine participants consented
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PCT selection and R&D 
approval
Selection and recruitment of 
PCTs
Primary Care Trusts in north-east England, 
Yorkshire and Cumbria were initially allocated 
between the STOOL and the LIFELAX trials. 
STOOL was allocated some of the more 
geographically distant Trusts (Cumbria & 
Yorkshire) as we believed fewer visits were needed 
to practices to set up that study, as there was no 
requirement to train practices in the delivery of 
the stepped-drug-regimen intervention. Training 
for the diet and lifestyle interventions meant that 
LIFELAX practices would require many more visits 
so Trusts closer in proximity to Newcastle upon 
Tyne were prioritised for that study.
LIFELAX initially sought PCT research and 
development (R&D) approval from 11 local PCTs 
(area 1 recruitment) (all PCT names that follow 
refer to the PCTs in existence at the time of 
practice recruitment – since that time there have 
been a number of mergers and a reduction in the 
overall number of PCTs): Newcastle; Gateshead; 
South Tyneside; Northumberland; Durham & 
Chester-le-Street; North Tees; Derwentside; 
Sedgefield; Craven; Harrogate & Rural District; 
Scarborough; Whitby & Rydale, and Hambledon 
& Richmond. Across these 11 PCTs there was a 
total of 308 practices available to us. We were able 
to contact only 306 of them for the trial, as two of 
the practices had been involved in the both the 
development of the diet and lifestyle interventions 
and taken part in the STOOL trial qualitative 
study and we were keen not to overburden their 
staff and patients. Due to poor GP response rates 
(14 practices) from this first wave of recruitment, 
it became necessary for LIFELAX to expand its 
recruitment area.
In a bid to capitalise on the increased profile of 
constipation raised by the STOOL trial and to 
Month (duration 
in months) Activity or comment
June 2006 (36) Approach made to SPPIRe to recruit practices in Scotland; approach to MREC to change the 
face-to-face baseline assessment to a telephone assessment
10 participants consented
July 2006 (37) Favourable opinion from MREC received
Seven participants consented
August 2006 (38) Nine participants consented
September 2006 (39) Three participants consented
October 2006 (40) One participant consented
November 2006 (41) Five participants consented
January 2007 (43) Recruitment in area 3 begins
February 2007 (44) Two participants consented
March 2007 (45) Three participants consented
May 2007 (47) The TSC met and discussed whether there was a viable future for the trial; HTA briefed of the 
intention to reconvene in October 2007 to make the final decision over a further extension or 
close down
Five participants consented
June 2007 (48) Two participants consented
July 2007 (49) 27 participants consented
August 2007 (50) Five participants consented
October 2007 (52) TSC make the close-down decision; recruitment is halted; participants already in the trial are to 
be followed up as per protocol
DH, Department of Health; HTA, Health Technology Assessment programme; R&D, research and development; 
SPPIRe, Scottish Practices and Professionals Involved in Research; TSC, trial steering committee.
a NoReN director agrees to act as PI. Any site joining the trial is part of the NoReN research consortium.
TABLE 9 Timeline for the trial (continued)
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take advantage of the STOOL trial manager’s 
local knowledge, it was agreed that once it had 
closed down [the Trial Steering Committee 
(TSC) agreed the closure of the STOOL Trial 
in May 2005] LIFELAX would contact those 
PCTs originally selected for ‘STOOL’. Thus, in a 
second recruitment wave, we approached North 
Tyneside, Sunderland, Langbaurgh, Durham 
Dales, Easington, Hartlepool, Middlesbrough, 
Darlington, East Yorkshire, Yorkshire Wolds and 
Coast, West Cumbria, Eden Valley, Carlisle and 
District, Eastern Hull, West Hull, Selby and York, 
Doncaster Central, Doncaster East, Doncaster 
West, and Rotherham. This second wave of 
recruitment yielded a further 24 practices agreeing 
to participate and being randomised.
The total number of participating practices from 
these two waves of recruitment was still, at 38, 
short of our target of 57 practices. Therefore, 
in a third and final round of recruitment, we 
approached Birmingham East and North, Heart 
of Birmingham, South Birmingham, Central 
Manchester, North Manchester, and South 
Manchester. In addition to these Trusts we also 
worked in collaboration with the Scottish Practices 
and Professionals Involved in Research (SPPIRe) 
network [SPPIRe evolved into the Scottish Primary 
Care Research Network (SPCRN) during the time 
it was involved in the promotion of the LIFELAX 
trial]. In England, our method was to contact all 
practices within a particular PCT. In Scotland, 
SPPIRe operated a different system whereby the 
node coordinator (there was one coordinator for 
each of the four nodes – north, south, east and 
west) approached practices that they knew to 
be research active, or had expressed an interest 
in joining primary care trials. A further 14 
practices (13 in England, 1 in Scotland) agreed to 
participate and were randomised following this 
third wave of recruitment.
With the advent of the National Institute of Health 
Research Clinical Research Network (NIHR CRN) 
and its development and support of a portfolio 
of ongoing trials, we also took the opportunity 
to promote the trial more widely in England. As 
a result, some UK PCRN managers contacted 
the study team asking for further information 
about the trial. (Many areas had existing PCRNs; 
in October 2008 the new PCRNs were officially 
launched.)
Although keen to help the study recruit, the 
decision of the TSC not to apply to the HTA for 
a further extension meant that these offers of 
assistance with recruitment were not taken up. 
With hindsight, it appears that this decision taken 
by the TSC was entirely appropriate, considering 
the number of insoluble barriers identified through 
the embedded process evaluation (see Chapter 6).
Obtaining PCT R&D approvals
The process of obtaining R&D approval from 
participating PCTs took varying lengths of time 
from 1 month up to a whole year. [For one PCT, 
approval proved impossible to secure, despite 
numerous unanswered approaches to them. On the 
advice of the neighbouring PCT’s R&D Manager 
(where we had secured approval) we waited until 
the two PCTs merged and we were given approval 
for the newly formed PCT.] In the majority of 
cases, approval was given within 1–2 months of 
our application. Most of the delays were caused 
by disagreements with respect to indemnity 
issues or honorary contracts. With respect to 
indemnity, the issue was concerned with where the 
responsibility for provision of indemnity for the 
study lay. The principle is that indemnity against 
negligent harm is available through the NHS 
indemnity scheme and/or through the GP’s own 
professional indemnity for practice staff. Members 
of the research team held honorary research 
contracts with the NHS, and this provided NHS 
indemnity for negligent harm in respect of their 
role in delivering the intervention (essentially 
in training practice staff in the intervention; 
members of the research team did not play any 
direct role in delivering the intervention to 
patients). Professional liability insurance carried by 
Newcastle University indemnified protocol authors 
(i.e. the research team) in respect of liabilities 
arising from negligence in study and protocol 
design. We made it clear to the Trusts that we did 
not anticipate there being any claims against either 
the NHS or the university in respect of negligent 
harm. The study design had been peer reviewed 
and the conduct of the study was monitored and 
reviewed on a regular basis by the funding body 
(NHS Health Technology Assessment programme) 
and by the TSC. However, we repeatedly needed 
to demonstrate to Trusts the professional liability 
insurance the University had in place to cover for 
negligent harm caused by the design of the study 
(as opposed to its execution, which was covered by 
NHS and GP professional indemnity, as indicated 
above).
The issue of non-negligent harm was a matter of 
concern for many PCTs. Our MREC deemed (as 
is usual for non-commercial studies, especially 
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those where no novel drug was being used) that 
there was no requirement for us to have indemnity 
against non-negligent harm. However, not all 
Trusts accepted this. These issues were eventually 
resolved, but the process was burdensome, time 
consuming and frustrating. We soon learned 
that the best policy was to send, at the time of 
application, every document we had ever been 
asked for by other Trusts in support of our 
application, even though the standardised R&D 
approval form was all we were obliged to submit. 
Our experiences were common to other studies 
at the time. STOOL also reported a frustrating, 
burdensome and time-consuming account of the 
R&D approval process,19 but it was not just primary 
care trials of constipation that experienced the 
vagaries of the Trust approval process.190
We were fortunate that all of the PCTs to which 
we applied were part of consortia. This meant that 
rather than an individual application for R&D 
approval being made to each individual PCT, 
one application could be made to the consortium 
to which the PCT belonged. LIFELAX did 
encounter one delay, as one of the PCTs in one of 
the Consortia would not approve the trial, despite 
the consortium’s lead PCT (which had reviewed 
the application) recommending that all member 
PCTs approve it. This issue was resolved after a 
discussion between the PCT responsible for the 
review and the non-approving PCT; although 
the delay was minimal, the frustration was not. 
Although the standardised NHS R&D form was a 
move towards a standardised approach by using 
a standardised application form, each of the 
consortia had their own application form. The 
detail required on the forms ranged from the 
minimal (akin to a study registration form – as 
LIFELAX was funded by the HTA and peer review 
was part of the funding process the R&D lead in 
this consortium required very little information 
about the methodology, sample size calculation 
and rationale for the trial, as this had been 
scrutinised previously) to the comprehensive (akin 
to the standardised R&D form).
All bar two consortia required that the trial be 
approved before approaches were made to any 
practices in their catchment area regarding their 
participation in the trial. One consortium (part 
of recruitment area 1) allowed us to approach 
practices while the governance issues (honorary 
contracts and individual PCT approval) were 
being resolved, on the proviso that no research 
activities were undertaken prior to approval 
being given. There was a further stipulation 
from this consortium that before a practice could 
actually ‘go live’, the R&D lead needed to decide 
on whether a practice was ‘suitable’. This was an 
interesting addition to the recruitment process, as 
this decision about a practice’s ‘suitability’ would 
have seemed to have been most appropriately 
made by the REC process; furthermore, the 
criteria to be applied by the R&D lead in assessing 
‘suitability’ were not transparent. Nonetheless, with 
LIFELAX having circumvented the SSA process, 
we understood that there might be a concern from 
the R&D lead that a practice was not assessed 
for suitability and we therefore accepted this 
additional check. However, this check for suitability 
was also routinely carried out for practices that had 
already had an SSA by an LREC. The level and 
methods of checking for suitability are unclear and 
their effectiveness could perhaps be questioned.
After approving the practices for participation 
in LIFELAX, one senior partner in a practice 
deemed ‘suitable’ had a number of allegations 
made against him and was suspended, prior to 
resigning and the practice being taken over by 
the PCT. The allegations were initially made at 
the time we were asking for the practice to be 
approved. This calls into question the effectiveness 
of the process for assessing practice suitability 
that was in place locally. In another practice the 
computer system was replaced by the PCT and 
this change and subsequent delay meant there 
were considerable difficulties in searching for 
participants. This upgrade to practice prescribing 
systems was being carried out to all practices in the 
Trust, yet it was not identified by the R&D lead as a 
potential barrier to timely recruitment.
In another recruitment round (part of recruitment 
area 2), we were asked by the PCT to recruit 
practices before any approach for R&D approval 
from the PCT would be considered. Here the view 
was that unless there was interest from practices 
then it was not worth processing the application. 
This in itself was frustrating as all of the trial 
materials stipulated that we had PCT approval 
at the point of writing; we felt that having this 
approval would demonstrate to practices and 
patients alike that LIFELAX was a legitimate study 
and would lend it an air of importance. For reasons 
of cost and logistics (including the need to have 
revised patient information sheets reviewed and 
approved by the MREC, and old versions of the 
sheets withdrawn and replaced), we did not revise 
the information sheets. We did have practices 
wishing to join the trial in the area and so the PCT 
did eventually need to consider and approve the 
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Trial management involves lateral thinking, good 
communication, ethical marketing and common 
sense.192 From the start of the trial, LIFELAX 
was looked upon as being very much a small 
business. We understood that we would need to 
find GPs and convince them to ‘buy into’ the study. 
However, when businesses market a product they 
are attempting to convince customers that they 
will gain benefits directly from their purchase 
of the product. In LIFELAX the marketing task 
was somewhat different in that we were seeking 
to gain a commitment from senior GPs to allow 
their practice to engage in the study, when they 
themselves would apparently make no direct 
material gain by doing so. Therefore, from the 
outset, it was vital for LIFELAX to identify the 
potential gains and benefits that would accrue 
from participation in the trial.
Although not specifically stated at the time that 
LIFELAX was being ‘marketed’, the subsequent 
publication of the Strategies for Trial Enrolment 
and Participation Study (STEPS) report193 and 
the influential ‘Marketing and clinical trials: a 
case study’194 allow us to retrospectively assess 
LIFELAX’s marketing strategies against these 
proposed models for success (Figure 8).
Developing ‘brand values’ (Ia)
Brand values define what a brand is and what it is 
not. Without this, it is impossible to communicate 
a coherent and persuasive perception of a trial’s 
‘promise’ – i.e. what the trial intends to deliver to 
medicine, doctors, patients, etc. We worked closely 
with professional designers and graphic artists to 
develop the LIFELAX brand. We had our own 
distinct logo, font and colour scheme that featured 
on all of our trial related materials to render them 
easily identifiable. The ‘promise’ of our logo was 
life and vitality.
Gaining legitimacy/prestige (Ib)
Trials need legitimacy – they need to be positively’ 
tagged’ by association with prestigious individuals 
and institutions. LIFELAX was ‘tagged’ to the 
Newcastle University ‘brand’ (using the recognised 
crest) and to NoReN/NYReN (PCRN-NE) and 
its Clinical Director, Professor Greg Rubin. 
Legitimacy and prestige provide persuasive 
credibility, which is key to gaining access to 
decision-makers who decide whether a trial should 
be supported and maintain engagement. Practice 
senior partners and staff, particularly those in 
north-east England, would have been familiar with, 
and respectful of, both Newcastle University and 
NoReN/NYReN.
study. Fortunately, none of the practices joining the 
study from the PCT questioned the timing of this 
approval, and it was in place by the time patients 
were approached to participate.
Honorary contracts (both applying for them and 
having them issued) was another source of delay. 
There was lack of agreement between PCTs on 
which members of the research team required an 
honorary contract, what constituted a ‘current’ 
Criminal Records Bureau (CRB) check (and what 
level – standard or advanced – was required) and 
whether an occupational health check was needed. 
Some PCTs were prepared to issue a covering letter 
to act as a ‘mirror honorary contract’ once they 
had seen evidence of an honorary contract being 
issued by another PCT. In a number of other PCTs, 
a new honorary contract from the PCT concerned 
was required; in some of these, we were told that 
a new CRB check would need to be carried out, 
as those that had been carried out at the start of 
the trial were no longer ‘current’. The University 
HR department made it clear that it would only 
process one CRB check per person per study. We 
eventually managed to get Trusts to accept the 
initial ‘study’ CRB check, arguing that it was not 
a requirement for Trust substantive employees to 
have 6-monthly or annual renewals of CRB checks, 
and therefore that it would be inappropriate to 
apply more stringent criteria to those seeking 
honorary contracts.
As should be clear from Chapter 2, it was never 
intended that any members of the research 
team [with the exception of the researcher (BH) 
conducting the interviews in the embedded process 
evaluation study] should have face-to-face contact 
with patients. Although this changed over time 
in line with the revised recruitment protocol 
(described later in this chapter), initially all face-
to-face contact for patients was to be with trained 
members of the GP practice staff. Most members 
of the research team were only ever to have access 
only to anonymised patient data, and in a few cases 
to practice premises and staff, and would not be 
materially affecting the quality of care received 
by patients, and so we felt that the stipulations in 
respect of honorary research contacts appeared 
overly cautious and added a level of unwarranted 
bureaucracy, delay and cost.
LIFELAX as a business
An RCT is a huge investment in time, money and 
people. For a long time it has been acknowledged 
that in order to succeed, trials need to be marketed 
and trial managers need to think like marketers.191 
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Signalling worthiness (Ic)
It is vital to signal to likely participants that 
‘this trial will create greater value than the costs 
(time, effort or money) involved’. In LIFELAX 
we negated the ‘money’ cost by securing the SfS 
funding. This effectively meant that all LIFELAX-
related ‘costs’ incurred by practices would be 
reimbursed. We were also able to present the 
training in the behaviour change techniques 
as a benefit to practice staff (training in such 
techniques is both costly and difficult to source) 
that would be generalisable and applicable beyond 
the LIFELAX study. By highlighting the benefits 
that changes to diet and lifestyle have on a range of 
conditions (not just constipation) we hoped to show 
the value of participation. The aim was to roll out 
the training in the behaviour change techniques to 
all participating practices at the end of the trial so 
this ‘value’ would be available to all.
Providing simple, complete processes (IIa)
Trials require participants to undertake work 
– for example, identifying, approaching and 
recruiting patients, delivering the intervention 
and completing study documentation – that is 
additional to their normal duties. Providing 
them with simple, complete processes reduces the 
opportunity and financial costs of participation 
and increases the chances that involvement will be 
affordable and manageable. We offered assistance 
with electronic queries to search for patients. We 
(following the protocol amendment) undertook the 
consent, recruitment and follow-up processes.
Devising strategies for overcoming 
resistance (IIb)
Potential participants frequently raise objections. 
Trials should have standard and persuasive 
answers to these. Having a persuasive answer 
for each objection increases the probability of 
‘making a sale’. This is an interesting premise 
for LIFELAX. Due to the ‘opt in’ nature of the 
practice recruitment process, we intuitively felt that 
post-enrolment resistance would be low. We were 
not ‘cold calling’ practices and trying to convince 
them to join. However, as shall be seen later in this 
IVc
Facilitating
incorporation
into routines
IVa Ensuring
positive
moments of
truth
IIIc Achieving buy-in
(in public)
IIIb Delivering a
multiaudience,
multilevel message
IIIa Engaging active
sponsors, champions
and change agents
IIc Adopting an 
explicit marketing
plan
IIb Devising
strategies for
overcoming
resistance
IIa Providing
simple, complete
processes
Ic Signalling
worthiness
Ib Gaining
legitimacy/prestige
Ia Developing
‘brand values’
IVb Providing
frequent positive
reinforcement
Maintaining
engagement
Building
brand values
Product and
market
planning
Making
the sale
IV I
IIIII
FIGURE 8 The 12-component reference model. Adapted from Francis et al.194
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chapter, resistance to participation (barriers) were 
identified. The strategies we devised to overcome 
them are also discussed below.
Adopting an explicit marketing plan (IIc)
The marketing of a trial is too important and 
too complicated to be done informally. A formal 
marketing plan is required and should include 
a definition of target market segments (groups 
that need to buy in to the trial) and the trial’s 
unique selling points (USPs). LIFELAX may not 
score highly in this component as we did not as 
such. We were aware that the ‘way in’ and ‘sign 
up’ for practices usually has to be via the senior 
GPs, rather than the practice nurses, managers. 
We actually targeted all three in our approach, 
as we describe below. So in this respect it can be 
argued that we did adopt a marketing plan, We 
identified the trial’s USP for each of the categories 
to highlight the benefits of supporting the study.
Engaging active sponsors, champions 
and change agents (IIIa)
Selling a trial to prospective participants requires 
persuasion. This requires enrolling sponsors 
(public advocates), champions (activists) and 
change agents (facilitators). Trial managers need 
a network of supporters to spread the message. 
Persuasion is more likely to occur if the advocate is 
respected and known personally to the prospective 
participant. LIFELAX did have local champions 
(via NoReN/NYReN). However, we failed in our 
early attempts to recruit public advocates and our 
patient representatives’ activities were confined to 
TSC duties (though they were extremely supportive 
of the study).
Delivering a multiaudience, multilevel 
message (IIIb)
Trials need to convey sales messages through 
publicity, presentations, training materials, etc. 
These should be tuned to the distinctive needs 
of target groups – for example, surgeons are 
likely to be persuaded by different messages 
to administrators or nursing staff. Speaking in 
the language of the person being targeted and 
addressing their particular pattern of motivation 
is more likely to succeed than a ‘one size fits 
all’ approach. In LIFELAX we understood the 
importance of this. Our presentations (contents 
and style) were tailored to fit with our target 
audience (GPs, nurses or practice managers).
Achieving buy-in (in public) (IIIc)
Public buy-in requires that intended participants 
announce their commitment to join the trial in a 
setting where others hear them. This is important 
because when someone states, in public, that they 
are willing to undertake an action, then they 
are more likely to abide by their commitment 
than if they take a silent decision – that can be 
forgotten easily. This was not done in LIFELAX. 
With benefit of hindsight, we wonder whether 
techniques such as regular publication of lists of 
signed up practices might have acted as a signal 
of commitment. Anecdotal evidence of the lack 
of awareness in practices signed up to the study 
suggests that in some cases the senior partner 
did not even announce commitment to, and elicit 
support from, the rest of the practice team, leading 
to a lack of awareness of the study and them 
feeling that they were ‘pressed’ men and women.
Ensuring positive ‘moments of truth’ 
(IVa)
People evaluate organisations (including trial 
management teams) on the basis of their 
experiences at moments of truth. For example, if 
a doctor has a technical question about entering 
a patient into a trial, she will gain a strong 
impression of the trial management team’s 
competence by the way that the query is handled. 
In LIFELAX we had a clear and efficient way 
of handling queries so that accurate and timely 
responses were given. We set up a dedicated 
‘LIFELAX.queries@…’ e-mail address so that 
practice staff could e-mail queries and questions 
to us directly. This account was checked routinely 
and the message passed to the most appropriate 
member of the trial team for response.
Providing frequent positive 
reinforcement (IVb)
Positive reinforcement for existing participants 
should be an important part of a trial’s participant 
retention strategy. It is more expensive to 
recruit new participants than to retain existing 
participants. We feel that we largely achieved this 
in LIFELAX. Those practices that underwent 
training and became active recruiting sites 
remained committed to the trial until the end.
Facilitating incorporation into routines 
(IVc)
Activities that become embedded as routines 
are more likely to be done than one-offs. Trial 
procedures should be incorporated into the 
routines of units undertaking the work. Due to 
the ‘stand alone’ nature of the patient search and 
mail out, it is difficult to see how this aspect of 
LIFELAX could be incorporated into practice 
routine. With regard to the intervention, we 
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were concerned that nurses who saw participants 
on an infrequent basis might feel less confident 
in engaging with the techniques. Recognising 
this, we attempted to show how the principles 
and techniques of behaviour change taught in 
LIFELAX could be incorporated into routine 
practice, and so LIFELAX should not be seen as 
study-specific training.
With reference to the 12 components above, we are 
able to demonstrate that the LIFELAX marketing 
strategy used does fit closely to the proposed 
STEPS model for success, although we did not 
apply it explicitly in designing and conducting the 
study (the STEPS publications193,194 appeared in 
2007).
Practice recruitment
Based upon knowledge from previous studies and 
from feedback from the practices involved in the 
development of the intervention, and in a bid to 
target the relevant information to key stakeholders, 
we sent three copies of all of the study paperwork 
to the practice. One copy was sent to the senior 
partner, one to the practice manager and one to 
the practice nurse. We felt that the trial would be 
most relevant to the practice nurse and in their 
letter they were encouraged to discuss participation 
in the trial with the senior partner or practice 
manager.
Recruitment of practices was managed in the 
following way:
•	 Three copies of a promotional flyer, containing 
brief details about the study and alerting staff 
that more information was on its way were sent 
to staff at each practice as described above.
•	 In the weeks following this, three personalised 
study packs (covering letter, information 
sheets, expression of interest form and SAE) 
were sent to staff at each practice as described 
above.
•	 After 2 weeks, if the expression of interest form 
was not returned, duplicate reminder packs 
were sent to practices.
The expression of interest form allowed practices 
to indicate whether they would like to join the trial 
or would definitely not like to join the trial and 
therefore wanted no further information about 
it. If they required further information prior to 
reaching a decision, contact details for the trial 
team were included.
In addition to the mailshot to practices, the 
LIFELAX team undertook a number of other 
‘profile-raising’ activities:
•	 contacting relevant PCRNs and asking for 
their assistance in identifying research active/
interested practices
•	 writing articles for inclusion in PCT and 
research network newsletters.
•	 attending PCT working groups, practice staff 
meetings and PCT nurse training events/
meetings to discuss the trial.
•	 attending PCRN research days and training 
events.
Recruitment of general practices to LIFELAX 
proved much more difficult and slow than 
originally anticipated. In the first round of 
recruitment (area 1) a total of 306 general practices 
(from 11 PCTs) were approached to join the study 
using the method described above (flyer, invitation 
letter, reminder letter). A total of 168 general 
practices (55%) responded to the invitation to join 
the study: 144 practices (47%) did not wish to join 
the study and did not wish for further contact 
about it, but 24 practices (8%) agreed to join and 
were randomised. Overall, 138 (45%) practices 
did not respond to either the initial recruitment 
letter or the reminder letter. Moreover, 10 of the 
practices that were randomised withdrew from 
the study before undertaking patient recruitment, 
leaving 14 (5%) practices as potential recruitment 
sites. Table 10 shows a breakdown of recruitment 
activity in each of the recruitment areas. Due to 
concerns over the low levels of expressed interest 
and practice recruitment rates, a decision was 
taken to telephone practices that had not returned 
a form to the trial team stating explicitly that they 
did not wish did to participate. Two members 
of the trial team rang 134 practices out of the 
138 that did not respond and spoke to either the 
practice manager or the practice nurse. After this 
process we managed to recruit a further three 
practices to the trial. One of the practices became 
a recruiting site. The second had very low patient 
numbers (the search yielding single figures) 
and decided not to participate and the third 
withdrew prior to conducting any patient searches. 
This telephone follow-up of non-responding 
practices was a very resource-intensive process 
for the research team (often requiring multiple 
calls before being able to speak to the targeted 
individual), and due to its lack of success, it was not 
used in other recruitment areas.
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Barriers to recruitment of practices
Due to the concerns about practice recruitment 
levels in both STOOL and LIFELAX, we 
considered it was essential to identify the barriers 
to recruitment to the trials and, where possible, 
address these barriers. Feedback about LIFELAX 
and the perceived barriers to recruitment was 
collected in a number of different ways:
•	 feedback from GPs, practice managers and 
practice nurses invited to take part in the study 
about what they thought were the difficulties of 
accommodating LIFELAX (this will be further 
explored in the embedded process evaluation 
– Chapter 6)
•	 informal telephone interviews with GPs, 
practice managers and practice nurses from 
‘non-responding’ practices as part of the 
recruitment drive described above
•	 feedback from research-active GPs (colleagues 
of the members of the research team)
•	 feedback from members of the extended 
research team and members of the TSC
•	 feedback from PCT R&D managers and 
facilitators
•	 feedback from the UK Trial Managers’ 
Network
•	 literature that was being published at the time.
There was a wide range of issues that appeared to 
be barriers to participation in LIFELAX. Some 
of them were common to both LIFELAX and 
STOOL; others were common across all primary 
care research at the time. Some of the issues were 
specifically related to the topic and methods of 
LIFELAX, some to the Research Governance 
requirements, some to the practice resources. 
As shall be seen in the chapter detailing the 
embedded Process Evaluation Study, none of these 
issues exists in isolation; no matter how small any 
individual barrier appears to be, both alone, and 
in combination with others, it can have a major 
impact upon the successful implantation of a 
trial. The key issues identified were (no order of 
importance is implied):
The workload for practice staff
•	 The burden to staff in identifying potentially 
eligible patients (i.e. running the searches).
•	 The burden to staff in posting out study 
information to patients identified as being 
potentially eligible.
•	 The burdensome nature of the LIFELAX 
recruitment process. There was a lack of 
nursing/staff time to carry out the informed 
consent process and baseline assessment.
•	 The time taken to train staff to deliver the diet 
and lifestyle intervention arms.
•	 The length of time needed to deliver the 
personalised intervention (45 minutes of clinic 
time + follow-up telephone calls).
•	 The fear that taking part in a trial might make 
participants ‘constipation’ aware and thereby 
increase the number of appointments about a 
condition that had been managed successfully 
to that point with repeat laxative prescriptions.
Practice space
•	 A lack of consulting space for the initial 
baseline assessment.
•	 The space needed to train staff to deliver the 
diet and lifestyle intervention arms.
•	 The clinic space needed to deliver the 
personalised intervention (rooms would be 
occupied for much longer).
Research and the research process
•	 Lack of interest in research in general.
•	 Lack of interest in the LIFELAX research 
question (as we shall see in the embedded 
process evaluation there is a very complex 
relationship in the perception of roles and 
responsibilities with reference to managing 
constipation; we were told that nurses were 
far more likely to deal with patients with 
constipation than were GPs, yet practice nurses 
felt that while they monitored drug regimes 
of patients with constipation the problem was 
essentially one that other staff dealt with – 
either GPs initially in prescribing laxatives or 
community nurses).
TABLE 10 A breakdown of recruitment activity in each of the recruitment areas
Recruitment 
area
Number of 
practices
Number of 
responses
Responded to say 
‘no’ to LIFELAX Recruited
Practices recruiting at least 
one patient in trial
1 306 138 144 24 7
2 456 352 90 14 6
3 352 317 29 6 6
Total 1114 807 263 44 19
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•	 Changes in research governance regulations 
meant that many of the tasks that researchers 
routinely carried out to assist practices (e.g. 
approaching and recruiting patients directly) 
were no longer possible.
•	 Paperwork and documentation required for 
research governance purposes (in particular 
the formal letter of agreement/contact) 
discouraged practitioners from taking part in 
research.
Changes in general practice
•	 The introduction of the new General Medical 
Services (GMS) contracts.
•	 Constipation did not form part of the Quality 
Outcomes Framework (QOF) and was therefore 
not as ‘valuable’ to practices as coronary heart 
disease, diabetes, etc.
•	 Research activity was not recognised or 
rewarded under the QOF.
•	 Lack of incentives (financial and staff 
provision) compared to commercially 
sponsored studies.
Reasons for practice withdrawal
As can be seen from Table 10, 16 of the recruited 
and randomised practices did not go on to become 
active recruiting sites. Feedback from these 
practices suggests a range of reasons for this. Being 
too busy (n = 9) was the most common cause cited. 
There was a concern among the research team 
that the perceived added workload for practices 
randomised to the personalised arm might make 
them more likely to withdraw post randomisation. 
In fact, we had three practices in each of the 
arms of the trial give this reason, suggesting that 
there was no one arm that appeared to be more 
burdensome than others to practices. Two practices 
gave staff shortages as the reason for withdrawal. 
In two further practices, too few patients were 
identified in the search for potentially eligible 
patients to make participation worthwhile. In 
another practice there was no one available to do 
the searches. In yet another, the senior partner 
had agreed to join the study without consulting 
the practice manager. The practice manager was 
not interested in the project and so the practice 
withdrew. The final practice that was recruited 
and then withdrew was the one discussed earlier 
regarding the complaint to the General Medical 
Council (GMC) in relation to a senior partner and 
was actually withdrawn at the behest of the PCT 
rather than the practice itself.
Protocol revisions and 
practice incentives to improve 
recruitment
After the decision was taken to close down STOOL, 
the LIFELAX research team approached the HTA 
in July 2005 with a request for an extension to 
the trial. The HTA was aware that the delays in 
the trial time line to that point were due in the 
main to bureaucratic issues outside the control of 
the research team. By taking an evidence-based 
approach, we were able to demonstrate to the HTA 
how we had identified barriers to participation in 
the study and to propose the measures we would 
put in place to overcome them. While we were only 
too aware of the difficulties for practices, we took 
the opportunity to investigate the recent literature 
on trial participation from the participant’s 
perspective and to incorporate this in our proposal 
to the HTA.
Evidence from trials to support 
the protocol amendment
There was good evidence to suggest that the 
amendments we proposed to make to the study 
protocol would allow LIFELAX to achieve the 
desired recruitment rate for the study. There was 
evidence from STOOL that the initial recruitment 
model was not effective. Consequently, this was the 
first aspect we addressed.
The practice and patient recruitment process in 
primary care research is much more difficult, more 
costly and takes far longer than expected.195 Trial 
recruitment problems are common, with up to two-
thirds falling short of their target, and one-third 
failing to enrol even 75% of their projected sample. 
Trials frequently over-run and 10% are abandoned 
with recruitment failure.196
Burden of participating
Taking part in research places ‘additional 
demands’ on participants.196 These additional 
demands included extra procedures, 
appointments, time, inconvenience and expense. 
The revision to the protocol we proposed 
minimised the number of additional demands 
taking part in LIFELAX made on participating 
practices and their staff. We no longer required 
patients to visit their GP practice to give 
informed consent and take part in the baseline 
assessment. Instead, we offered that a member 
of the research team would visit them at a time 
and place convenient to them, following ‘opt in’ 
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by the patient. This change to the protocol meant 
that the burden and expense of the recruitment 
and consent procedure was borne by the research 
team and not the practice. This amendment had 
the additional bonus that patients could be visited 
on an evening or weekend should they wish, and 
therefore had the potential to increase patient 
participation rates.
From a practice perspective, this amendment 
immediately freed up clinic time and space for 
other activities and reduced the burden for them. 
For patients with transport or mobility problems, 
there was an additional benefit as there was no 
need for them to travel to the surgery for the 
baseline assessment.
Treatment preferences
Treatment preference and worries about treatment 
efficacy were also highlighted as potential barriers 
to participation. In LIFELAX, regardless of the 
intervention arm (we hoped that those in the diet 
and lifestyle arms would be able to reduce their 
laxative use), participants were able to request a 
laxative from their GP or self medicate using OTC 
products (the qualitative element of the STOOL 
study indicated that patients were reluctant 
to change or give up their laxatives, once an 
acceptable treatment regimen had been found). We 
felt that this would lessen these concerns.
Concerns about research
Distrust of, and unfamiliarity with, the research 
process and concerns about information and 
consent were also raised as points of concern by 
participants. We believed that by allowing patient 
participants to contact the study team anonymously 
or in confidence to discuss any aspect of the trial, 
we would be able to lessen this to an extent. At the 
face-to-face meeting with a member of the team 
we would be able to explain fully the research 
process, and clarify why we were doing what we 
were doing and to what ends. We were also able to 
explain fully just what data were being collected 
and why they were being collected. We were also 
able to explain fully how security and anonymity 
were achieved and maintained. The benefit of 
reallocating this task to the research team, as 
opposed to leaving practices to undertake it, was 
that there was no time constraint. A researcher 
was able take as much time as a patient participant 
needed and was better placed to answer questions 
regarding the study design and protocol.
The personal touch
It has been claimed that the most important 
aspect for researchers to control is the patient 
recruitment process and that during this phase of 
the study researchers needed to maximise their 
personal involvement.196 Gabbay and Thomas196 
believed that most of their recruitment was 
successful because they undertook it themselves. 
Working with other health professionals was, for 
them, helpful at times; however, they found that 
relying on others to conduct the recruitment was 
fraught with difficulties. Recruitment problems, 
they maintained, could be reduced if the research 
team carry it out. Foy et al.197 recommend a range 
of ways in which patient recruitment to trials can 
be improved. Based on evidence from a systematic 
review of the literature and from seven RCTs, they 
concluded that the research team should conduct 
both the consent and recruitment aspects of trials, 
although current guidance on not releasing patient 
identifiable data to those outwith the clinical team 
without the patient’s consent, and on the need for 
‘opt-in’ rather than ‘opt-out’ approaches presents a 
challenge in this respect.
Copies of the original protocol and the final 
protocol can be found in Appendix 1. The major 
changes between the protocols were in patient 
recruitment (including giving informed consent 
and the baseline assessment).
Original recruitment protocol (version 2, 
18 February 2004)
1. Potentially eligible (by reference to inclusion 
criteria) patients were identified by practice 
staff from practice-held records.
2. GPs then screened these patients for 
contraindications and comorbid conditions 
that were exclusion criteria.
3. Patients meeting the study eligibility criteria 
were then written to by their practice and 
were sent the study information sheets. An 
appointment at the practice was also made for 
a future date and details of this appointment 
were included with the above paperwork.
4. Patients were asked to contact the practice 
to (1) confirm that they would attend the 
designated appointment or (2) rearrange a 
suitable appointment time. Non-attendance at 
the clinic was taken to imply that the patient 
did not wish to participate in the study. No 
reminders were sent to those who did not 
respond to the initial invitation.
5. Patients wishing to take part in the LIFELAX 
study were required to attend their GP 
practice, first, to give informed consent, 
and, second, to take part in a baseline 
assessment (on the same day, and subject to 
informed consent having been given). Practice 
staff were responsible both for taking the 
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informed consent and conducting the baseline 
assessment.
6. After consent and the baseline assessment, 
participants in the control arm were able to 
collect their laxative prescription. Participants 
in the diet and lifestyle arms were required 
to make a further appointment for the 
intervention to be given.
Recruitment protocol, version 3+
1. Potentially eligible patients were identified by 
practice staff from practice-held records with 
assistance from the NoReN research nurse [the 
NoReN research nurse post was created to help 
practices take part in research; as the research 
nurse held a substantive NHS contract she was 
able (with permission from the practice) to 
help with patient identification]
2. GPs then screened these patients for 
contraindications and comorbid conditions.
3. Patients meeting the study eligibility criteria 
were then written to by their practice and were 
sent the study information sheets.
4. Patients also received a form on which they 
are asked to provide their contact details if 
they wish to join the study. Patients were asked 
to return this form to the study team in a 
prepaid envelope, i.e. an ‘opt-in’ approach. No 
reminders were sent to non-responders.
5. When a completed form was received by the 
study team, they arranged for an appropriately 
trained person (with an NHS honorary 
contract and CRB check) to arrange a suitable 
time and place to take informed consent and 
conduct the baseline assessment with a patient 
(as LIFELAX eventually recruited in Scotland 
and it was not possible to send staff there 
to take consent and carry out the baseline 
assessment, this was done over the telephone 
from protocol V4 onwards)
6. Once informed consent was given and the 
baseline assessment completed, a copy of the 
signed consent form was sent to the practice 
with instruction for them to contact the patient 
to arrange an appointment for the intervention 
to begin.
Support for Science funding
One of the barriers to practice participation 
was the ‘cost’ to practices in terms of staff time 
and practice resources. Feedback from research 
active GP colleagues and from the UK Trial 
Managers Network suggested that if we were able 
to demonstrate to practices that there would be 
no financial penalty to taking part in research 
that they would be more likely to get involved. 
To address this, an application was made to the 
Department of Health (DH) to secure funds 
to reimburse practices for their time spent on 
LIFELAX activities via the SfS (ad hoc) funding 
stream. We worked closely with NoReN (as a holder 
of Budget 1 funding, NoReN was eligible to receive 
and disburse SfS funding, unlike the majority of 
PCTs and general practices) during the application 
process. We agreed with the DH that all activities 
would be reimbursed at a Nurse, H-grade spine 
point 13a equivalent, including NI contributions, 
superannuation and increments. This equated 
to approximately £20.00/hour. We felt that this 
was a generous rate and most of the practice staff 
involved in LIFELAX would not be employed at 
as high a grade as this. The costing algorithm we 
agreed with the DH also took into account the hire 
of practice space, heating/lighting costs, postage 
costs and the cost of telephone calls during the 
trial.
We were able to access funding for both service 
support costs (in respect of practice activity 
in identifying, recruiting and consenting 
patients, and completing study assessments 
and documentation) and excess treatment costs 
(in respect of the additional time required to 
deliver the diet and lifestyle interventions). 
With the change in the recruitment protocol, 
informed consent and the baseline assessment 
were undertaken by the research team and the 
NoReN research nurse and so no reimbursement 
(in the form of service support costs) was due 
to practices for time spent on these activities. 
Practices were, however, asked to identify patients 
from records and send them a study pack. The 
rate of reimbursement for this was £7.31/patient. 
However, due to the way the SfS funding was 
allocated, this payment was dependent on a patient 
joining the study. This meant that if practices did 
write to all eligible patients and none decided 
to take part in LIFELAX, a claim could not be 
made. As a goodwill gesture, practices were paid 
a ‘site set-up’ fee of £50 from the project budget to 
cover the patient search and mail out, just in case 
no participants were recruited from a particular 
practice.
Excess treatment costs could also be reimbursed to 
practices. However, the DH was exacting on what 
constituted excess treatment. Only payments for 
genuine ‘excess treatment’ costs could be made. 
The DH was of the opinion that for the duration 
of LIFELAX each participant would be entitled 
to one appointment at their practice for their 
constipation and, as such, this appointment was 
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not ‘excess treatment’. It was only trial activities 
in excess of this appointment that would qualify 
for reimbursement. As the control arm did not 
generate ‘excess treatments’ (it was standard care) 
no claim could be made. For practices randomised 
into either of the diet and lifestyle intervention 
arms, claims could be made as there was some 
excess treatment time for each patient (5 minutes 
per patient in the ‘standardised arm’ and 
85 minutes per patient in the ‘personalised arm’); 
per-patient claims were agreed with DH at £2.73 
and £46.35, respectively. While we recognised that 
these rates were vastly short of industry trial rates, 
and LIFELAX could not be considered to be a 
‘cash cow’, we were confident that practices would 
not face any financial penalty by joining our trial.
Importance of research and constipation
One of the major frustrations we encountered 
when recruiting practices was the perceived lack of 
importance GPs attached to the research question 
posed by LIFELAX. We understood that it was 
most probably practice nurses who would deal with 
patients with constipation and attempted to target 
them with our trial literature (see Chapter 6 for 
a fuller discussion on practice nurses’ interests); 
however, in most cases it was a GP who would make 
the final decision about participation and unless 
they were convinced of the importance of the study 
there was little chance of the practice participating. 
Due to the new GMS contract and the QOF, there 
was less motivation for GPs to sacrifice staff and 
clinic time for an activity that was not part of 
the QOF (regardless of the SfS reimbursement). 
Hitting QOF targets was the priority in most 
practices.
It was ironic and frustrating that the majority of 
QOF target conditions (obesity, coronary heart 
disease, etc.) would benefit from changes in 
diet and lifestyle and so the training offered by 
LIFELAX on behaviour change in these areas 
would have been appropriate to the QOF topics 
as well as constipation (which was not part of the 
QOF). It was interesting that a number of the 
nurses who we worked with on the trial saw the 
skills they learned were generalisable and could 
form part of their routine clinical practice.
Patient recruitment
Identifying patients in practice
While it could be argued that LIFELAX had 
some success with the number of practices initially 
recruited into the trial (75% of the target) the 
number of patients from within the recruited 
practices to join the trial was far short of target. 
Patient recruitment was difficult right from the 
point of identification from practice records. What 
we had envisaged as being a routine first step in 
the process proved to be a hurdle for a number of 
practices.
We had commissioned a bespoke ‘electronic 
query’ that practices could use to help identify 
eligible patients from their databases. The query 
was designed to be used on the EMIS practice 
computer system, widely used in north-east general 
practices. Not all practices used EMIS. Even in 
EMIS practices, implementing the query was not 
always straightforward. The query was designed 
to be ‘read by’ the practice database, but it soon 
transpired that not all practices had staff with the 
IT skills needed to ‘run’ a query of this nature. The 
electronic query that we had hoped would reduce 
practice workloads actually proved to be more 
burdensome.
As all of the systems had search and query facilities 
with which practice managers and support 
staff were familiar, most practices preferred to 
conduct their own searches using their own search 
techniques. It soon became apparent that there 
was a great deal of variation between practices on 
the level of detail recorded on their databases and 
a lack of consistency in coding diagnoses. Using a 
diagnosis of ‘functional constipation’ often meant 
that no eligible patients were identified. Very few 
practices recorded this information. With this in 
mind, we asked for the searches to be ‘built up’ 
using either a diagnosis of functional constipation 
or three or more laxative prescriptions in the 
previous 12 months. With the introduction of the 
QOF we were aware that some practices in one area 
in particular (area 3) were prioritising (in terms 
of ensuring accurate and up-to-date coding) the 
patients and conditions that would form part of the 
QOF data submission process.
The account thus far may appear to present a very 
negative picture about the abilities of practices to 
carry out research. There was indeed a great deal 
of variability in the time and effort it took for us 
to recruit, train staff and for them to write out to 
patients (from 10 days up to 1 year). However, it 
must be stressed that, despite huge workloads and 
administrative and bureaucratic demands, those 
practices that did engage with LIFELAX did so 
fully and worked tirelessly to support the study.
Recruitment of participants
The first participants were recruited to the 
LIFELAX trial in July 2005. Poor response to 
the practice recruitment mail out to patients (as 
DOI: 10.3310/hta14520 Health Technology Assessment 2010; Vol. 14: No. 52
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
53
indicated above, only one letter of invitation, with 
no reminders, was allowed by MREC), and lack of 
attendance at scheduled baseline assessment clinics 
were experienced in all active sites recruited in the 
early days of the trial (using the burdensome V1 
protocol). As soon as this became apparent, plans 
to amend the recruitment protocol began.
Barriers to recruitment of patients
As discussed above, it appears that the number 
of patients we expected to find and recruit in 
practices was lower than we had anticipated.
Conversations with nurses, and practice managers 
highlighted a number of reasons why they thought 
that people were not participating in the trial. It is 
interesting that some of the reasons mirror what 
patients said when they rang the LIFELAX trial 
team to discuss participation.
Because most of the practices in the trial were from 
deprived wards, with low socioeconomic status, 
practices thought that their patients probably 
would not be interested in research and would 
probably not read (or be able to comprehend) the 
information sheets sent to them (despite our efforts 
to write in a user-friendly and accessible manner). 
They also expressed concern at the questionnaires 
and daily diary as being particularly onerous 
and complex to complete. Based on experience, 
practice nurses also thought that their patients, in 
most cases, would not engage with any aspect of 
behaviour change.
Patients who rang the trial team often reported 
research as ‘not being for them’. They told us 
that they were not eligible as they did not have 
constipation and therefore could not take part. 
Their evidence for not having constipation was 
that they were able to ‘go’ every day (even though 
this required them to take laxatives which, by 
our definition, meant they had constipation). 
This perception of ‘not being constipated’ and 
therefore being ineligible reflects experience in the 
STOOL trial19 and is therefore a major threat to 
the ability to recruit prevalent cases. However, as 
discussed in Chapter 2, the option of opportunistic 
recruitment of incident cases (new presentations of 
constipation) was deemed inappropriate from the 
outset of the trial.
One potential participant went to great length to 
point out that they ‘knew all there was to know 
about healthy eating’ and that nothing their nurse 
could say would be new and therefore participation 
was ‘rather pointless’.
Due to comorbidity, a higher proportion of patients 
than that originally estimated by the research team 
were taking high-dosage codeine-based pain-killers 
and failed to meet the trial inclusion criteria.
Recruiting the required number of 
participants
From the 19 practices that recruited participants 
for LIFELAX, 1473 patients were identified as 
being eligible (an average of 77 per practice, higher 
than our anticipated number of 40 per average 
practice). The final number of patients recruited to 
the trial was 154, just under 10% of those eligible. 
In our initial power calculation for the trial we 
had expected that 75% of eligible patients would 
consent to be randomised to take part in the trial. 
Ultimately, the consent rate proved to be nearer to 
10%. Using this figure, the size of the recruitment 
task becomes apparent. In order to recruit 1500 
participants, LIFELAX would need to have 
identified 15,000 eligible patients. Based upon our 
experience, we would need to have recruited in the 
region of 200 practices.
Summary and implications
The implementation of the LIFELAX trial appears 
to have been unsuccessful for several reasons, 
related both to procedural issues (resulting from 
changes in ethical review and research governance 
processes) and to disappointingly low levels of 
interest and participation at both a practice and a 
patient level.
It was acknowledged by both the funding body 
for the trial (HTA) and the TSC that LIFELAX 
was operating at a time of considerable change 
and uncertainty around ethical and research 
governance issues. The process of seeking a 
favourable opinion from an ethics committee 
underwent several major changes during the 
duration of the trial. The initial approach 
LIFELAX made to MREC used the paper-based 
MS word form. The application system then 
underwent several electronic iterations, first using 
the ‘form filler’ program, and then the online 
COREC form, the National Research Ethics 
Service (NRES) form and the Integrated Research 
Application System.
Ethics committees reacted to a number of 
landmark documents and events, including the 
report of the Alder Hey inquiry,198 the European 
Human Rights Act199 (and its implementation) and 
preparation for the enactment of the EU Clinical 
Trials Directive. At this time the guidelines to 
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which ethics committees adhered became more 
prescriptive, and committees became more risk 
aware and took measures to mitigate risk where 
possible. The guidance from COREC, at times, 
appeared to be inconsistent and inflexible, and 
anecdotal evidence from meetings with other trial 
managers at the UK Trial Managers Network 
annual meeting suggests that the differences 
between RECs were immense. Although LIFELAX 
had a good working relationship with its MREC, 
the process of ethical review was, and continued 
to be across the study’s lifetime, increasingly 
bureaucratic.
The publication of the Research Governance 
Framework200 created further challenges, 
with guidance and decisions taken at a local 
level appearing to be, at times, and at least, 
contradictory to national advice. The need for 
all members of the core research team deemed 
to be ‘hands on’ (including those such as the 
statistician and health economist, who were never 
expected to interact with practices, their staff or 
patients, or to have access to patient identifiable 
data) to undergo a full occupational health check 
(including, in some instances, throat swabbing) 
seemed to be time consuming, resource intensive, 
mildly unpleasant and a somewhat unnecessary 
procedure. Similarly the securing of honorary 
contracts was rather challenging. The information 
at a local level as to which members of the research 
team required an honorary contract was often 
contradictory, ranging from any person involved 
with the running of the trial to only those making 
visits to Trust premises, handling (identifiable) 
patient data or meeting patients. Although we 
welcomed the move by Trusts to implement the 
Research Governance Framework, the variability 
in interpretation of it and the lack of resources in 
some Trusts to implement it created a burdensome, 
often inefficient and slow process. These 
experiences are mirrored by others researchers 
undertaking studies in similar settings at a similar 
time.201–203
In addition to the inevitable delays created by 
these developments, one of the major issues 
of concern to both the research team and the 
TSC was the necessity for participants to ‘opt 
in’ to LIFELAX and the apparent removal of 
contact with the research team until much later 
in the research process. This model has major 
implications for health services research in 
the future.204 By implementing such a model, 
one immediately decreases the likelihood of 
participation and increases the risk of participation 
bias.205 Communication between the trial team 
and the participant is crucial to the success of a 
trial. Opportunities for those most familiar with 
the study design and processes (i.e. the research 
team) to explain the trial or discuss any aspect 
of participation diminish once the GP practice 
becomes the primary contact point for information 
in the early stages of the trial and the ‘gate-keeper’ 
to trial participants. While practices in LIFELAX 
were happy to deal with medical queries arising 
from participation in the trial, they were reluctant 
and lacking in confidence to discuss general 
questions about the study, trial design and general 
participation, as they felt that this was the remit 
of the research team. Initial communication with 
potential participants was by covering letter from 
the GP, accompanied by the PIS. The information 
required by COREC/NRES to be included in the 
PIS is very detailed and complex. Our concern 
was that the PIS might appear so daunting that 
potential participants would simply ignore it 
rather than read it, and would either decide not 
to participate or would not be fully informed, 
as required for the consent process. Having 
successfully used a ‘brief’ and ‘full’ PIS system in 
another RCT concerning patients with ulcerative 
colitis,206 the same approach was used in LIFELAX. 
It was hoped that interested patients would be able 
to see from the brief PIS the essentials of what 
the study entailed and then, should they wish to 
participate, they would read the full PIS prior to 
giving consent.
The LIFELAX trial also coincided with the 
introduction of the new GP contract, including 
the QOF. Practices were heavily involved in setting 
up the necessary audit and IT systems required 
to meet the quality targets associated with this 
contract. As the new contract offered minimal 
incentives for research, any research activities were 
viewed by many GPs and their practice staff as a 
luxury and an unwelcome distraction from the 
other demands of practice life after the adoption of 
the new GMS contract.
The feedback that we gathered from both 
participating and non-participating practices 
suggests that there was a perception that the cost 
of taking part in LIFELAX was too great in terms 
of time, space and practice resources. For some, 
constipation was not a sufficiently interesting 
or important topic, a barrier also encountered 
in the STOOL trial.19 The barriers to patient 
participation are less clear. Socioeconomic status 
may have been a factor – so too might the lack of 
understanding as to the pragmatic nature of the 
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trial with regard to current and future laxative 
use. In STOOL, GP participants suggested that 
their patients would be unwilling to change from 
their preferred treatment regime, particularly if 
it were currently being successful.19 It may be that 
in LIFELAX there was reluctance from potential 
participants to give up a strategy that worked 
for one in favour of another that may not. It may 
also be the case that constipation is not such an 
important or interesting topic for patients, as well 
as GPs and practice nurses, especially for those 
who are taking laxatives and are not currently 
constipated, at least by their own definition.
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Chapter 5  
Results
Baseline characteristics of 
the LIFELAX participants
Here we report on the baseline data collected via 
the self-completion questionnaire and the face-to-
face interview. Daily diaries were also completed 
for 6 months from the date of the start of the 
intervention. Diary data will be reported separately 
(below) from the two baseline measures. Further 
reporting on the effects on HRQoL at baseline can 
be found in the economic evaluation section below.
Baseline postal questionnaire
This questionnaire collected the following data:
•	 basic demographics (age, education, 
employment, etc.)
•	 experiences of constipation (PAC-SYM127 and 
PAC-QOL38)
•	 health in general
•	 lifestyle and mobility
•	 usual eating habits [Dietary Instrument for 
Nutrition Education (DINE)139 and a fluid 
counter]
•	 satisfaction with treatment
•	 anxiety and depression [Hospital Anxiety and 
Depression Scale (HADS)207].
Baseline face-to-face 
questionnaire
This questionnaire collected the following data:
•	 general bowel health
•	 use of prescription laxatives (length of time 
taking prescribed laxatives, use in previous 
7 days, class of laxative)
•	 use of OTC laxatives (length of time taking 
OTC laxatives, use in previous 7 days, class of 
laxative)
•	 the main thing participants wanted to achieve 
by taking a laxative
•	 participant-defined ‘successfully managed 
constipation’.
Following the recommendation of the TSC not to seek a further extension for the LIFELAX 
trial it was agreed with the funders that patient 
recruitment should cease, but follow-up should 
continue for already recruited participants. Due 
to the low number of patients in the trial, and 
therefore the lack of statistical power, it was 
agreed that we would not carry out a formal 
analysis of effectiveness, as anticipated in the 
original proposal. More specifically, we agreed 
that we would not conduct any hypothesis-driven 
statistical analyses. Rather, we agreed that our 
analysis of patterns of response to the patient-
reported outcome measures would be largely 
descriptive.
As LIFELAX used a range of data collection 
tools (some previously validated, but in other 
populations, and others developed specifically 
for the trial) it was agreed to be beneficial to 
collect data on completion rates, item response 
rates, measures of validity and reliability, and 
marginal comments (indicative of acceptability and 
comprehensibility of the tools) to inform future 
trials that propose to use these tools in similar 
populations and conditions. This we do below for 
the self-completion questionnaire at baseline, 3, 6 
and 12 months.
As psychometric properties of validity and 
reliability of existing scales (e.g. PAC-SYM and 
the PAC-QOL) may vary according to population 
and setting, we undertook these analyses on the 
baseline data in the belief that it would contribute 
to a general understanding of the performance of 
these measures in our sample and the general body 
of knowledge regarding the chosen instruments.
Due to the low number of participants it was not 
possible to conduct the formal comparative analysis 
of cost-effectiveness originally planned. A lesser 
level of comparative cost-effectiveness is presented, 
along with a descriptive analysis of the costs of 
living with, and managing, constipation.
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Baseline postal 
questionnaire
Demographics
The number of participants recruited by a 
practice ranged from 2 to 24; the average 
number of participants recruited by a practice 
was approximately eight. Patients came from 
19 practices in 13 different areas. In total, 141 
(92%) of the possible 154 self-completion postal 
questionnaires were returned, although not all 
data items were completed by all respondents.
Overall, 140 respondents provided details of 
gender (61 men and 79 women). Dates of birth were 
completed in 137 of the returned questionnaires. 
Based on age as calculated from date of birth and 
date of questionnaire completion, the youngest 
participant in the study was 51 years old, the oldest 
was 96 and the average age of participants was 71. 
On average, male participants were 3.5 years older 
than female participants. In the personalised arm 
the average age was 69, in the standardised arm 
the average age was 72, and in the control arm it 
was also 72. Of the 139 responses to the question 
asking about current situation in relation to paid 
work, 122 participants were retired, three were in 
full-time work, four in part-time work and two did 
not work as they were looking after their home and 
family. Eight participants were unable to work due 
to long-term sickness or disability.
Of the respondents 11% had remained in 
education beyond 17 years of age, whereas 44% 
of participants had no formal qualification. 
Only one respondent in the sample was not 
white, listing his/her ethnic group as ‘black’.
PAC-SYM
The PAC-SYM is a 12-item scale measuring stool, 
rectal and abdominal symptoms. Respondents 
report the severity of each symptom on a scale 
from 0 to 4, (with ‘4’ representing the greatest 
severity). An overall score (PAC-SYM global score) 
is computed by taking the average item response 
across the 12 symptoms. The three subscale scores 
are computed in the same manner, based on the 
symptom groupings (abdominal – four items; rectal 
– three items; stool – five items); algorithms for 
data imputation in the case of missing data mean 
that subscale scores can be calculated when one or 
two items in the subscale are missing. The mean 
scores and standard deviations for the PAC-SYM 
subscales and global score can be found in Table 11.
Figure 9 shows a histogram of the distribution 
of responses on the PAC-SYM global scale. This 
provides some evidence that there was a ceiling 
effect (patients scoring the lowest possible score 
at baseline, and therefore with no ‘capacity’ to 
capture improvement over time) in the study 
population.
In the development of the PAC-SYM,127 Cronbach’s 
alpha for the total PAC-SYM score was reported as 
being 0.98. Subscale Cronbach’s alphas were 0.80 
for stool symptoms, 0.84 for abdominal symptoms 
and 0.87 for rectal symptoms. Our findings were 
consistent with these figures with Cronbach’s 
alpha for the global score being 0.91 and the 
subscale alphas being 0.84 for stool symptoms, 
0.87 for abdominal symptoms and 0.81 for rectal 
symptoms; all of these values exceed the criterion 
of 0.70, indicative of adequate internal consistency 
reliability at the group level.208
The PAC-SYM mean scores suggest that the level 
of constipation symptoms experienced by our 
sample was low. This is supported by evidence 
from the objective measure of bowel movement 
frequency collected in the daily diary. The mean 
number of daily bowel movements was 1.5. This 
again supports the findings of the STOOL report19 
that patients did not define themselves as having 
constipation, once a preferred pattern of bowel 
movements was established, regardless of whether 
it took the use of regular laxatives to achieve this.
TABLE 11 Mean scores (and standard deviation) for the PAC-SYM subscales and global scales
PAC-SYM n Minimum Maximum Mean SD
Abdominal 123 0.00 3.75 1.07 0.92
Rectal 119 0.00 4.00 0.74 0.92
Stool 122 0.00 3.25 1.38 0.94
Global 120 0.00 3.17 1.10 0.79
SD, standard deviation.
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PAC-QOL
The PAC-QOL questionnaire was developed as 
a patient-reported outcome measure to evaluate 
the impact of constipation on QoL over time.38 
In development work, the PAC-QOL scales have 
been established as being internally consistent 
(Cronbach’s alpha > 0.80 on each of them). Our 
findings were consistent with this. Cronbach’s 
alpha for the 28 items forming the global score was 
0.93. For the subscales (dissatisfaction – five items; 
physical discomfort – four items; psychosocial 
discomfort – eight items; worries or concerns – 11 
items) the Cronbach’s alphas were: dissatisfaction 
0.86; physical discomfort 0.89; psychosocial 
discomfort 0.87; worries or concerns 0.93 – again, 
all in excess of the threshold level of 0.7 indicative 
of adequate internal consistency at the group 
level.208
The correlations of the PAC-SYM and the PAC-
QOL global scores at baseline were in line with 
what we would expect, with there being a greater 
impact upon QoL with increased symptoms 
(r = 0.76, p < 0.01).
The box plot shown in Figure 10 offers some 
suggestion that the groups were not evenly 
balanced with respect to constipation-related QoL 
at baseline.
Longstanding disability and 
mobility
Overall, 73% of respondents reported having 
a longstanding disability or infirmity. The 
distribution across the intervention arms was not 
even, with 84% of respondents in the personalised 
intervention arm and 71% in the standardised 
intervention arm reporting this. In the control arm 
it was 67%. In total, 86% of respondents reported 
that their disability or infirmity limited their 
activities. As, due to small numbers of patients, we 
are not able to analyse formally the effectiveness of 
the intervention strategies, this baseline imbalance 
is not such an issue. However, any intervention that 
requires people to make changes to their lifestyle 
in terms of being more mobile and active would 
need to consider the level of disability or infirmity 
in its population.
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None of our sample reported that they were either 
bedbound or chairbound at baseline. However, 
the groups were not well balanced in terms of the 
assistance they needed in order to carry out an 
activity such as getting up from their chair or bed 
and crossing the room: 76% of the control group 
reported they could do this without any assistance, 
whereas only 42% of the personalised intervention 
group and 63% of the standardised intervention 
group did not require assistance.
In terms of being able to undertake any vigorous 
activities, 59% reported that they would be unable 
to undertake these and 36% that they could but 
with difficulty. Again there was an imbalance in 
the groups with 74% of the personalised group 
reporting that they were unable to undertake any 
vigorous activity as opposed to 46% in the control 
group and 59% in the standardised group.
This finding that the control group was somewhat 
‘fitter’ than the other intervention arms was 
consistent in all of the other questions that covered 
functions, such as bathing and dressing self, 
walking 100 yards and walking half a mile. As 
stated earlier, although not relevant to the analyses 
reported here, it may have had an impact on the 
intervention as not all arms were the same.
Diet
The data on the food and drink that we collected 
at baseline were intended to be used to explore 
changes in consumption over time, as each 
participant took part in the trial. As we are not 
able to provide such analyses, here we describe the 
baseline dietary data.
We collected data on the amount of bread (number 
of slices/rolls) consumed each day. Due to the 
range of bread types and their fibre content levels, 
and the contents of the other elements of each 
participant’s diet, it is difficult to fully assess the 
impact of bread consumption on bowel health 
and function. Nonetheless, it is possible to express 
some generalities. White bread is lower in fibre 
than a granary or wholemeal alternative. In our 
sample 47% did not consume any white bread at 
baseline; 44% ate at least one slice of wholemeal 
bread per day, but 55% reported that they did 
not eat any wholemeal bread. It is difficult to say 
whether these figures have a significant role to play 
in the bowel function of our sample, but it does 
suggest that there were a significant number of 
people who could have made a switch from white 
to granary or wholemeal bread and, depending on 
the remainder of their diet, this might have had an 
impact on their bowels.
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With regard to breakfast cereal, we collected data 
on the frequency that different types of cereal were 
consumed. Sugary cereals tend to be lower in fibre 
than porridge/wheat/muesli or bran-type cereal. 
In our sample only 8% reported eating sugary 
breakfast cereals daily with > 70% never eating 
this type. Forty-two per cent of the respondents 
ate porridge/wheat/muesli cereal daily and a 
further 16% ate a bran type cereal daily. This 
would suggest that, in terms of the breakfast cereal 
of choice in our sample, those cereals that can 
benefit bowel health were being most frequently 
consumed. The scope for dietary improvement in 
this respect may therefore have been quite limited.
Approximately 41% of respondents said that they 
ate more than one serving of rice or pasta per 
week. Again we know little about the impact of 
this on bowel function; however, it does suggest 
that rice and pasta were not ‘alien’ foods to this 
population and that as wholemeal/brown varieties 
are available they could be incorporated into the 
diet without radical changes to current eating 
patterns.
Potatoes were eaten more frequently than rice and 
pasta, with 28% of the sample reporting that they 
had at least one serving of potatoes each day. We 
do not know from our data whether the skins of 
the potatoes were eaten too, so can draw no firm 
conclusion as to the fibre contribution potatoes 
made to the diet.
Vegetables were eaten by most people on most 
days with only 5% reporting eating less than one 
serving of vegetables per week. Pea and bean/lentil 
consumption were recorded as separate categories 
to ‘vegetables’. Approximately 70% of respondents 
reported eating at least one serving of peas per 
week and 54% reported eating at least one serving 
of beans/lentils a week.
Only six respondents (4%) said that they ate less 
than one serving of fruit in an average week. 
We were aware that eating fruit and vegetables 
is often difficult for older adults with dental 
issues; however, it would appear that the majority 
of respondents could eat these types of food 
and potentially increase consumption to the 
recommended five portions of fruit and vegetables 
per day.
Using the fibre calculator from the DINE 
questionnaire,139 upon which the fibre items in the 
baseline questionnaire were based gives us insight 
into the amount of fibre our sample was consuming 
at baseline. (Although the DINE was designed to be 
used in a consultation setting we found it to be an 
effective method for capturing data on the amount 
of fibre consumed, as it referred to ‘servings’ of 
particular food rather than requiring respondents 
to carry out any measuring or weighing prior to 
reporting.) The average score was 34, which falls 
into the ‘moderate’ consumption category. This 
does suggest that while fibre consumption was 
not low in our population, there was potential 
to increase consumption to the ‘high’ category 
recommended by the DINE authors.
With regard to fluid consumption, 85% of our 
sample reported that they drank less than the 
recommended eight glasses of water a day. This 
finding in itself is not unsurprising as we do know 
that the urge to drink decreases with age and 
often there is a worry that drinking more leads 
to more frequent visits to the toilet which can be 
inconvenient to people with mobility problems. 
However, hot drinks such as tea and coffee were 
consumed very frequently and although water may 
not be consumed to the level recommended, it 
appears that with the levels of consumption of fruit 
and vegetable juice, hot drinks and soft drinks 
(sugared and sugar free) the amount of fluid 
consumed is in keeping with the guidelines.
While we acknowledge that the baseline data may 
not tell us exact quantities of which foods make 
up the daily diet of our sample, they do provide 
a guide to the intake of our sample. It would 
seem that there were a number of areas in which 
changes to diet could be made and this may have 
an impact upon bowel health.
Satisfaction with prescription of 
laxatives
Evidence from the STOOL trial19 suggests that 
once someone has found a laxative regime that 
works satisfactorily then they would prefer to 
remain on it and not embark upon a new regime. 
When designing the LIFELAX intervention we 
were able to take this into account and rather than 
requiring people to give up on their laxatives 
(prescription or OTC) we made a decision to allow 
people to continue taking laxatives. We had hoped 
that, for those embarking on any diet and lifestyle 
changes, over time their reliance on laxatives 
would lessen as the changes began to improve 
bowel function.
From our sample, 60% of respondents indicated 
that they were satisfied with the ability of 
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their prescription laxatives to treat or prevent 
constipation; 53% were satisfied with the way 
in which the prescribed laxatives relieved the 
symptoms of constipation; and 55% of respondents 
were satisfied with the amount of time it took for 
the prescription laxatives to start to work.
A total of 68% from our sample reported that they 
did not experience any side effects from taking 
their prescribed laxatives. Only 3% reported 
that they had any difficulty taking the laxative, 
as prescribed by their GP, in its prescribed form, 
and only 9% reported that they had any level of 
difficulty planning when to use their prescribed 
laxatives; 80% of the respondents said that it was 
convenient to take their laxatives as prescribed 
and only 9% felt that taking their laxatives was not 
a good thing; 70% of our sample reported that, 
taking everything into account, they were satisfied 
(satisfied, very satisfied or extremely satisfied) 
with their prescription laxatives. All of these data 
suggest that there was little reason or incentive 
for our population to give up their prescribed 
laxatives, a finding that is entirely in keeping with 
the findings in the STOOL report.19
PAC-SYM, PAC-QOL and 
anxiety/depression
Studies investigating the link between 
psychological illness and disturbed defecation 
suggest that people with anxiety and depression 
often have bowel symptoms, with depression being 
positively associated with constipation209 and 
anxiety with increased bowel frequency.210
On the HADS, each item is marked on a four-point 
(0–3) response category. Scores can range from 0 
to 21 for anxiety and 0 to 21 for depression. These 
scales are independent. A score of 0–7 for either 
subscale could be regarded as being in the normal 
range, with a score of ≥ 11 indicating the probable 
presence of disorder and a score of 8–10 being 
just suggestive of the presence of anxiety and/or 
depression.
In our sample the mean scores on the HADS show 
there was no evidence of anxiety or depression 
either in the group as a whole or arm by arm 
(Table 12).
Although there was no evidence of even ‘probable’ 
anxiety or depression in our sample, there was 
evidence that these scales did correlate with the 
global scales of the PAC-SYM and PAC-QOL 
(Table 13), providing further evidence of the 
construct validity of those measures. As stated 
earlier, the mean PAC-SYM and PAC-QOL 
scores suggest that although our sample did not 
experience extreme symptoms, as symptom scores 
rose so too did the impact upon QoL. These 
findings are entirely consistent with the view 
that people who experience greater symptoms 
of constipation experience both higher levels of 
depression and impact upon their QoL. Previous 
research210 indicates that anxiety is linked to 
TABLE 12 Mean (standard deviation) HADS anxiety and depression scores
Intervention arm
HADS
Anxiety Depression
Personalised Mean 1.10 0.97
n 31 31
SD 0.65 0.53
Standardised Mean 0.77 0.69
n 65 63
SD 0.63 0.43
Control Mean 0.88 0.71
n 44 44
SD 0.65 0.36
Total Mean 0.88 0.76
n 140 140
SD 0.65 0.44
SD, standard deviation.
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increased gut transit time. Our results are at odds 
with this finding as our anxiety scores were also 
positively correlated with constipation symptoms. 
As our population’s mean anxiety score was not 
clinically significant, it would be both naive and 
erroneous to expect evidence of increased gut 
transit time in this case. It is understandable that 
people experiencing constipation may feel more 
anxious and perhaps this is one way to account for 
our findings.
Baseline face-to-face 
questionnaire
General bowel health
We began our face-to-face interviews with a very 
broad open question ‘Thinking back over the 
last month or so, how have your bowels been in 
general?’. On the advice of the clinicians attached 
to the study, a question such as this served a very 
important role. While it focused the interview on 
bowel health rather than general health, it also 
allowed interviewees to talk about themselves. 
There was a concern that often people did not have 
an avenue to talk about their bowels and a question 
such as this would be a welcome opportunity to 
talk about any aspect of their bowel health before 
moving to the more specific structured items. This 
was not designed to be an analysed question.
Over 45% of our sample had at least one bowel 
movement per day during the 7 days prior to 
interview. As normal frequency of bowel movement 
ranges from at least three in the previous 7 days, it 
is worthy of note that only 7% reported fewer than 
this number of motions per week. Over one-third 
of our sample passed a stool without straining 
in the 7 days prior to their assessment. However, 
two-thirds did strain and nearly 20% reported 
straining either on most days or daily.
In total, 36% of participants reported the absence 
of hard or lumpy stools, but about one-third of 
the sample experienced at least one or two per 
week; 88% of respondents experienced a feeling 
of incomplete emptying of their bowels, and half 
of them said that they felt that at least on one 
occasion in the previous 7 days when they were 
answering the call to stool, the stool could not be 
passed; and 30% of people had needed to press 
around their bottom to assist with the passing of 
a stool on at least one occasion in the week before 
interview.
Use of prescription laxatives
In our sample, over 30% of respondents had been 
taking a prescription laxative for 10 years or 
longer, and 90% had been taking a prescription 
laxative for more than a year. A breakdown of the 
duration for which respondents had been taking 
laxatives can be seen in Figure 11.
Nearly 90% of our participants had used a 
prescription laxative in the previous 7 days, with in 
excess of 41% of them being prescribed a stimulant 
laxative by their GP; 30% had been prescribed 
a second laxative and 5% of our sample was 
prescribed a third.
Half of the respondents had never taken an OTC 
laxative and approximately 15% had been taking 
them for 10 years or more.
Main thing participants wanted 
to achieve by taking laxatives
This was an open-ended question. The responses 
were varied, including references to an end to the 
feeling of lethargy associated with constipation 
and a belief that if the bowels were not completely 
emptied they could make you ill. The most 
common achievements that participants wished 
from their laxatives were ‘ease’ of stool; soft 
consistency for their stools; frequency and 
regularity in their visits to the toilet. As only 7% 
of our sample fell outside the ‘normal’ frequency 
TABLE 13 Correlation between the PAC-SYM and PAC-QOL (global) and the HADS scales
HADS
Anxiety Depression
PAC-SYM: global score Pearson correlation 0.306 0.237
n 120 120
PAC-QOL: global score Pearson correlation 0.553 0.381
n 135 135
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for bowel movements, it suggests that the laxative 
regimes in our sample were working in terms of 
frequency and approximately one-third of our 
sample were achieving the wish not to strain at 
stool.
Participant-defined ‘successfully 
managed constipation’
The results of this question broadly reiterated what 
people wanted to achieve by taking a laxative, i.e. 
successfully managed constipation would mean 
ease, frequency, regularity and soft consistency 
of stools. However, only 10% of respondents to 
this question said that successfully managed 
constipation would mean ‘without the use of 
laxatives’. This finding again reiterates belief that 
managing constipation without a laxative is not a 
priority for many people.
Postal questionnaire follow-
up response rates
The self-completion questionnaire was sent 
at three time points (3, 6 and 12 months). At 
3 months the response rate was 80%; at both 6 
and 12 months it was 85%. This suggests that, 
despite length of the questionnaire, the time 
taken to complete it and the added burden of the 
daily diary at the first two time points, respondent 
fatigue was not an issue.
Daily diary
The daily diary that we used in LIFELAX had 
been developed during the qualitative study that 
accompanied the set-up of the STOOL Trial.19 The 
diary method was chosen in a bid to minimise 
recall bias. Data on bowel habits and symptoms 
based on the Rome II criteria122 were gathered 
in a structured way (tick box format), completed 
daily and returned each month for 6 months. 
In addition to these data, the diary collected 
information on adverse events, relapse rates, use 
of laxatives, costs of food purchased or activities 
undertaken as part of any diet or lifestyle changes 
made; and any out-of-pocket expenses associated 
with constipation and its management.
Although previous experiences of diaries in studies 
with older people suggested that 90% of diaries 
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would be returned completed,132,133 we could find 
no evidence that a diary such as this had been 
used to collect data on bowel function/health and 
associated costs on a daily basis for such a length of 
time.
The greatest number of diaries was returned 
in round one, and the response rate was 
approximately 73%. In subsequent rounds there 
was a slight decrease in response rates (Table 14). 
The overall response rate to the diaries was 64%.
While these response rates were not of the 
magnitude of those in the previous studies cited 
above, we would not go as far as to say that as a 
data collection tool a daily diary of this sort for this 
population was inappropriate.
Anecdotal evidence from telephone conversations 
with participants suggests that there was sometimes 
a concern that they were just saying the same 
thing every day, or that nothing had changed, so 
there was nothing new to report and therefore a 
perception that it was not necessary to fill in the 
diary and send it back. Cognisant of this, we would 
recommend that any researchers contemplating 
using such a tool consider clearer instructions 
to participants regarding the importance of 
completing the diary even when they think 
that they have nothing of interest to report, 
and perhaps make use of regular reminders to 
encourage completion and return.
We also know from telephone calls to the 
LIFELAX office that some participants found 
the diary burdensome to complete. Given its 
physical size, the sensitivity of the subject area 
(a few respondents remarked that the diary was 
not something they wished to have on public 
view, so kept it in the bathroom or toilet), and the 
duration of the task, this sentiment was not entirely 
unexpected. As highlighted in the CONSORT 
diagram (see Chapter 4, Figure 7) we encountered 
a complex withdrawal pattern, with a number of 
participants partially withdrawing and selecting 
which assessment tools they would continue to 
complete. We had several participants electing to 
continue to receive the postal questionnaires and/
or telephone interviews but not the diary.
Item response rates
Analyses of the item response rates suggest that 
the daily diary contents were not troublesome to 
participants.
Each day participants were asked to record the 
number of bowel movements during that day. 
This question was fully answered (i.e. a response 
on every day in the diary) in over 88% of diaries. 
In the remainder it was partially answered (i.e. 
a response was recorded, but not on every day). 
This suggests that the diary may be a useful way of 
collecting such data.
The items taken from the Rome II criteria 
(straining, hard/lumpy stool, incomplete 
evacuation, stool not passed and digital evacuation) 
were completed in full on 97% of occasions.
The item response completion rate was of a 
similarly high percentage for the items dealing 
with taking medication for constipation prescribed 
by the GP, bought OTC or any other measures 
taken to relieve constipation.
TABLE 14 Diary response rates for the LIFELAX daily diary over six rounds
Diary number Number returned Response ratea (%)
1 112 73
2 109 70
3 103 66
4 93 60
5 90 58
6 84 55
Total 591 64
a As the levels of withdrawal and partial withdrawal were complex, we elected to use n = 154 (the total number of 
participants consented and eligible to complete a round 1 diary) as the denominator for all these calculations.
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These data would suggest that the individual 
items within the diary used to collect information 
about bowel function and medication were not 
burdensome to complete, and that a diary is a 
satisfactory way of gathering them. However, the 
duration over which the diaries needed to be 
kept and the daily repetition may have led some 
participants to withdrawing from this aspect of the 
study.
Table 15 reports the estimated effects on our 
primary outcome measure (patient-reported 
QoL); however, we must stress that we feel that the 
interval estimates are too wide to be of very much 
use. In reporting them, if so desired, they can be 
entered into a meta-analysis. We do not believe 
the data collected would merit further analysis, 
but they will be banked. Should any future meta-
analysis be undertaken we will share then with 
the investigator and they can decide whether to 
include them.
Economic evaluation
Resource usage and costs
Information was collected about visits to a 
general practice, visits to hospital and telephone 
consultations between the start of the intervention, 
and at 3 months post intervention. The total 
resource use across each arm is shown in Table 16.
The main comparison of interest was between the 
control arm and the two intervention arms, so 
common costs were ignored as they do not affect 
the choice between interventions.211 Information 
collected on the use of health-care resources was 
strictly in connection with the condition being 
studied. Table 17 shows the unit cost data that were 
used to calculate results in Table 19.
The mean per-case recorded costs for the 
intervention and control arms over 3 months were 
similar, and are shown in Table 18.
TABLE 15 Estimated effect of the interventions on the primary outcome measures
Time 
(months)
Comparison of intervention
Personalised vs control Standardised vs control
Mean 95% CI Mean 95% CI
PAC-QOL overall scorea
3 0.08 –0.19 to 0.36 0.14 –0.09 to 0.37
6 –0.11 –0.41 to 0.20 0.04 –0.19 to 0.27
12 –0.09 –0.38 to 0.21 –0.04 –0.32 to 0.23
PAC-SYM global scoreb
3 0.10 –0.25 to 0.45 –0.00 –0.25 to 0.24
6 –0.27 –0.72 to 0.18 –0.17 –0.50 to 0.17
12 –0.08 –0.47 to 0.30 0.18 –0.20 to 0.56
CI, confidence interval.
a At baseline the overall mean and SD of the PAQ-QOL overall score were 1.30 and 0.77, respectively.
b At baseline the overall mean and SD of the PAQ-SYM global score were 1.10 and 0.79, respectively.
The difference at each of the three time points was obtained by comparing each of the groups that received an active 
intervention with patients in the control group. Baseline scores were included as a covariate; variation between 
practices was included as a random effect. Models were fitted using the ‘xtreg’ procedure in stata 8.
TABLE 16 Total resources utilised by all trial participants by arm
Arm Control Personalised Standard
GP visit 26 out of 27 12 out of 13 40 out of 42
Outpatient 2 out of 27 0 out of 13 1 out of 42
Telephone GP 0 out of 27 1 out of 13 2 out of 42
Telehone practice nurse 0 out of 27 1 out of 13 2 out of 42
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TABLE 18 Mean costs per case in each trial arm
Arm Mean costs (£)
Control 47.04
Personalised 33.69
Standardised 38.40
The amount of data collected about resource use 
was sparse due to the low number of respondents. 
In the 3 months of follow-up, there were two 
hospital visits for the control group, one telephone 
consultation with a GP, and one with a practice 
nurse for the personalised arm; and one hospital 
visit, one telephone consultation with a GP and one 
with a practice nurse for the standardised arm.
Table 19 shows that differences were found for the 
personalised arm in hospital visits and telephone 
consultations. For the standardised arm these 
differences were also found. These differences are 
based on resource use of a small numbers of cases 
in each arm and care should be taken if using 
these findings for predicting changes in service 
use.
TABLE 19  Significant reductions in probability of resource 
category use at 3 months
Arm
Difference (%)
Hospital visits
Telephone 
consultations: 
GP and 
practice nurse
Personalised –0.074 0.077
Standardised –0.050 0.071
Negative numbers represent a decrease in probability 
of using resource compared with control.
Across both intervention arms there had been a 
relative reduction in hospital visits at 3 months 
and a relative increase in the use of telephone 
consultations. For the personalised arm there 
was a 7.4% decrease in hospital visits and there 
was a 5% decrease for the standardised arm. For 
telephone consultations the personalised arm 
is associated with a 7.7% increase, compared to 
the control group, and the standardised arm is 
associated with a 7.1% increase. Table 20 shows that 
these differences translate to a small reduction in 
hospital costs for the intervention arms compared 
to the control arm and a smaller increase in 
telephone consultation costs.
The estimated savings in NHS costs are £13.34 
for the personalised arm and £8.63 for the 
standardised arm.
TABLE 20 Costs savings (increases) in treatment arms 
compared to control at 3 months
Mean difference (£)
Personalised
GP visit 1.36
Outpatient 14.30
Telephone GP (1.62)
Telephone practice nurse (0.69)
Total 13.34
Standardised
GP visit 0.36
Outpatient 9.70
Telephone GP (1.00)
Telephone practice nurse (0.43)
Total 8.63
Figures in parentheses represent increased costs 
compared with the control arm.
TABLE 17 Resource costs for non-common items
Item Cost 2007–8 (£) Source
Outpatient hospital visit 193 2007–8 payment by result tariff for an outpatient 
gastroenterology, first visit (£95 if second visits)a
General practice visit 34 £31, 2006–7 PSSRU,b 3.5% inflator per annum
Telephone consultation: practice nurse 9 £8, 2006–7. PSSRU,b 3.5% inflator per annum
Telephone consultation: GP 21 £24, 2006–7. PSSRU,b 3.5% inflator per annum
a www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHSFinancialReforms/DH_077279
b PSSRU Unit Costs of Health and Social Care 2007; www.pssru.ac.uk/pdf/uc2004/uc2007.pdf
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Patient costs
Ideally, the above would be supplemented by costs 
incurred by patients while accessing NHS care. 
However, the participants supplied insufficient 
information for these to be computed.
Summary
In describing the participants in LIFELAX we are 
confident that the mean PAC-SYM and PAC-QOL 
scores at baseline suggest that our sample did not 
experience extreme symptoms or impact upon 
QoL. The mean scores on the HADS show there 
was no evidence of anxiety or depression either in 
the group as a whole or arm by arm.
Only a very small minority (7%) of participants 
fell outside the range for normal frequency of 
bowel movement. However, this frequency was not 
necessarily satisfactory to our participants.
In our sample over 30% of respondents had been 
taking a prescription laxative for 10 years or longer 
and 15% of the respondents had taken an OTC 
laxative for 10 years or more. This reinforces the 
chronic nature of the condition.
Item response rates suggest that the items within 
the diary used to collect information about bowel 
function and medication were not burdensome 
to complete and that a diary is a satisfactory 
way of gathering them. However, the number of 
diaries and the daily repetition may have led some 
participants to withdrawing from this aspect of the 
study.
Due to the quality and quantity of data collected 
we are reluctant to draw any firm conclusions as to 
the effectiveness of the intervention.
Regarding the economic evaluation, the recorded 
related health-care costs show a cost saving 
of £13.34 (£47.04 – £33.69) for those in the 
personalised arm compared with the control arm, 
and a smaller saving of £8.63 (£47.04 – £38.40) for 
the standardised arm. These savings occurred 
because of reduced hospital costs, offset by 
a smaller increase in costs incurred through 
additional telephone consultations. As there was 
no significant change measured in utility, cost 
minimisation would suggest that the personalised 
arm would be the preferred course, as it produced 
the greatest cost savings. This finding is qualified 
by the fact that the reduction in health-care costs 
was due to a relative small number of cases in a 
relatively small sample.
Effects on HRQoL
Baseline characteristics
Health-related quality-of-life data were collected 
from the trial participants at baseline (before 
the commencement of the arm appropriate 
intervention) and at 3 months (primary end 
point). HRQoL was measured using the EQ-5D,212 
with 89 participants providing data at both time 
points. The EQ-5D is designed to be administered 
in the form of a self-completed questionnaire. 
Respondents are asked to define their own health 
state in terms of the five dimensions (mobility, 
self-care, usual activities, pain/discomfort, anxiety/
depression) and their level (no problems, some/
moderate problems/extreme problems) for each of 
the dimensions by ticking which statement applies 
for each dimension (see Appendix 4). EQ-5D is 
used to determine a utility value between 0 and 1, 
with ‘0’ representing death and ‘1’ perfect health.
The mean utility,213 at baseline, of the personalised 
intervention arm was lower than that of the control 
arm, as shown in Table 21.
TABLE 21 Mean utility at baseline of trial arms, and 
comparison of mean utility of intervention arms with control 
arm
Arm
Mean 
utility SD n
Control 0.714 0.231 29
Personalised 0.536 0.307 16
Standardised 0.711 0.269 44
SD, standard deviation.
Within-arm differences
Table 22, shows that all arms experienced a 
reduction over the a 3-month period. The largest 
reduction in utility scores was experienced by 
the control arm, the smallest reduction by the 
personalised arm.
Between-arm differences
Table 23 shows the change in mean utility of 
each of the treatment arms compared with the 
change in the control arm. The effect of both the 
personalised and standardised intervention arms 
was to relatively increase the utility or lessen the 
absolute reduction; the standardised arm having 
the greater effect and experiencing the smallest 
reduction in utility.
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TABLE 23 Differences in utility between control arm and 
intervention arms between baseline and 3 months
Arm
Difference in 
mean
Variance 
pooled
Personalised 0.02 0.04
Standardised 0.01 0.04
Summary
All of the trial arms experienced a reduction in 
utility, as measured by EQ-5D.
TABLE 22 Within-arm differences in mean utility between baseline and 3 months of trial arms
Arm
Baseline 3 months
nMean SD Mean SD
Control 0.714 0.232 0.680 0.305 29
Personalised 0.536 0.307 0.523 0.300 16
Standardised 0.711 0.268 0.686 0.288 44
SD, standard deviation.

DOI: 10.3310/hta14520 Health Technology Assessment 2010; Vol. 14: No. 52
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
71
Chapter 6  
Results: the process evaluation
did not offer an immediate advantage to primary 
care practices. Indeed, quite the reverse was 
true. In this context, the trial team worked hard 
to find innovative solutions to potential barriers 
and reduce the amount of work required of NHS 
staff, while maximising the attractiveness of the 
research topic and experimental interventions. 
These issues, and the approach adopted by the 
trial team, have been described in more detail in 
Chapter 4, specifically with regard to assessing 
strategies against those proposed in the STEPS 
report,193 and other literature.194 We draw primarily 
on interview data to describe the ‘technology of 
the RCT’, as transcripts of the trial team meetings 
provide a less concise and at times less explicit 
account of key issues. (In LIFELAX trial team 
meetings, many problems associated with RM&G 
guidelines or MREC decisions emerged over 
successive meetings. The trial team shared some 
understanding of the history of RM&G guidelines 
and MREC stipulations, and therefore the contexts 
underpinning particular problems were not always 
made explicit. In interviews, however, these issues 
were articulated overtly and unambiguously by 
the interviewees as they attempted to inform the 
ethnographer.)
In the latter half of the chapter we describe 
the ‘second technology’ of LIFELAX, namely 
the development and deployment of training 
packages for practice nurses. In the first instance, 
the trial team developed a training package in 
BCC techniques, and the production of diet and 
lifestyle materials (information sheets, a video and 
behaviour change manual). The second activity 
was the delivery of BCC training by the research 
dietitian and nutritionist to nurses in the BCC arm 
of the trial. The intention of the trial team was that 
the nurses receiving training in BCC would then 
deploy these skills with recruited participants in 
their own practice. Due to the pragmatic design 
of the trial, the interactions between the nurses 
and participants were unobserved by the trial 
team. In this chapter, we describe the perceived 
utility and reported use of the BCC materials and 
training through the accounts of practice nurses, 
GPs and practice managers enrolled in the trial. 
The reports from primary care staff suggested 
that the topic of the trial was not seen as a clinical 
Introduction
Within the LIFELAX trial the process evaluation 
provided a unique opportunity to investigate the 
stages of development and implementation of an 
RCT in ‘real time’ as events occurred. We observed 
that the trial team’s activities centred on two key 
‘technologies’. The first was the development of 
the RCT itself, which – in common with other 
forms of research – required the investment 
of expertise, finance, clinical and bureaucratic 
support, and the sustained collaboration of a 
number of contributors. The second technology 
at stake was the development of training 
packages and materials for the diet and lifestyle 
interventions, and subsequent deployment of 
this training by the trial team, in particular the 
research dietitian and nutritionist, to an audience 
of practice nurses. The research dietitian and 
nutritionist delivered the training packages with 
the intention that the nurses would later deploy 
target skills and materials with patients in the 
practice. An important observation was that the 
underlying factors that supported each technology 
differed, such that while the trial team were able to 
overcome a number of barriers to the deployment 
of the RCT, many of the factors influencing the 
nurses’ reception of the training packages were 
beyond the trial team’s control.
In the first section of the chapter we discuss the key 
barriers that taxed the implementation of the RCT, 
and the trial team’s efforts to implement the trial 
in primary care practices. At the time of LIFELAX, 
the organisations on which the trial depended 
were in a stage of transition with regard to their 
interpretation of Research Management and 
Governance (RM&G) guidelines. Consequently, 
there was some ambiguity across these 
organisations about how the RM&G guidelines 
should be implemented and this had a number of 
effects on the trial team’s capacity to deploy the 
trial. In particular, the trial team received different 
instructions across PCTs regarding how the trial 
should be implemented. In most cases practices 
contemplating involvement in the trial were faced 
with the prospect of additional work on behalf of 
the trial team. In this regard, the LIFELAX RCT 
– in common with almost all forms of research – 
Results: the process evaluation
72
priority when considered alongside targets 
identified in the GMS contract, and that diet and 
lifestyle approaches were informally considered 
part of the current skill set and training of practice 
nurses. In attempting to find meaning in the 
trial’s interventions, the practice nurses suggested 
that community nurses might benefit from the 
BCC techniques, as these staff were viewed as 
being more likely to work with patients suffering 
chronic constipation. Finally, we report how the 
interventions were perceived by participants 
through their interactions with enrolled nurses.
Technology of the RCT: 
bureaucratic work and the 
organisation of resources
The specific difficulties encountered by the trial 
team in meeting the requirements of the MREC 
and local governance bodies have been reported 
earlier in this report (primarily in Chapter 4). 
Consequently, we do not reiterate them in detail 
here. Nevertheless, we describe the overarching 
structural constraints that consumed much of the 
trial teams’ resources through the course of the 
research, and the key role of social networking in 
surmounting these barriers.
The LIFELAX RCT was set in primary care, where 
a number of organisations shaped the possibilities 
of the research. In particular, the trial protocol 
was required to be flexible enough to meet the 
requirements of various sites (general practices) 
and governing bodies (PCTs, the MREC, LRECs), 
while maintaining the scientific rigour of the 
RCT. In the opening phases of the RCT, the trial 
team’s activities were focused on the identification 
of relevant stakeholders, meeting the requests of 
regulatory bodies, negotiating the cooperation 
of organisational networks, procuring resources 
from these networks, and arranging access and 
integration in busy clinical environments. The 
sequence of work followed a trajectory set out 
by the RM&G framework for clinical trials in 
the UK.214 However, some of these milestones 
proved to be difficult for the trial team to reach 
in practice. In particular, at the time of the 
trial, RM&G guidelines were under a process of 
continuous development, with a number of official 
documents being issued throughout the life of 
the trial and changes in policy, expectations and 
practice emerging over this period. This climate 
contributed to localised and sometimes stringent 
interpretation of the RM&G guidelines by 
different governance bodies. Consequently, both 
the LIFELAX and STOOL trial teams struggled 
to fit the design and conduct of their respective 
RCTs to RM&G requests across PCT sites.19 As 
demonstrated by a growing number of reports 
in the literature (e.g. Wald215), the LIFELAX 
and STOOL trial teams were not alone in 
experiencing these difficulties. During the initial 
implementation of the LIFELAX RCT, the trial 
team encountered substantial difficulties in their 
attempt to meet the requirements of their MREC, 
and in particular, its request for SSAs. If the trial 
team had attempted to obtain SSAs at the level 
of individual general practice sites, recruitment 
may have been severely hampered. However, 
the trial team negotiated a workable solution by 
naming the head of a local PCRN as PI for the 
region.216 SSAs for all practices within the domain 
of the research network were then obtained 
through the credentials of this one key individual. 
Although this strategy was effective in speeding 
administration for the trial and improving the 
possibility of successful practice recruitment, it 
required ad hoc problem-solving and negotiation 
on the part of the trial team. Responding to an 
article published in the British Medical Journal215 
decrying the bureaucratic, seemingly obstructive 
process of seeking MREC/COREC approval, the 
trial manager explained how this strategy was 
developed for LIFELAX:216 ‘A casual remark from 
an LREC secretary, during another telephone 
conversation, about two or more sites “working 
together” opened up another possibility. I could try 
and find out whether practices would collaborate 
and therefore have one PI assuming responsibility 
for more than one site’.
The solution for the trial team was thus organised 
through informal networking and circumstantial 
conversation. Moreover, within the MREC there 
appeared – through access to several e-mails – to 
be a lack of agreement regarding what constituted 
‘high risk’ to patients, and how workable solutions 
should be arranged, and a cautious approach 
was specified. In the execution of the LIFELAX 
trial, issues surrounding the interpretation of 
ethics and research governance placed a great 
deal of pressure on the trial team to continually 
develop creative and workable solutions. However, 
it is unclear to what extent these issues stemmed 
from the unsettled climate at the time of the 
LIFELAX trial, and what were more generic issues. 
Unfortunately, in the process evaluation we did not 
interview or otherwise investigate the perspective 
of the MREC or other governance bodies. 
Therefore, our report is based on the observed and 
reported experiences of the trial team, practice 
staff and participating patients.
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The progression of the LIFELAX trial depended 
on cooperation between the trial team and 
key individuals from a number of external 
organisations. To facilitate the allocation of 
resources and other administrative tasks, 
the trial manager actively pursued external 
contacts and developed working relationships 
through a sequence of telephone calls, written 
communication, site visits and social gatherings, 
some of which occurred in ‘out of hours’ time. 
In this regard the trial relied heavily upon the 
social networks constructed and maintained by 
the trial manager to achieve various milestones. 
Social aptitude was a vital component of the trial 
manager’s repertoire, especially when teamed 
with skills more overtly recognised as desirable 
in the research context: such as those based on 
organisation, procedure and methodological 
rigour. Box 1 presents an abbreviated extract from 
a meeting in which the trial manager’s role in 
securing funding is explicitly recognised.
The extract in Box 1 provides some useful 
information regarding the imperative of social 
networking. Given the very slow rate of recruitment 
observed in a sister trial (STOOL19), NHS SfS 
funding was perceived as being crucial – ‘very 
attractive indeed’ – for the successful recruitment 
of practices into LIFELAX. Although the 
necessary step of ‘filling in … forms’ to secure 
this funding was mentioned by the CI, flexibility 
and responsiveness in the bureaucratic system 
was ascribed to personal interaction; in this case 
the ‘super duper relationship’ formed between 
the trial manager and ‘Jane’ (a DH Research and 
Development Manager).
The trial team worked within MREC guidelines 
regarding methods of recruitment. In particular, 
the trial’s design was shaped by an MREC ruling 
that the trial team could not directly access patient 
information or make direct contact with patients, 
but instead needed to work ‘through’ general 
practice staff. Consequently, much of the work 
of identifying, contacting and processing eligible 
patients was assigned to practice nurses. After 
experiencing a slow recruitment of practices, 
the trial manager reassessed the work asked of 
these staff, and proposed a new process. This 
was designed to simplify work by integrating it 
more fully into routine procedures, in accord 
with principles set out in the STEPS framework.193 
Essentially, the trial manager discovered, through 
discussion with practice representatives, that 
Chief investigator: now the support for science funding and many, many, many thanks and congratulations in particular 
to [the trial manager], also to [trial manager 2] for filling in these forms and for [the trial manager] developing a 
super duper relationship with Jane [a science funding administrator] … erm but er, the bottom line is we have got the 
support for science funding so we will be able to offer practices a per patient recruited amount of approximately 
£60, … So [in summary] I think that’s going to be very attractive indeed to the practices erm, you and Jane and Claire 
[a second administrator] are still sorting out the nitty gritty for the administration
Trial manager: Indeed yes, the, Jane made some requests and we weren’t quite sure what the requests actually meant 
so I contacted Claire … Jane has been out until today and won’t be back until later this afternoon so [I’m] just 
working between the two of them
(Trial project meeting, 24 May 2004; authors’ emphasis, p. 6)
Trial manager: … we haven’t been able to recruit the number of practices and that has implications for recruitment 
of patients … it’s this level of work that we are expecting [practices] to do for us that’s the sticking point and that’s 
what we have got to work around … [in particular] I have a concern about practices writing to patients with this 
appointment for a clinic, and I thought well it’s a pragmatic trial, and we need to really do things as they would 
happen in the real world, … if [the practices’] local custom is to ring patients to invite them [to talk] about their 
condition why are we insisting that they have to write to patients, that’s not what they would routinely do, and the 
whole point of this trial is that it maps onto routine practice life, as much as it possibly can. So I thought well we could 
always suggest an amendment to the protocol allowing GP’s and nurses and receptionists to ring patients …
(Interview II, trial manager, authors’ emphasis, pp. 1–4)
BOX 2  Restructuring recruitment procedures to reflect ‘routine practice’
BOX 1 Social aptitude as a key component of trial management
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‘normal’ (i.e. non-trial) invitations for patient 
appointments weren’t made on paper, but rather 
were initiated by a telephone call. This new means 
of patient contact was built into the amended 
recruitment process. The new process also fitted 
closely with the pragmatic design of the trial, 
which emphasised a ‘naturalistic’ application of 
trial procedures. Box 2 presents an extract of an 
interview in which the trial manager outlined the 
rationale for his plan.
The trial manager’s account serves two purposes: 
demonstrating both personal enthusiasm and 
commitment to the trial, and an attempt to find a 
workable solution despite the limitation of having 
no direct access to patient details. In this instance 
the suggested course of action was to integrate trial 
work with existing patterns of activity in primary 
care settings. Nevertheless, the MREC reached 
the decision that the planned approach was 
unworkable on the basis that telephoning patients 
at home would constitute a form of harassment. 
The MREC decision also prevented recruited 
practices from telephoning patients to check if they 
had received an information letter or to see if the 
patient wanted to reschedule an appointment for 
the trial. This combination of barriers, in addition 
to those cited earlier in this chapter, contributed 
to a growing level of frustration within the trial 
team. Box 3 presents an extract from an interview 
with the trial’s CI in which she explained her 
assessment of the current climate of research 
governance.
The CI began her account by describing what she 
perceived as an ‘overinterpretation’ of RM&G 
and ethical principals by localised administrators 
and MRECs, respectively. Two effects of this 
bureaucratisation were identified: the process 
of research was stalled, ‘[held] up’, and more 
significantly an ‘unethical’ consequence was 
manifest through patients being denied the 
benefits of clinical research (either through 
participation in a research study or benefitting 
from evidence-based care). The CI also offered 
a description of the roles and responsibilities 
implicit in the deployment of clinical trials. In 
particular, she described fundamental differences 
between the work of three groups of actors: 
administrators, researchers and clinicians. 
Researchers, in the context of a pragmatic RCT, 
were described as having an understanding of 
the ‘grass roots’ issues of clinical practice with 
regards to research involvement. In particular, 
researchers were described as being aware that 
clinicians were unlikely to invest resources in 
purely research-based activities without significant 
incentives. Conversely, administrators were not 
‘understand[ing] the realities’ of what was needed 
‘to make things work’ in the context of primary 
care research. Thus the problem was identified as 
one of governance, and not the (mis)translation 
of research priorities to clinical practice. The CI’s 
account is underpinned by a powerful discourse of 
ethics and pragmatics: the trial team are identified 
as being qualified to deploy a sound clinical trial, 
while governance administrators risk generating 
‘unethical’ practice through an overly cautious 
Chief investigator: Erm, I think initially there were very significant barriers … and also considerable delays in 
getting trust R&D approval sorted out for the [the trial], and I, you know, fully appreciate the need for … the 
research governance framework … but I think there has been overinterpretation of some of the stipulations and 
the requirements to the extent that it holds up research and I am thinking here not just of the experience with [the 
current trial] but with various other studies … since the research governance framework came into being erm, 
I think that its swung so far the other way now that people are being so ultracautious that there is a danger of 
research that is potentially beneficial to patients not actually being undertaken and in my opinion that’s as unethical 
as doing poor research and research that’s potentially detrimental to patients.
… I also think that some of the restrictions and the stipulations and the things that people in ethics committees 
and in trust R&D offices are asking for are probably symptoms of … [them being] primarily administrators and 
actually [they] have never done hands-on research themselves and don’t understand the realities of what its like 
doing research and the approaches that one needs to take to make things work so er, so for example the whole 
notion that in the interests of patient confidentiality, you know that we would all respect, that you have to have this 
kind of two stage approach to patients and that their names cannot possibly be released in any way to the research 
team until the patient has given their consent I think that shows perhaps a lack of understanding of barriers for busy 
practitioners, those very barriers that [the trial manager] has been talking about all along; that really practices don’t 
have the time and the resource to write out to patients, get them in, go through the whole process of explaining the 
study to them
(Interview, CI, authors’ emphasis, pp. 1–2)
BOX 3 Frustration with the Research Governance Framework
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approach and seemingly arbitrary variations in 
judgement.
The issues affecting the successful deployment 
of LIFELAX and its sister trial STOOL were 
recounted by a senior member of the trial team 
(Senior Researcher 2 – SR2) in an interview, an 
excerpt of which is presented in Box 4.
In Box 4, SR2 describes a problematic intersection 
between: (1) an evolving research governance 
framework; (2) the agenda of academic researchers; 
and (3) the concerns of primary care. In the first 
paragraph SR2 describes a change in the way 
ethics committees and research governance bodies 
have responded to research, citing escalating 
bureaucratic procedures that are not matched 
to the potential risks posed to participants. The 
quote contains a description of how research 
may have been conducted prior to changes in 
the research governance framework over ‘… the 
last 3–4 years’. Specifically, where studies posed 
little clinical risk to patients, researchers were 
able to deliver recruitment information that 
was tailored to this low level of risk and to the 
research design, keeping technical information to 
a minimum where appropriate, and thus making 
the process of consent ‘straightforward’ for both 
patients and researchers. However, SR2 explains 
that recent research governance stipulations 
universally require a more complex approach to 
consent, often involving the input of clinical staff. 
Therefore, although originally the research team 
‘would do everything’ in the research process, 
the burden of patient recruitment in primary 
care has now passed to practice staff. SR2 adds a 
qualifying statement to his criticism of research 
governance, by identifying the ‘… need [of ethics/
governance frameworks] to operate’ in matters 
where patient wellbeing is in question. Finally, 
SR2 summarises that the key concern is an 
increase in the undiscerning application of research 
governance stipulations in an uncritical and 
generally uniform manner across research studies. 
This approach requires, at times, unnecessarily 
complex recruitment procedures, greater input 
from clinicians, and correspondingly affords the 
trial team less control over the delicate recruitment 
process.
In the second paragraph of Box 4, SR2 explains 
why greater involvement of clinicians in the 
recruitment process is problematic. Specifically, 
the agenda of GPs and other primary care staff 
is shaped by the changing General Medical 
Services (GMS) contract. While researchers 
have the enthusiasm, resources and interest in 
implementing their own research projects, primary 
care staff are ‘… very very busy’ and have ‘… other 
priorities’. These priorities it is argued do not 
Senior researcher 2: … I think the real barriers are in primary care and this is where the situations have changed over 
the last 3–4 years with research governance framework so in the past doing the trial in primary care, you would 
make sure that having got agreement from the primary care team that they would allow their patients to participate 
in the trial, and the research team would do everything else … Er the consent form would be straight forward ‘I am 
willing to participate in the trial or I am not’, its … something which doesn’t have any major impacts on your life, 
you know, … its not a, a dangerous drug, its not a dangerous procedure, its nothing life threatening its just ‘will you 
participate in the research’. So the procedures were much more tailored to the severity of the risk is my view and 
… you know if I had been doing a study of heart transplants then clearly we would not have been using the same 
procedure then, then the procedure would be much closer to the way ethics committees and research governance 
need to operate, there would be a much fuller explanation by the consultants, exactly what it involved, etc., so it’s 
about matching risk to er bureaucracy
… you see it’s the enthusiasm of the researchers, … the focus of the research team that this is the only thing 
which is important to them, enables you to build a rapport with the participants, ensure they understand fully 
what’s going on, explain it to them, er and so that they are quite clear that it has no detrimental effect on their 
outcomes, etc. What you have got now though is a very very busy primary care and I no way am going to lambaste 
or criticise primary care, you’ve got very very busy primary care, these individuals have other priorities which are 
at the moment far worse than they probably were 5 years ago too, because of the new GP contract so primary 
care contracts have changed so that they are having to meet all these prevention targets making sure everybody, 
plenty of people have had flu vaccines with the number of kids out there who have been coughing all those things 
have to be met. So their work load is substantially more than it was say 5 years ago, life is far more complex, there 
is big business here, [a] division of labour, and none of the individuals involved have … anywhere near the same 
kind of commitment to the project as you or I do, as researchers, so no wonder the enthusiasm is not there for 
recruitment. So the barriers are not you know primary care, the barriers are about the way that research has to be 
done because of research governance so I think that’s the biggest barrier
(Interview: SR2, 22 April 2005, authors’ emphasis, pp. 2–3)
BOX 4 Different priorities in research practice: research governance, researchers and primary care
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always overlap with those of research. Therefore 
the enforced transition of control over recruitment 
– from dedicated researchers to busy clinicians 
– is counterproductive. SR2 reiterates that the 
central problems to implementing research are 
not to be found in primary care, but in ‘… the way 
that research has to be done because of research 
governance’.
The LIFELAX RCT required bureaucratic 
approval and coordination across a range of 
organisations, including those concerned with 
ethics, administration, finance and human 
resources. Congruence between relevant 
networks was sustained by the social, largely 
hidden work of the trial manager in identifying, 
creating and maintaining relationships, with 
key individuals in relevant positions of authority 
in these organisations. Subsequently, in order 
for the trial to progress and meet milestones, 
the trial team had to rely on non-standardised 
and previously unreported methods. Although 
the trial team worked hard to promote the RCT 
and to enhance recruitment, the research was 
hampered by three key features of an ‘unstable 
research governance environment’, namely: (1) 
differences in interpretation and implementation 
of RM&G guidance across administering bodies; 
(2) an interpretation of RM&G guidance by PCTs, 
and ethical decisions by the MREC, that was 
viewed as ‘overcautious’ by senior research staff; 
and (3) by the trial team’s limited access to patient 
data and contact procedures as stipulated by the 
MREC. Reasons for particular interpretations of 
research governance and ethics, and disparities 
in interpretation, require further investigation. 
Notably the process evaluation did not include 
a detailed investigation of the perspectives of 
the MREC – other than via available e-mail 
correspondence and letters – or the views of PCT 
officials. However, an endemic fear of litigation 
in light of the incidents at Alder Hey, and more 
recently Northwick Park Hospital, may be a 
contributing factor to the ‘cautious’ approach of the 
MREC and PCTs, as perceived by the trial team.
A summary of the findings from observation of the 
trial team at work is presented in Table 24.
The ‘second technology’ of 
the LIFELAX trial: training 
packages for practice nurses
Studies investigating patients, their data or the 
work practices and systems implicated in their care 
often rely on the cooperation and commitment 
of medical staff. However, factors that affect 
the attractiveness of research participation for 
clinicians in various settings are multiple and 
poorly understood.217–219 Moreover, given the 
level of commitment required of clinicians, it is 
perhaps not surprising that poor recruitment 
of this group to RCTs is an established subject 
within the literature.220 Subsequently, in the 
LIFELAX trial, the research team attempted 
to maximise the attractiveness of the study by 
promoting its applicability for primary care 
medicine, following strategies set out in published 
research.193,194 In particular, the introductory 
materials and presentations to practice staff 
emphasised the potential benefits of reducing 
laxative prescriptions, decreasing patient contacts 
and upskilling staff, by equipping them with 
transferable skills in patient education and 
delivery of lifestyle advice. Nevertheless, despite 
some initial expressions of interest, the trial team 
found it difficult to secure the commitment of 
practice managers and senior partners. While 
some of the barriers to practice recruitment have 
already been described in this report, additional 
TABLE 24 Barriers to the integration of the RCT in primary care
The trial team were primarily engaged in meeting administrative and practical objectives and completing ancillary 
paperwork. However, the RCT relies heavily on cooperative networks. Cooperation (congruence) between networks 
was sustained by the social – and largely ‘hidden’ – work of the trial manager in identifying, creating and maintaining 
relationships with key individuals in various organisations
Due to differences in the application of RM&G guidelines across sites, and interpretations of the guidelines that were 
not ‘research friendly’, the trial team were under pressure to continually develop creative and workable solutions to 
emerging practical problems. This formed a barrier to the satisfactory and timely achievement (disposal) of essential 
milestones in the delivery of the trial
The MREC ruled that the trial team could not directly access patient information. Consequently, much of the work 
of identifying, contacting and processing eligible patients was assigned to practice nurses. As practice staff were often 
busy, the recruitment process was initially very slow
Additional barriers to the trial included a research topic that did not match the clinical priorities established through a 
new GMS contract and numerous problems in acquiring RM&G approval, such as a slow response from some PCTs, out-
of-date application procedures and ‘broken’ or old web resources
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– less readily apparent – concerns overlaid these 
practical obstacles. In particular, the nursing staff 
appeared to be unenthused by various aspects of 
the research. Nurses interviewed in the BCC arm 
of the trial described the counselling techniques 
as being familiar, or as one nurse commented; 
‘… the information [was] … given to experienced 
health-care professionals; it wasn’t something 
we were unfamiliar with’ (Nurse 4, interview, 11 
October 2004). Most of the nurses across all three 
arms of the trial described chronic constipation as 
a comparatively ‘uninteresting’ topic, and an issue 
that seldom arose in their routine encounters with 
patients. Consequently, interest in both the topic 
of the trial and the experimental interventions 
was low. In this section of the chapter we describe 
feedback from a range of practice staff regarding 
their perception of the research topic, and the role 
of practice nurses in implementing the LIFELAX 
RCT.
Barriers and facilitators to normalisation 
of the LIFELAX nurse training packages
Through the nurses’ accounts it is possible to 
identity two features of the training packages that 
were salient to them. The first was the central 
topic of the trial – chronic constipation, perceived 
by most respondents as a problem not routinely 
encountered by practice nurses in their interactions 
with patients. In this regard the LIFELAX trial 
was perceived by most of the nurses as presenting 
them with an additional clinical responsibility. In 
particular, chronic constipation was regarded as an 
issue that was typically managed fairly successfully 
by laxatives and that was typically within the remit 
of care delivered by other professionals (GPs, 
community nurses). The second issue for nurses 
in the personalised arm of the trial, were the BCC 
techniques. The nurses who received instruction 
in BCC described the training package as not 
offering new skills, but rather reinforcing current 
approaches. Nurses in both personalised and 
standardised advice arms of the trial reported 
the diet and lifestyle materials as having some 
relevance to their standard practice (for conditions 
such as obesity and healthy living). However, these 
comments were made in the context of a generally 
negative report of trial involvement, and it is not 
possible to determine how or if these materials 
would be used beyond the life of the research.
When presented with resource-intensive work that 
is poorly defined – such as the management of 
some chronic conditions – medical professions may 
attempt to divert responsibility for the condition 
to another closely aligned professional group 
(e.g. Viner221). Across the interviews with practice 
nurses, chronic constipation was described as 
falling outside the boundaries of their routine work, 
and as a responsibility distributed across community 
nursing teams and GPs. Box 5 presents a more 
detailed explanation through the independent 
accounts of two nurses.
Nurse 9 explained that the topic central to the 
trial’s interventions – chronic constipation – was 
not a key feature of practice nursing. Specifically, 
she identified the condition as a concern ‘ for the 
doctor’ or ‘nurse practitioner’. In this regard, Nurse 9 
viewed the topic of the research – and by extension 
the training packages – as having little direct 
relevance to her day-to-day work. In the second 
account, Nurse 4 echoed this interpretation. 
In particular, she explained clearly that the 
Interviewer: … did you find [the research consultation] differed from how you would normally interact with those 
patients or –
Nurse 9: Ah yes I would say so because I don’t, I mean unless we are doing a medication review with patients who 
are already on lactulose or the, whatever medication, then we probably wouldn’t; it’s not a question [chronic 
constipation] that ever comes up unless people are coming in, and I mean they wouldn’t come [in to see] the practice 
nurse anyway, to discuss that, if they had any problems they would come in to see the doctor or the nurse practitioner. 
So it’s not a subject that ever comes up really
(Interview: nurse 9, brief intervention, authors’ emphasis, p. 2)
Also:
Nurse 4: I don’t specifically counsel people about the their bowel habits, erm it doesn’t tend to come into my role 
… I don’t get involved in it other than I give healthy eating advice, erm in the process of a lot of other consultations 
that are just a part of it, well-woman, well-man checks, we always give dietary advice we always give exercise advice 
… I think maybe the district nurses have a lot more to do with [chronic constipation in particular], because they get 
the other extreme – they are out in the community with elderly people who are really bunged up
(Interview: nurse 4, personalised intervention, authors’ emphasis, pp. 2–3)
BOX 5  Defining roles: the appropriateness of ‘constipation work’ for practice nurses
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management of chronic constipation did not 
‘come into [her] role’. Nevertheless she added that 
‘healthy eating advice’ was part of a wider package 
of work including ‘well-woman’ and ‘well-man’ 
checks. Therefore, although the topic of chronic 
constipation was not considered a central area of 
work for practice nurses, they viewed the provision 
of diet and lifestyle information as part of their 
core skill set.
Regarding the second account in Box 5, an 
additional point is Nurse 4’s use of the term 
‘dietary advice’. One concern among the trial team 
was that nurses in the personalised (BCC) arm 
of the trial would conflate directive advice giving 
with the counselling approach. However, while 
nurse 4 – who attended the BCC training – used 
the term ‘advice’ in her account, most of the nurses 
in the personalised arm described the techniques 
as being familiar, distinct from paternalistic 
approaches, and in routine use through their 
smoking cessation and obesity work.
Nurse 4 finished her response by emphasising that 
district nurses see ‘… the other extreme’ of chronic 
constipation with ‘… people who are really bunged 
up’. In this regard, Nurse 4 made a distinction 
between the preventative work of practice nurses 
through well-person initiatives, and the work of 
community nurses whose responsibilities include 
the ‘other extreme’ of chronic constipation: 
amelioration and treatment. In this example the 
aim of the trial – to train practice nurses to prevent 
rather than treat chronic constipation – is lost in 
the nurses’ explanation of why the trial’s topic is a 
low priority.
It is important to consider that while one 
interpretation of the nurses’ accounts is that they 
were attempting to pass responsibility for chronic 
constipation to community nurses, this glosses 
over a valuable message consistently delivered in 
the nurses’ interviews: that chronic constipation 
was not a problem that was pertinent to the nurses 
within their routine interactions with patients. 
Therefore, the trial team had to work within a set 
of parameters that were not conducive to the trial’s 
success; namely asking practice nurses to engage 
with a problem that was largely ‘invisible’ to them. 
Moreover, while some practice managers viewed 
chronic constipation as a financial burden to their 
practice, they reiterated the nurses’ position that 
it was a condition addressed more directly by a 
GP (through laxative prescription) or by nurses 
working in the community. One practice manager 
provided a ‘bird’s eye’ view of the distribution 
of work across the practice. An extract from this 
interview is presented in Box 6.
Throughout her account, the practice manager 
made a series of important points regarding the 
division of labour within the practice, and the 
specified skill sets of various groups of nurses. 
While the age of patient populations was not 
used by the nurses as a means of demarcating 
professional boundaries, in the interview the 
practice manager alluded to a broad sector of work 
that was conducted between community nurses and 
‘… our older group’. Following this perspective, the 
practice manager suggested that the community 
nurses ‘should be and would probably benefit from’ 
involvement in the research, but ultimately did 
not ‘support’ the practice in this instance. From 
this point onwards in the extract, the practice 
manager sets out the context for the ‘failure’ of 
the interventions in her practice. Specifically, the 
practice nurses were described as an inappropriate 
substitute to the community nursing team. In 
this regard the practice managers’ response is to 
assign responsibility for the problem of chronic 
constipation to health-care professionals beyond 
the control of the practice. As described earlier, 
the redirection of responsibility for particular 
patient populations from one professional group 
to another has been documented elsewhere in 
the NHS.221 In the current account, the practice 
manager described the practice nurses as having 
responsibility for defining their own skill sets 
Interviewer: … I think we were talking about why this particular project could be tricky, you mentioned that it’s –
Practice manager D: Right okay I think number one was the fact that this particular research project involves older 
people by default you tend you, it tends to be from the nursing side it tends to be our community nurses who are 
involved with our older group, erm, and they are the people who should be and would probably benefit from looking at 
a research project like this, unfortunately … we were unable to engage them to support us … So [it had to be] our 
practice nurses involved, and they felt that it really wasn’t erm their erm remit, you know chronic constipation and 
advice does very much tend to be outside the practice erm unfortunately it hasn’t worked!
(Interview, practice manager D, authors’ emphasis, p. 1)
BOX 6 Constipation as a problem ‘outside the practice’
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and spheres of activity. Specifically she explained 
that ‘…they felt that it really wasn’t erm [within 
their] remit’. Consequently, the extract suggests 
political tensions within the practice regarding 
the distribution of work implicated by LIFELAX. 
An investigation of the everyday running of 
practices enrolled into the RCT was beyond 
the scope of the process evaluation. However, 
task designation issues within each practice are 
likely to have contributed to how the trial was 
perceived in each site, particularly as the trial’s 
topic was comparatively ‘unglamorous’, involved a 
population of patients not prioritised in the QOF, 
and – like all research – included additional work 
for the clinical staff involved. In some instances 
practice nurses explained that there had been 
some direction by senior practice staff – ‘a little 
bit of pressure’ (Nurse 9, 16 April 2007) – to 
cooperate with the trial team, and consequently 
these nurses may have felt little ownership in the 
research. This situation arose in part due to the 
manner in which the trial team contacted and 
enrolled practices to the trial. Practice enrolment 
occurred via negotiations between the research 
team and GPs and practice managers, although 
most of the research tasks were targeted at nurses. 
Unfortunately, it was not possible to monitor the 
degree of consultation that occurred in each 
practice between senior and nursing staff.
A pertinent issue raised by primary health-care 
staff enrolled in the trial was the unsuitability 
of the interventions for practice nurses, and 
correspondingly their appropriateness for 
community nurses. However, while community 
nurses were initially included in the trial protocol, 
they were quickly identified as a potential 
confounding factor in the trial design. Box 7 
includes an extract from an audio-recorded 
subgroup meeting in which the trial team explore 
reasons for excluding community nurses.
Several interesting methodological points are 
raised through the extract in Box 7. The first 
is an observation that community nurses are 
employed by the PCT rather than the practice. 
This point links to the comments of the practice 
manager in Box 6, namely that the practice did 
not have absolute authority over the work of the 
community nurses, and therefore were unable to 
secure their cooperation in delivering the trial. 
Nevertheless, as described earlier, the practice 
manager capitalised on these differences to excuse 
practice staff from the tasks asked of them by 
the trial team. The practice manager suggested 
that in the context of chronic constipation, the 
research work was more appropriately suited to 
‘outsiders’ in the community; in this example, PCT 
employed nurses. The second point is that the RCT 
design – specifically the rationale and practice of 
randomisation – precluded, or at least rendered 
very difficult, delivery of training to the most 
‘appropriate’ group of staff: community nurses. 
As the senior dietitians explains ‘The problem 
is that [community nurses] go from practice to 
practice so you will end up training a community 
nurse with the behaviour change [approach] 
who then goes into your standardised practice 
[and contaminates the trial]’. In this regard, 
the methodological limitations of even a cluster 
RCT design undermined some aspects of the 
interventions’ assessment. Although in principle 
Dietitian: I don’t er, I just think it’s very hard to get hold of community nurses, they’re not employed by the practice, 
they’re employed by the PCT
Trial manager: PCT
Senior dietitian: Can I just put another little fly into that ointment?
Health psychologist: The randomisation
Senior dietitian: The problem is that they do go from practice to practice so you will end up training a community 
nurse with the behaviour change who then goes into your standardised practice
Health psychologist: That’s right, yes
Trial manager: Right
Dietitian 2: Who says ‘you should be doing this’?
Senior dietitian: Yes. And they also if they find something that they like, they are really very good at photocopying, 
and I have experience of this, and they distribute it to every practice that they go to, give it to nurses and say ‘do 
you like this?’. Em in [another study] we trained community nurses if the practices wanted them to be involved and 
we had our leaflets popping up in our control practices
(Subgroup meeting transcript, 16 March 2004, pp. 23–24)
BOX 7 Excluding community nurses from the RCT
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it would have been possible to use the community 
nurse as the unit of randomisation in this trial 
design, this would have required the trial team to 
identify the case load for each nurse, and to then 
recruit these patients to the trial. It is unlikely that 
this approach would have been feasible given the 
trial team’s limitations on access to patient data. 
Finally, the third related point is that the trial 
design, despite embracing a pragmatic agenda, 
conflicted with ‘real world’ practices regarding the 
dispersion of skills and materials. At the end of the 
extract the senior dietitian recounts an episode 
of normalisation-in-process, when she states ‘if 
[community nurses] find something that they like 
… they distribute it to every practice that they go 
to’. Ironically, the RCT disrupted the potential 
for normalisation by prohibiting the transfer 
of those techniques and materials that nurses 
found practically useful in their daily work. These 
limitations were unavoidable given the brief for a 
RCT.
Nurses in the personalised arm were sceptical that 
the training sessions they attended would furnish 
them with new skills, or improve their practice 
with patients. The BCC techniques were identified 
by the nurses as overlapping considerably with 
their current skill sets. Framing this feedback 
through the terminology of the NPM, the trial’s 
personalised intervention failed to dispose of 
clinical problems relevant for practice nurses, 
and did not enhance their confidence in working 
with chronically constipated patients. Neither 
the ‘problem’ of chronic constipation, nor the 
suggested ‘solution’ via BCC, were reported as 
valuable or significant for the nurses in their daily 
work. Given this context, the materials associated 
with the interventions (leaflets, BCC manual) were 
praised in their capacity to facilitate a sharing 
of ideas, or congruence, about diet and lifestyle 
issues between nurse and patient. Box 8 presents a 
summary of these points through the account of an 
additional nurse.
Importantly the quote from Nurse 3 demonstrates 
some perceived value in the behaviour change 
tools, particularly with regard to improving 
congruence between the nurse and patient. 
However, this positive assessment was made 
alongside Nurse 3 suggesting that the materials 
were ‘the best bit’ of participation in the trial. 
It is therefore not clear if Nurse 3’s praise of 
the materials was due to their practical merit in 
facilitating consultations or an attempt to find 
something positive to report to the interviewer. 
Nevertheless, Nurse 3 commented that she would 
value the use of the materials ‘in the clinic’ with 
patients outside a trial setting; conspicuously 
using the term ‘our patients’. Based on this 
particular account, the tools could be considered 
as a potential means of facilitating the disposal of 
some clinical problems relating to diet and lifestyle 
generally. However, none of the nurses described 
an intention of applying the tools post trial with 
patients suffering from chronic constipation 
specifically.
In a recent paper, Salmon et al.219 identified factors 
affecting the relative attractiveness of research 
participation for practitioners in primary care 
in contrast with those in secondary care. The 
authors suggest that although a research portfolio 
might boost the careers of clinicians working in 
hospital settings, the same cannot be said for 
those established in primary care where research 
involvement may hold little or no incentive. 
Nurse 3: … [the leaflets could be] ideal because [patients] could look at the pictures and identify ‘well yeah I’m 
having so many of those a day or this amount of veg, this amount of fruit, or I’m not eating any at all’, I did find that 
one really good to use and I thought it would be good eventually if we could maybe have some to use in the clinic to 
use with our patients, or along those lines, because sometimes you speak to people and you ask them ‘which veg do 
you eat’, and they class two peas and things like that as veg, and they’re not really aware that there is not a lot of 
fibre, etc., you know and I found that was a good way of getting [the information] across to people
And later in the interview:
Interviewer: Do you think the techniques that [the dietitian] was demonstrating, do you think they differ much or at 
all from your usual practice? I mean … was there anything in the techniques themselves that’s different about how you 
interact with patients?
Nurse 3: Well nothing really apart from those leaflets, … I think those information leaflets were really good … I think 
that was the best thing, [the dietitian] had obviously or whoever had thought a lot about what went into them, and 
making them easy to use [lowering voice] I think that was the best bit
(Nurse 3, personalised arm, authors’ emphasis, p. 2 and p. 5)
BOX 8 Finding value in the intervention materials
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Through the process evaluation we explored how 
practice-based staff viewed involvement in the 
LIFELAX trial specifically. Although we cannot 
comment on their experiences in other research 
settings, the feedback of our respondents suggests 
that they generally held little interest in the 
interventions or overall success of the research. 
Three out of the eight practice-based nurses 
countered this position by expressing interest 
in the RCT’s topic and success. However, two of 
the trio were employed as research nurses and 
the third held aspirations for a career as a nurse 
practitioner: a goal possibly facilitated by research 
involvement.
The topic of the trial – and, to some extent, the 
nature of the interventions – had been preset 
in the commissioning brief for the research. 
Consequently, the trial team attempted to meet 
the brief while also working to meet the realities 
and demands of clinical practice. With regard to 
the practice nurses, the trial team experienced 
frustration as their aspirations for the training 
packages were not realised. Likewise the nurses 
struggled to make sense of trial work within the 
context of their working practice. In attending the 
training sessions and applying relevant skills with 
participating patients, the practice nurses were 
frequently left perplexed by their participation. 
An analysis of their accounts suggest that they 
understood the trial as a request to tackle an 
already successfully managed ‘problem’ with an 
untested and time consuming ‘solution’. The 
nurses were therefore unconvinced that their time 
was being used appropriately, and for a worthwhile 
exercise. These findings lead us to reflect on 
the importance of programmes of work that use 
research methods in a timely and appropriate 
manner. In the case of the LIFELAX trial, an 
accumulation of evidence regarding the clinical 
effectiveness of BCC for chronic constipation, prior 
to a pragmatic trial of nurse training packages, may 
have been valuable. In particular, such evidence 
may have added weight to the argument that 
changing current patterns of work within primary 
care was worthwhile. More importantly, a feasibility 
study that identified problems with recruitment, 
low clinical interest, and RM&G issues may have 
precluded investment in LIFELAX. At the time 
of funding the HTA did not commission pilot or 
feasibility studies, although currently the HTA’s 
position on this issue has changed.
A summary of the findings from the practice 
nurses is presented in Table 25. In the third and 
final section of this chapter, we explore the views of 
the participating patients.
Making sense of 
participation in the context 
of chronic illness
Some of the barriers to the success of the 
LIFELAX trial, as explained earlier in the chapter, 
were due to a range of issues concerning RM&G 
guidelines and MREC rulings, and a notable 
lack of interest in the research across primary 
care sites. However, the participants’ accounts of 
their experience also offer a useful perspective 
TABLE 25 Barriers and facilitators to the normalisation of LIFELAX nurse training packages in primary care
Summary
The nurses reported that the topic of the trial was ill matched to the current work of practice nurses and the way in 
which chronic constipation was currently managed in primary care. Although the trial assessed the value of changing 
current practice from treatment of the condition to nurse-led preventative measures, the nurses generally focused on 
current patterns of work. Nevertheless some nurses argued that chronic constipation was a comparatively low-priority 
complaint, that it was successfully treated via laxatives in most cases, and that they were sceptical that motivation was 
instrumental in patients’ experiences of chronic constipation
Additional points
The BCC techniques were identified by some nurses as overlapping with their current skill sets and therefore were not 
described as providing the nurses with new skills or tools
The materials associated with the interventions (primarily pamphlets) may facilitate a sharing of ideas (congruence) about 
diet and lifestyle issues between nurse and patient, although praise of these materials was made in the context of a 
comparatively negative description of trial involvement
Some of the nurses questioned the validity of attempting to motivate patients whose constipation was caused by lifestyle 
factors beyond their control. Consequently, rather than enhancing confidence in the conduct of their work, some 
nurses described the BCC approach as potentially undermining the interaction they had with patients
Due the implementation of randomisation, the community nursing teams who may have found the techniques most 
applicable were excluded from the trial
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regarding how the trial was deployed, and the 
significance of the interventions for patients 
suffering chronic constipation. The meaning 
of the trial for participants was shaped by their 
individual ‘illness trajectories’ or, specifically, 
the manner in which participation met ongoing, 
idiosyncratic priorities regarding their illness.222 
Specifically, although some participants had 
reached personally satisfying treatment decisions 
prior to the trial, others were actively seeking 
new solutions to the management of their chronic 
constipation. Participants in the two ‘active’ 
diet and lifestyle arms of the trial experienced 
an interaction with one of the practice nurses. 
Consequently, in these arms, the participants’ 
perception of the research was shaped by how the 
nurses conveyed – deliberately or subconsciously 
– their own views of the trial. It was difficult 
therefore to discern through a single interview 
with a given participant, sometimes a considerable 
time after the consultation with the nurse, 
how these factors independently affected the 
participants’ experiences. Nevertheless, three 
key topics were central to all accounts. These 
were: (1) reported motivations for participation; 
(2) experience of interacting with a nurse in the 
research consultation (in applicable arms); and (3) 
understanding of the outcomes of participation in 
the RCT.
Participation in the LIFELAX 
trial
The participants’ explanations regarding 
motivation for involvement in LIFELAX centred 
on the manner in which the trial met their 
priorities and expectations with regard to their 
illness. Participants who described having 
successfully established a means of coping with 
chronic constipation reported that the trial was a 
means of benefiting others. However, participants 
who were seeking solutions to their experience of 
symptoms identified the trial as an opportunity for 
adjunct therapy. In some interviews participants 
moved between these conceptualisations. Data 
for the process evaluation was collected from 
each participant through a single interview. 
Consequently, the motivations expressed by any 
one individual for participation may have changed 
over the course of their involvement with the trial. 
Box 9 presents the accounts of two participants 
when asked to describe what they hoped to achieve 
by participating in the trial.
Interviewer: … did you have any particular motivation in being part of this trial, other than you said you had 
experience of [being in other studies]?
Participant: I was suffering from a combination of [complaints] … we went through a variety of treatment options 
and we settled I think on [a medication] which seemed to do the trick … only just now unfortunately I’m having 
[side effects] … Er, in addition to having the [the side effects] I found that I’ve been [suffering constipation again], 
even though I was taking the [medication] …
Interviewer: … so do you think in terms of your motivation for being part of this trial, would you say then that you 
were looking for a solution? Do you think, would that be a fair summary, that you were –
Participant: (interjecting) – Yes, I have been looking for a solution for a long, long time
(Interview, participant ID 1315001, personalised consultation, pp. 1–2)
And:
Interviewer: I think to start with if we could just talk a little bit about how you first came to be involved in the trial, 
that would be really good
Participant: Right. Um, well first of all I think I had a letter from the [trial team] asking if I would like to take part … 
Now I didn’t think that I suffered from constipation at all so I was very surprised when I got this letter and I rang the 
[trial team] up and said ‘Well look I don’t suffer from constipation’. I do have [a related illness] so I think perhaps the 
doctor put my name forward because I’m on [a relevant medication] all the time … I think that’s why I was involved 
in it, but I’ve never had any history of constipation. But the people said well that was OK they would go ahead with 
it
Later in the interview:
Interviewer: Do you mind if I ask you if you had any particular motivations for taking part?
Participant: Er no, except, well, no I mean it was sort of they asked me, would I? And I said yes I would. It was just 
as simple as that really, I’d no objection to it … No, no, um as I say I was quite willing to take part in this, in the survey. 
Um and quite willing to leave it at that
(Interview, participant ID 1018009, standardised consultation, authors’ emphasis, pp. 1–3)
BOX 9 Retrospective accounts of motivation for participation in the RCT
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In the first extract the participant expressed his 
motivations as trying to find a satisfactory ‘solution’ 
to the problem of chronic constipation. Notably, 
he described a prolonged period of dissatisfaction 
with his current medication prior to the LIFELAX 
trial: ‘I have been looking for a solution for a 
long, long time’ (ID 1315001). In this respect 
the participant may be described as orientating 
towards the trial – at this particular instant – as a 
‘patient seeking treatment’.223,224 Conversely, the 
second participant describes themselves as ‘[not] 
suffer[ing] from constipation at all’ (ID 1018009), 
a theme also identified in the STOOL trial.19 
Throughout the extract the second participant 
explains their surprise at being asked to contribute 
to the LIFELAX trial, and offers an explanation 
as to why they might have been identified: ‘I 
think perhaps the doctor put my name forward 
because I’m on [a relevant medication] all the 
time’ (ID 1018009). In this regard, while the 
participant understood that they were taking 
laxative medication, the perceived effectiveness 
of the treatment was such that constipation (and 
the taking of laxatives) were not regarded as a 
problematic feature of daily life.
This perception (of laxatives being an effective 
solution to constipation) was so entrenched in the 
accounts of some respondents, that the purpose 
of the trial was put into question. Therefore, 
for this individual participation was a result of 
meeting a request from the trial team; ‘… I mean 
it was sort of they asked me, would I? And I said 
yes I would. It was just as simple as that really, 
I’d no objection to it’ (ID 1018009). The second 
respondent is an example of those participants 
who identified themselves primarily as ‘research 
subjects’ in an RCT, in much the same manner as 
participants described in a previous paper.223 For 
these participants the trial was largely an altruistic 
exercise that might, potentially, benefit other 
patients in the future. These conceptualisations 
were helpful tools in understanding the trial’s 
significance for various participants. Those who 
were seeking treatment as patients may have 
benefited most from the personalised BCC 
consultation as they were by definition actively 
seeking intervention. However, we found that 
regardless of randomisation status or orientation 
to the trial as ‘patient’ or ‘research subject’, most 
participants struggled to make sense of their 
involvement in the LIFELAX trial. This finding 
does not reflect on the quality of the LIFELAX 
participant information materials, but is a 
common finding in qualitative research exploring 
the understandings of participants in RCTs.225 
In recent years researchers have focused on the 
importance of making sure participants understand 
RCT concepts, rather than simply being able to 
recall them by rote; however, to date there is no 
clear method of facilitating this process.226,227 The 
practice nurses involved in the trial described 
the intervention techniques as ‘familiar’, and 
therefore the participants may have also struggled 
to understand the experimental components in 
the trial design. This is a point discussed in detail 
below.
The second topic central to the participants’ 
accounts was their understanding of the role of 
the practice nurse in the trial. The nurses were 
described both in regard to their perceived role 
and their performance. Participants tended to talk 
about these topics as they articulated what they 
perceived as poor or unexpected behaviour on 
the part of the practice nurse. Box 10 presents 
two accounts by participants disappointed by the 
perceived behaviour of the practice nurses.
In the first interview presented in Box 10, the 
participant offered an evocative description of 
meeting with a practice nurse in the setting of a 
LIFELAX consultation. The nurse is described 
as having an attitude quite opposed to the trial, 
which the participant used in her account to 
contrast with her own position as a citizen ‘happy’ 
to ‘benefit … others’ (ID 1101003). Throughout 
the account the participant used a number of 
explanations for why the nurse may not have 
been enthused by the study such as having ‘an 
awful lot to do’ (ID 1101003) and ‘dealing with 
patients who are ill and who need attention’ 
(ID 1101003). Nevertheless, the participant was 
disappointed that the nurse ‘[gave] the impression 
that she thought it was all going to be a waste 
of time’ (ID 1101003). Finally, the participant 
contrasted this description of clinical activity 
with the work of the trial – ‘filling in forms’ (ID 
1101003). In this instance the participant appeared 
to be disappointed and frustrated by the nurse’s 
attitude, although she demonstrated that she could 
understand some of the contextual reasons why the 
nurse might respond in this manner to the extra 
work involved. Both the nurses and participants 
shared similarities regarding their participation 
experience. Both struggled at times to make sense 
of their participation, and both were required to 
complete additional work. Consequently, we may 
interpret the participant’s account of the nurses’ 
behaviour as a means of expressing her own 
frustrations to the researcher. For this participant 
the trial was an exasperating experience, and the 
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nursing staff served as ‘visible’ representatives of 
the trial, essentially the subjects of blame for an 
unsatisfactory participation experience. Some of 
these themes reoccur in the second participants’ 
account. However, here, the participant explained 
why receiving ‘common sense’ (ID1018001) advice 
was helpful when suffering from a condition such 
as chronic constipation. In this instance the nurse’s 
role was identified as being more than a neutral 
provider of information, but as a person interested 
in the participant’s complaint. The nurse therefore 
provides information that ‘… you’ll already 
know’ (ID 1018001), but the act of discussing the 
topic, face-to-face with another individual, was 
potentially helpful. Unfortunately, the participant’s 
perception was that the nurse was uninterested in 
the consultation and the trial as a whole.
It should be noted that the inner mechanisms 
of the trial – and therefore the work of the trial 
team – were almost entirely hidden from the 
participants. Consequently, within the participant 
interviews the most ‘visible’ components of 
the trial were the interactions with nurses and 
the diary exercises. The nurses were therefore 
expected to perform RCT work, and in this regard, 
the participants did not consider the nurses as 
independent agents with their own agenda and 
concerns. Consequently, the work of the practice 
nurses’ was commented upon in a manner that 
tended to draw criticism as and when problems 
arose.
The third topic central to the participants’ 
accounts was their attempts to make sense of the 
outcomes of participation. Regardless of their 
explanation for involvement or the randomised 
status of their practice, most participants’ accounts 
were marked by disappointment with respect to 
their experience in the trial. The participants 
described having difficulty understanding 
the manner in which the RCT might produce 
beneficial outcomes for themselves or others. 
This difficulty stemmed from the perceived 
ineffectiveness – or invisibility – of the trials’ 
interventions. For example, it was not clear 
to either the nurses or the participants how a 
BCC consultation might differ from a routine 
interaction – other than in topic and length of 
time available. Nevertheless, in some instances 
the participants attempted to positively frame 
the meaning of participation by emphasising 
the realised or expected benefits, even if the 
mechanisms by which these benefits might 
occur were not fully understood or articulated. 
One participant, who did not find remediation 
for her symptoms, expressed hope that others 
might benefit in some way from her participation 
(Box 11). The account, however, is marked by an 
overt desire for a personal solution.
In this example the participant was clear that after 
taking part in the personalised arm of the trial, 
they did not expect to be able to ‘change [their 
condition] … at the minute’ (ID 0815005). For this 
Participant: … when I went to the practice nurse [for the trial consultation] … I think the attitude was, ‘eeh, oh 
yeah’ (rolling eyes) you know, ‘something else that we’ve got to do’. Er, well my own attitude was, em, if it’s going to 
be of benefit to others then I’m quite happy to go along with it
Later in the interview:
Participant: … it was at that time, that I gained the impression … oh this terrible, but I did gain the impression that 
she thought it was all going to be a waste of time. Right, now that is probably because they have an awful lot to do, 
and their time is, as you have just mentioned, a few minutes ago, it’s spent, dealing with patients who are ill and who 
need attention. Er, not filling in forms. You know what I mean?
(Interview, participant ID 1101003, standardised consultation, p. 3 and p. 6)
Another participant shared her perceptions:
Interviewer: … I know that we’ve already covered this slightly before, but when you went to see the nurse for this 
particular trial and she went through the information leaflets, did you get a sense that was different from the con-
versations that you’d had before, that there was a bit more time there to go through some of that information, or 
did you not really get that sense?
Participant: Well I got the sense really that ‘oh I’ve been asked to do this as a job, I’m handing out information’ erm, 
but it’s, it’s information; … you’ll already know it, but if you read it and it’s just common sense, you know – which okay 
things are common sense, – but when you’re troubled with constipation it’s, you know you would like other little 
bits of erm, any kind of snippets you can get really
(Interview, participant ID 1018001, standardised consultation, p. 7]
BOX 10 Participant accounts of practice nurses in the RCT
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participant, ‘the value’ of participation hinged on 
having ‘helped somebody’ (ID 0815005) at some 
other point in time. Consequently, they asked for 
feedback from the trial team in order that they 
themselves might have some ‘hope’ (ID 0815005).
For most participants’ involvement in the trial 
consisted primarily of the daily diary exercise. 
Participants in both ‘active’ arms of the trial 
received information leaflets and advice or BCC 
that was reported as being unremarkable. Indeed, 
many participants struggled to recall having ‘an 
intervention’ at all. Box 12 presents an extract from 
two interviews in which participants explained 
their interpretation of the trial design, and for one 
participant, their hope for ‘an intervention’ at some 
point in the future.
In the first quote presented in Box 12, a participant 
in the control arm of the trial explained that the 
diary exercise was a precursor to an intervention: 
‘… what you have to do before anything sort of 
concrete came out of it’ (ID 0223004). Specifically, 
the diary exercise was seen as a means of 
assessing ‘what’s happening’ (ID 0223004) for 
the participants before an intervention could 
be developed and implemented. Arguably, we 
might expect an explanation of this type from 
participants in the control arm of the trial, where 
an absence of any novel intervention by the trial 
team was an intentional design feature. However, 
in the second quote, a participant randomised 
to the personalised arm of the trial explained 
how their contribution primarily consisted of ‘… 
remembering to fill the book in every day’ (ID 
0815005). In an attempt to attach some meaning 
to their experience in the trial, the participant 
explained that his participation had been valuable 
if it ‘help[ed] anybody else’ (ID 0815005); however, 
he was left seeking a solution to a ‘wind problem’ 
(ID 0815005) that had been troubling him long 
before his participation in the trial. In this respect 
the trials’ interventions were reported by most 
of the interviewed participants as having little 
potency with regard to helping them with their 
health problems. Interestingly, for both the nurses 
and the participants, the BCC interventions were 
not regarded as offering anything ‘new’. In the case 
of the participants it is not possible to ascertain 
if this finding was due to the way in which the 
nurses deployed the BCC, the inherent qualities of 
the interventions themselves or a combination of 
factors. A summary of the findings from interviews 
with participants is presented in Table 26.
Discussion
The assessment of complex interventions can be a 
challenging process.228 In the process evaluation, 
we observed two ‘complex interventions’: (1) diet 
and lifestyle training for practice nurses, but, more 
specifically, (2) the practical conduct of an HTA 
RCT. In light of the trial’s premature closure, data 
from the qualitative evaluation help to explain 
some of the processes that led to the trial’s closure, 
and how they might be avoided in future RCTs. 
Although we can comment on the structure 
and implementation of LIFELAX (and offer 
recommendations for future implementation of 
HTA research), the relative importance of clinical 
topics such as ‘chronic constipation’ and the merit 
of ‘BCC’ per se are less clear. Specifically through 
the process evaluation we observed the confluence 
of several ‘trajectories’ or processes:
•	 The implementation of a pragmatic RCT 
in an ‘unsettled environment’ of research 
governance interpretation and ethical 
judgements.
Participant: I wait for something to happen, I am eating [a recommended diet] and what have you but it hasn’t 
changed anything
Later in the interview:
Participant: I would think that there [are] not many different avenues that you could go down with [the personalised 
consultation], it’s either different treatments, I don’t think you will change my [condition] with that at the minute er, 
no I think I will just go along … just follow the lead and hopefully in the end will get a little bit of feedback I’m quite 
happy with a little bit of feedback on what’s going on
Interviewer: Well I think that’s quite important isn’t it for people who are involved to get some –
Participant: (interjecting) Oh yes, I just want to know sort of, if you have helped somebody if you have helped 
somebody then it gives me hope for some reason
(Participant ID 0815005, personalised consultation, authors’ emphasis, p. 2 and p. 4)
BOX 11  Coping with disappointment: hope in benefit for others
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•	 The response of practice staff to involvement 
in an RCT concerning a condition not 
prioritised in GMS contracts.
•	 The response of practice nurses to proposed 
changes in their work patterns.
•	 The responses of practice staff to the 
problematisation of chronic constipation: 
practice nurses perceived chronic constipation 
to be a condition already successfully managed 
by laxatives.
•	 The response of the nurses to BCC training as 
delivered by dietitians or nutritionists.
•	 The response of participants to involvement in 
a pragmatic RCT (including management of 
expectations and research-related tasks, such 
as the daily diary).
•	 The response of participants in the diet and 
lifestyle arms to the combined stimuli of the 
LIFELAX trial and an interaction with a 
practice nurse.
In this report we have attempted to describe the 
interaction of these processes on the success of the 
LIFELAX trial. Nevertheless, RM&G and ethics 
issues aside, it is not possible to isolate the factors 
from one another. For example, had the training 
been delivered to community nurses the response 
of these staff may have differed from that of the 
practice nurses in LIFELAX.
As the embedded process evaluation study was 
ethnographic, qualitative research techniques were 
employed, and it was therefore not appropriate 
to set out our research questions in hypothetical 
form. However, at the outset, we attempted to 
address the following specific questions:
1.  Formation How are ideas about the 
appropriateness of health technologies 
and their clinical applications formed and 
mobilised in practice; how are the interests 
Interviewer: … apart from obviously getting the diaries that you didn’t expect, has other aspects of [the trial] been 
what you thought it would be or has it been different?
Participant: Erm I thought initially this was what you would have to do before anything sort of concrete came out of it, … 
obviously you have got to take a wide survey of exactly what’s happening and then you obviously take it from there so 
expect something different after they have all sort of consulted all the diaries belonging to everyone that’s participated in 
the trial and then I think something might be gained from it
(Interview, participant ID 0223004, control arm, authors’ emphasis, pp. 2–3)
And:
Participant: … no [the trial] hasn’t been a hassle like I mean er, its just remembering to fill the book in every day like ya 
know just at the end of the week … I just put no no no all the way down and when I was bad I just wrote in that I 
was bad and when I was on holiday I just put in the book there that I was on holiday and had a bout of diarrhoea and 
what I took to stop it and er but I have never had any hassle or anything out of it no
Interviewer: Right well thank you very much
Participant: It has been worth er you know if it can help anybody else well that’s fair enough like so just that I would like 
to get rid of this problem what I have got this wind problem and I cannot at the moment its gone on for a long time
(Interview, participant ID 1105001, standardised consultation, authors’ emphasis, pp. 6–7)
TABLE 26 Factors affecting the experience of the LIFELAX trial for participants
Some participants reported a lack of understanding (congruence) between themselves and the practice nurse regarding 
the value of the research. For some participants, their encounter with the practice nurse was a demoralising 
experience. In particular, while some participants viewed their chronic constipation as an important problem they 
reported that the nurse did not appear to see the research as worthwhile
For most of the participants seeking medical interventions, the BCC or standardised advice consultations failed to 
help them find solutions to problems related to health, diet or lifestyle issues. In contrast, three participants explicitly 
reported some benefits (either psychological and/or physiological) from a behaviour change consultation and described 
making a number of lifestyle changes as a result
It is not possible, due to the pragmatic design of the trial, to separate the effects of BCC from its delivery by nurses
The participants made sense of their participation largely through the daily diary exercise. Due to this exercise, some 
participants interpreted the trial as ‘survey’ research
BOX 12 Attempting to make sense of participation in the face of disappointment
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of consumers and other users defined and 
incorporated in the organisation of the trial?
The process evaluation explains some of the 
reasons for the early closure of LIFELAX and 
we draw a number of conclusions about the 
structural processes of HTA assessment from these 
data. However, it is not possible to make claims 
about specific public health topics, such as the 
significance of chronic constipation for primary 
care medicine. We did observe that practice nurses 
and managers perceive chronic constipation to be 
successfully managed by laxatives, and that roughly 
one-half our sample of participants also considered 
themselves either not to suffer from constipation 
or that they successfully managed their symptoms 
through the routine use of laxatives. However, 
the nurses also explained that they did not work 
with patients presenting primarily for chronic 
constipation. The ‘problem’ of chronic constipation 
may largely be one of economics for senior practice 
staff, or an issue of concern for community nurses, 
or an issue for some, but certainly not all, patients.
If we consider the ‘lessons learnt’ for future HTA 
trials, it is important to understand how and why 
the LIFELAX trial was commissioned considering 
the response of practices. A systematic review 
underpinning the commissioning of LIFELAX, 
identified both chronic constipation and diet/
lifestyle interventions as pertinent topics in 
primary care. This finding, taken on face value, 
appears to be at odds with the outcome of the 
process evaluation. However, the cost of laxatives 
and the dependence of patients on medication 
were issues that concerned some practice staff in 
interviews. Nevertheless, the relative priority of 
this problem when compared with others in the 
practice was not high.
Most of the trial team’s efforts were invested in 
ensuring that the RCT was successfully embedded 
in individual practices and across PCT sites. 
However, the response of practice staff to the trial’s 
topic and interventions were identified only after 
the RCT had been deployed. These issues may 
have been identified through a prior feasibility 
study, if one had been funded. A small pilot study 
was conducted during the development of training 
materials. However, this work was focused on the 
development of BCC materials and not on the 
feasibility of a larger trial.
2.  Integration How are specific clinical and 
methodological problems within an RCT 
identified and resolved within professional 
groups and networks; how is the trial 
integrated into the existing organisation 
of clinical service provision, and what 
professional and organisational dynamics 
are involved in this integration; how is 
participation in the RCT negotiated and 
understood by subjects?
This is a multifaceted question and, as such, we 
have addressed it in the current chapter via several 
different means. With regard to the clinical and 
methodological problems of the LIFELAX trial, 
the trial team engaged in a considerable amount 
of negotiation and bureaucratic work in order to 
integrate the trial in clinical environments, and 
to meet RM&G and MREC requests. We have 
discussed this process through the NPM constructs 
of interactional workability and contextual integration. 
Notably, we found that the RCT relied heavily on 
cooperative networks. Cooperation and a shared 
understanding of goals (congruence) were achieved 
through the social skills of the trial manager and 
his ability to negotiate access to resources with 
relevant personnel across NHS organisations 
at both a national, and local (PCT) level. This 
observation highlights the necessary (though 
potentially underacknowledged) skills required of 
trial managers in the current climate of primary 
care research.
Due to the decision of the MREC regarding SSAs 
and access to patient data, the evolving nature of 
RM&G guidelines, and various interpretations of 
these guidelines across PCT sites, the trial team 
were under pressure to continually develop creative 
and workable solutions to emerging problems. This 
formed a barrier to the satisfactory and timely 
achievement (disposal) of essential milestones – 
such as recruitment – in the delivery of the trial. 
A review of the practical implementation of MREC 
decisions and RM&G guidelines in primary care is 
also necessary in order to identify how to promote 
quality research while meeting ethical standards.
We addressed the research question ‘how 
is participation in the RCT negotiated and 
understood by subjects?’ through the NPM 
constructs of interactional workability and relational 
integration. Specifically, we found that some 
participants reported a lack of understanding or 
congruence between themselves and the practice 
nurse regarding the value of the research. For 
some participants, their encounter with the 
practice nurse was a demoralising experience as 
the nurse appeared to view the trial’s interventions 
as a poor use of time. Moreover, for most of the 
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participants who sought medical interventions, the 
BCC or standardised advice consultations failed 
to help them dispose of problems related to health, 
diet or lifestyle issues. When describing their 
experiences in the RCT, the participants reported 
that the daily diary exercise was the most salient 
part. Most of the participants therefore struggled 
to make sense of the mechanics of the trial and 
how such a diary might usefully contribute to 
the amelioration of their, or others, chronic 
constipation. Therefore, whether participants 
viewed their constipation as problematic or not, 
both groups reported that they struggled to see 
how the trial would lead to results that would 
benefit suffers of chronic constipation. This 
finding may result from the intrinsically confusing 
experience of trial participation as reported 
in the literature,229–231 an issue more specific to 
the LIFELAX trial, such as the practice nurses’ 
perceptions of the research and their subsequent 
behaviour with participants, or a combination of 
factors.
3.  Implementation How are the production of 
results negotiated and organised within 
networks of researchers; how are its results 
mediated to the wider community and how is 
this negotiated and organised, both formally 
(through report writing and presentation), and 
informally how are the mechanisms and results 
of the trial understood by subjects?
Following the premature closure of the LIFELAX 
RCT it was not possible to collect data relating to 
the development and publication of outputs from 
the trial. However, we have discussed the manner 
in which the participants attempted to understand 
the mechanisms and results of the trial through 
the context of their own illness trajectories and 
the NPM constructs of interactional workability and 
relational integration.
4.  What lessons can be learned that will improve the 
organisation and conduct of HTA RCTs in the UK 
– and further afield? The study holds important 
implications for the organisation and conduct 
of HTA. It is important that its results can 
inform and develop both policy and practice?
A number of issues regarding the development 
and implementation of RCTs have been identified 
through the conduct of the process evaluation. The 
problem of the trial’s topic, setting and training 
packages may have been identified had a prior 
feasibility study been conducted. At the time of 
the LIFELAX trial the HTA did not fund pilot 
studies of this nature, although the HTA have 
now changed their policy in this regard. However 
numerous system wide problems – such as the 
changing RM&G guidelines and research briefs 
that did not match GMS contracts – also taxed the 
capacity of the trial to be successful. Following the 
results of the process evaluation, and the input of 
several of the reviewers of this report, we suggest 
the following:
•	 Improved means and methods of 
communication are required between 
governance bodies, MRECs and researchers 
regarding the best way to conduct RCTs that 
are ethically, methodologically, and practically 
sound.
•	 There is a need for a clear and consistent 
means of applying for RM&G approval across 
PCTs.
•	 There is a clear need for pilot studies prior to 
the design and implementation of HTA RCTs. 
The pilot study should:
 – Assess the feasibility of all aspects of the 
intended research but specifically ensure 
that the assumptions underpinning the 
study are correct. These assumptions 
may be multiple but should ensure 
that: (1) there is an identified need for 
a technological intervention; (2) the 
intended beneficiaries also perceive a 
need for intervention and are in equipoise 
regarding the proposed interventions and 
control; and (3) the definition of the need 
or problem is commensurate between 
researchers, users and beneficiaries.
 – Pilot studies should assess whether the 
interventions will enable the intended 
users and/or beneficiaries to achieve 
relevant goals (such as disposal of 
symptoms).
 – Pilot studies should assess whether the 
intended interventions fit within existing 
patterns of work, and where they do 
not, assess the likely disruption and 
acceptability to intended users.
 – Pilot studies designed to assess the 
feasibility of the research should be 
conducted prior to any significant 
investment in the development of an RCT.
Conclusions
Through application of the NPM we were able 
to identify a number of factors that contributed 
to the premature closure of the LIFELAX 
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RCT. Evaluation of the trial raises a number of 
important considerations for the deployment 
of other trials of complex interventions in 
primary care. In particular, the administrative 
difficulties encountered by the LIFELAX trial 
team, regarding the application of RM&G 
guidelines and research ethics, were indicative of 
the unsettled climate at the time of the trial, also 
experienced and reported by other researchers.19,215 
Nevertheless, research should be conducted to 
explore how the processes of implementing RCTs 
in primary care can be practically facilitated, 
and how procedures may be standardised and 
streamlined. In addition, it is important for 
funders such as the HTA to commission studies 
using appropriate forms of assessment. RCTs 
may not always be the most suitable method, 
particularly in the initial stages of development for 
new and complex technologies.
The trial team developed innovative solutions 
to practical problems of implementation. This 
work illustrated the importance of social, as well 
as technical, competence in the delivery of a 
multicentred RCT. However, there is a significant 
gap in the literature exploring how RCTs are 
practically accomplished. While the process 
evaluation contributed towards addressing this 
shortfall, further research is needed to explore 
the practical conduct of RCTs in different contexts 
in order to better understand the processes 
underpinning the formation of medical evidence.
Conventionally, when a large project fails, 
stakeholders attempt to identify the causal factors 
for this outcome. However, in the LIFELAX 
RCT, there was no central agent of blame for the 
trial’s failure. A number of significant problems 
accumulated across the life of the research to 
prevent the RCT from moving forwards. These 
structural problems included the contemporaneous 
climate of uncertainty regarding interpretation 
of ethical and RM&G governance, changing 
priorities in primary care expressed though the 
GMS contract, and a general lack of enthusiasm 
or commitment for research in primary care. 
Specifically, the clinical environment in which the 
LIFELAX trial was situated was largely indifferent 
to the research. Although the trial team worked 
hard to develop workable solutions to these 
problems, the numerous and unforeseeable issues 
encountered by the trial team exhausted the 
capacity of LIFELAX to be a workable trial.
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Chapter 7  
Conclusions
Defining ‘eligibility’ for 
studies of constipation
The experiences of both the STOOL Trial19 and 
LIFELAX would suggest that being able to define 
‘constipation’ in a way that is both measurable 
and acceptable to all stakeholders is vital to 
future research in this field. When people do not 
think that they have a particular condition then 
it seems unlikely that they would be interested in 
or motivated to participate in research into that 
condition.
Though a common complaint of industrialised 
societies,9 there is much variability in definition 
of constipation, both within the medical literature 
and between patients and medical professionals.8 
Some attempts as at a definition have used the 
frequency of bowel movements.20,21 Clinical 
definitions do exist within the Rome II22 and III23 
criteria for functional constipation.
In the Rome II criteria for functional 
constipation,22 two or more of the following 
symptoms must have present for at least 12 
consecutive weeks in the previous 12 months for a 
diagnosis of constipation:
•	 straining in more than one in four defecations
•	 lumpy or hard stools in more than one in four 
defecations
•	 sensation of incomplete evacuation in more 
than one in four defecations
•	 manual procedures (e.g. digital evacuation or 
support of the pelvic floor) in more than one in 
four defecations; and
•	 fewer than three defecations per week.
In the Rome III criteria a somewhat less restrictive 
time frame has been introduced.23
Practitioners, however, appear unlikely to apply 
the above criteria in their clinical practice and 
constipation is typically a subjective diagnosis.18 
Nonetheless, a level of consensus does exist 
among clinicians over the wide variation between 
individuals in the normal frequency of bowel 
Due to the low number of participants in the trial, we are unable to draw any firm 
conclusions about the effectiveness of the 
interventions in LIFELAX. Nonetheless, at the 
conclusion of this study, there are a number of 
issues that we wish to highlight as they had a major 
impact upon the conduct and progress of the 
trial. We believe that they are relevant to anyone 
else conducting research on a similar topic or in a 
similar population.
Pilot studies
At the time of commissioning, the HTA did not 
fund pilot studies. If a rehearsal (external) pilot 
trial or feasibility study had been conducted first 
then it is likely that the full LIFELAX trial would 
either never have been commissioned or if it had, it 
would have had a major methodological overhaul. 
We are pleased that pilot and feasibility studies are 
now part of the HTA commissioning process.
Choice of data collection 
methods
Our findings suggest that the range of data 
collection methods we employed in LIFELAX were 
acceptable for use in a population of this age with 
constipation. The self-completion questionnaire 
response rates in excess of 80% suggests that 
despite the length of the questionnaire, the time 
taken to complete it and the added burden of the 
daily diary, at the first two time points at least 
respondent fatigue was not an issue.
Analyses of the response rates and item response 
rates suggest that the daily diary was not 
troublesome to participants. We would propose 
that a diary of this nature to collect information 
about bowel function and medication is not 
burdensome to complete and is a satisfactory way 
of gathering such information.
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movements (from three times per day to three 
times per week being normal).12 The perceptions 
of older people reported by a small number of 
previous studies suggest that lay definitions of 
constipation differ from professional criteria.14,16,17 
From the STOOL report it is apparent that 
frequency and ‘ease’ of bowel movements, however, 
are key components of constipation for the 
majority of older people.19
Our belief is that while there is such a lack 
of agreement – both within clinicians and 
patients, and between the two parties – as to 
what constipation is then recruiting to studies of 
‘patients with chronic constipation’ will remain 
difficult. If objective criteria such as Rome II/III, 
or the number of laxatives prescribed in a given 
time frame are met with the circular argument 
from patients of ‘I take laxatives which produce 
my desired frequency of bowel movements, and 
therefore I am not constipated’ it would seem 
there is a hurdle that is particularly troublesome to 
overcome.
Difficulty implementing the 
LIFELAX trial
LIFELAX fulfilled all the criteria of a ‘marketable 
trial’.232 LIFELAX was designed as a pragmatic113 
three-armed cluster RCT to compare laxative 
treatment (current practice) of chronic constipation 
in older people with both standardised, non-
personalised dietary and lifestyle advice (delivered 
in a single, short consultation) and personalised 
dietary and lifestyle advice (delivered in a long 
consultation, or two shorter consultations, with 
telephone reinforcement) in the management of 
chronic constipation in older people. LIFELAX 
was to be conducted in north-east England and was 
to recruit patients aged ≥ 55 years, registered with 
practices participating in the trial, with a current 
diagnosis of functional constipation.
Like the STOOL trial, LIFELAX was not successful 
in recruiting patients to the trial and experienced 
difficulty in encouraging general practices to fully 
engage with the research.
Though largely anecdotal and based upon the 
experiences and beliefs of the wider research 
team and collaborating GPs since the turn of the 
century, the climate of research has changed and 
there are now considerable barriers to complex 
trials of ‘routine’ interventions.
Ethics committees reacted (some would say over-
reacted) to a number of landmark documents 
including the report of the Alder Hey enquiry,198 
the European Human Rights Act199 (and its 
implementation) and preparation for the 
enactment of the EU Clinical Trials Directive. As 
a result, the guidelines to which ethics committees 
adhered became more prescriptive and committees 
became more risk aware and averse, and took 
measures to mitigate risk where possible. The 
publication of the Research Governance Framework for 
Health and Social Care200 created further challenges 
with guidance and decisions taken at a local level 
often appearing to be contradictory to national 
advice. Ethics committees and NHS Trusts, faced 
with the introduction of a more prescriptive 
and bureaucratic framework, were unable to 
respond to the increasing workload generated. 
Our experiences in these respects are echoed by 
other researchers conducting multicentre research 
involving primary care at a similar time.201–203
In addition to the inevitable delays created by 
these developments, the necessity for participants 
to ‘opt in’ to LIFELAX and the apparent removal 
of direct contact with the research team until 
much later in the research process was one of the 
major issues of concern to both the research team 
and the TSC. This model has major implications 
for health services research in the future204 and 
by implementing such a model, one immediately 
decreases the likelihood of participation and 
increases the risk of participation bias.205 
Communication between a committed trial team 
and the participant is crucial to the success of a 
trial. Opportunities for those most familiar with 
the study design and processes (i.e. the research 
team) to explain the trial or discuss any aspect 
of participation diminish once the GP practice 
becomes the primary contact point for information 
in the early stages of the trial.
We are pleased that, since LIFELAX, many of the 
proposed measures to streamline the research 
process are slowly being implemented. The 
Integrated Research Application System is now 
running and continues to be revised. This will 
simplify the entire ethics and research governance 
approval process, especially for multicentre studies. 
The Research Passport (its imminent introduction 
was heralded during the set-up of LIFELAX), 
when available, will add to innovations such as the 
Central Sign-off Process for NHS R&D approval, 
and will hopefully further reduce the bureaucracy 
of the research process.
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Insight from process 
evaluation
Through application of the NPM233 we were able to 
identify a number of factors that contributed to the 
premature closure of the LIFELAX RCT. However, 
it is important to note that within the constraints 
set by the commissioning brief – including the 
topic of the trial and nature of the interventions 
– the trial team could not have produced a 
successful outcome. Evaluation of this trial raises 
a number of important considerations for the 
deployment of other trials of complex interventions 
in primary care. In particular the bureaucratic 
difficulties encountered by the LIFELAX trial 
team, regarding the application of RM&G 
guidelines and research ethics, were indicative of 
the unsettled climate at the time of the trial, also 
experienced and reported by other researchers.19,215 
Nevertheless, research should be conducted to 
explore how the processes of implementing RCTs 
in primary care can be practically facilitated, 
and how procedures may be standardised and 
streamlined.
The trial team developed innovative solutions to 
practical problems of implementation. This work 
illustrated the centrality of socially-mediated 
processes across the lifespan of the RCT. There is 
a significant gap in the literature exploring how 
RCTs are practically accomplished. While the 
process evaluation contributed towards addressing 
this shortfall, further research is needed to explore 
the practical conduct of RCTs in different contexts 
in order to better understand the processes 
underpinning the formation of medical evidence.
Conventionally, when a large project fails, 
stakeholders attempt to identify the causal factors 
for this outcome. However, in the LIFELAX 
RCT, there was no central agent of blame for the 
trial’s failure. A number of significant problems 
accumulated across the life of the research to 
prevent the RCT from moving forward. These 
structural problems included the contemporaneous 
climate of uncertainty regarding ‘correct’ 
interpretation of ethical and RM&G governance, 
changing priorities in primary care expressed 
though the GMC contract, and a general lack of 
enthusiasm or commitment for research in primary 
care. Specifically, the clinical environment in 
which the LIFELAX trial was situated was largely 
indifferent to the research. Although the trial 
team worked hard to develop workable solutions to 
these problems, the numerous and unforeseeable 
issues encountered by the trial team exhausted the 
capacity of LIFELAX to be a workable trial.
Recommendations
The issues raised in this report are many and 
complex, some are condition and time bound 
(RM&G framework), and, as such, we are reluctant 
to make stringent recommendations as there may 
be little usefulness in doing so. However, there 
are a number of key learning points that we can 
highlight in the belief that these can be of use 
to researchers planning an RCT of a complex 
intervention in the future.
•	 Our experience suggests that the topic under 
investigation needs to be relevant to both the 
people delivering the intervention and those 
receiving the intervention.
•	 Rather than launching straight into conducting 
a full-scale intervention and trial, work needs 
to be undertaken to ascertain whether such 
a trial is feasible (we are pleased that pilot 
and feasibility studies are now part of the 
commissioning process for the HTA).
•	 The inclusion criteria need to be clear and 
comprehensible to both the people identifying 
participants and the participants themselves.
•	 If a ‘train-the-trainer’ approach is to be 
used for intervention delivery, there needs 
to be confidence that the trainees are fully 
supportive and motivated rather than 
participating because their institution has 
agreed to take part.
Although it is unclear whether ‘payment’ 
or financial incentives would make a future 
intervention a success, attention needs to be paid 
to the current funding arrangements and priority 
topic areas for the health-care practitioners with 
whom researchers will be working. Topics within 
the QOF have a much higher profile, interest and 
importance.
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LIFELAX protocol, version 2 (18 February 2004)
1 
LIFELAX Protocol Version 2 – 18/02/2004 
LIFELAX – Diet and lifestyle vs. laxatives in the management of chronic constipation 
in older people 
Protocol for a randomised controlled trial 
1 Planned investigation 
1.1 The research brief 
The commissioning brief (HTA 01/10) specifies the key research question: “What is the 
comparative cost-effectiveness of laxatives compared with dietary and lifestyle changes in the 
treatment of elderly patients with chronic constipation”.   Dietary interventions are to be 
differentiated from bulk laxatives, such as bran, and dietary and/or lifestyle changes may be 
compared with single laxative agents. 
1.2 The research questions addressed by this study 
In studies of individual behaviour change strategies, particularly those relating to dietary change 
and exercise1-3, personalised interventions have been shown to be more effective than standard, 
non-customised approaches.  Elements of personalisation variously include: assessment of the 
importance of making a behaviour change and confidence in carrying out the new behaviour, 
where the individual is situated in the ‘stages of change’ model4, motivational interviews5; 
discussion of current behaviour and of facilitators of and barriers to change; agreement of 
individualised goals  and provision of personalised information and advice on behaviour change2;6;7; 
and follow-up reinforcement contacts7.  Such personalised interventions, however, are typically 
more resource-intensive than non-individualised approaches5.  For these reasons, it is important to 
ascertain not just the effectiveness but also the cost-effectiveness of these strategies.  
We therefore propose a pragmatic three-armed trial to compare laxative treatment of chronic 
constipation in older people with both standardised, non-personalised dietary and lifestyle advice 
(delivered in a single, short consultation) and personalised dietary and lifestyle advice (delivered in 
a long consultation – or two shorter consultations, with telephone reinforcement).  Through the trial 
we will address the following key questions, derived from the research brief: 
• What is the comparative clinical and cost-effectiveness of laxatives versus a combination of 
dietary and lifestyle advice? 
• What is the comparative clinical and cost-effectiveness of brief, standardised, non-personalised 
dietary and lifestyle advice versus personalised dietary and lifestyle advice, including 
reinforcement? 
1.2.1 Objectives 
1. To investigate the clinical and cost-effectiveness of laxatives versus dietary and lifestyle 
advice. 
2. To investigate the clinical and cost-effectiveness of standardised versus personalised dietary 
and lifestyle advice. 
1.3 Detailed plan of investigation 
1.3.1 Trial design 
The trial will take the form of a prospective, pragmatic8, three-armed cluster randomised trial with 
an economic evaluation. Analysis will be on an ‘intention to treat’ basis. Participating practices will 
be randomised to one of three arms: (1) prescription of laxatives; (2) provision of standardised, 
non-personalised dietary and lifestyle advice; (3) provision of personalised dietary and lifestyle 
advice, with reinforcement. 
A randomised controlled trial is the optimum design when evaluating behaviour change 
interventions. However, in this study, if the unit of randomisation was to be the individual patient, 
there would be a risk that health care professionals might provide elements of the dietary and 
lifestyle package to patients randomised to laxatives only. A solution to this problem is to ‘cluster 
randomise’ at the level of an entire practice, while collecting data about outcomes of care at the 
individual patient level. As patients within any one cluster are more likely to respond in a similar 
manner, such a design violates the assumption that the outcome for an individual patient is 
completely independent of that for any other patient. Therefore a cluster randomised design is not 
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as statistically efficient as a patient randomised design; it has lower statistical power than a patient-
randomised trial of equivalent size9 and sample sizes need to be inflated to compensate for this 
(1.3.6).  
1.3.2 Setting 
General practices in Northern England and the homes of older people (aged 55 years and over) 
from these practices. 
1.3.3 Health technologies being assessed 
1.3.3.1 Treatment strategies at the patient level 
Study participants will be randomised to one of three treatment strategies (1.3.1).   
Within the laxatives arm, free choice of class of laxatives will be allowed.  There is at present 
insufficient evidence10;11 of the relative superiority of one class of laxatives over another, or of 
combination therapies as opposed to single preparations (a separate, but parallel, trial (STOOL) by 
the same research team is comparing stimulant, bulk and osmotic laxative, singly and in 
combination).  Free choice of laxative therapy will more closely replicate the situation which will 
pertain in routine clinical practice; adherence to treatment protocol is therefore expected to be 
better than where a change in drug is required.  For similar reasons, leeway in dosage will be 
permitted, within dose ranges commonly used in clinical practice.  To minimise the risk of 
prescribing sub-therapeutic doses, the intervention protocol will remind participating GPs of the 
therapeutic dose ranges for the available laxative preparations. 
The dietary and lifestyle interventions will be informed by findings from previous trials of diet and 
lifestyle interventions1;2;6;7. They will also draw upon theories of individual behaviour change, 
including the concept of self-efficacy12 and the stages of change model4.  
In both the standardised and personalised arms, the ‘information package’ will comprise practical, 
target-based advisory sheets on: diet – increased consumption of non-starch polysaccharides 
(NSP (fibre)) of both cereal and fruit and vegetable origin13 and of bread and bran products14; 
hydration15; dentition16; mobility and exercise17;18; abdominal massage18; toilet habits17; what 
constitutes normal bowel function19; the action and potential side-effects of laxative use. Locality-
specific information (e.g. details of local exercise programmes for older adults and of fruit-and-
vegetable buying clubs) will be included in the package for those allocated to the personalised 
dietary and lifestyle intervention. 
In both arms, this package will be delivered by practice or community nurses (according to local 
custom).  Appointments will generally be offered at the surgery, though home visits will be an 
option where appropriate. In the standardised, non-personalised arm, there will be a single short 
(maximum of 10 minutes) appointment, with delivery of a standard pack of information and brief, 
general explanation of these information materials. In the personalised arm, there will be an initial 
long (30-45 minutes)5 appointment (though this may be undertaken in two shorter appointment 
should clinic time so dictate) and the technique of ‘motivational interviewing’ – ‘a directive client-
centred counselling style for eliciting behaviour change by helping clients to explore and resolve 
ambivalence’ 5 – will be employed.  The personalised approach will include a patient-specific 
assessment of barriers to and facilitators of change and delivery of a personalised pack of 
information with individual targets.  Patients in this arm will receive a follow-up motivational 
telephone call from the nurse at one week and one month after initial appointment. 
A potential threat to patient recruitment and retention in this trial is patients’ unwillingness to forego 
medication.  For this reason, although diet and lifestyle will be the first-line treatment for patients 
allocated to those arms, the option of continuing laxative use (either prescribed or over-the-counter) 
will be available if required; the need for and use of such medication will be captured in patient 
diaries (1.3.5.1 and 1.3.5.3). 
1.3.3.2 Training strategies for health professionals 
An orientation and training programme will be developed for the practices recruited to the study. All 
practices will be have on-site training in patient recruitment and the treatment protocol.  In addition, 
a dietician with experience in health promotion will deliver in-practice training in how to deliver the 
dietary and lifestyle intervention to patients, as follows:  
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• Standardised dietary and lifestyle intervention – all primary health care professionals (general 
practitioners, practice and district nurses, health visitors) in the practice will be invited to a 
single, one hour session to introduce the programme and the patient pack. 
• Personalised dietary and lifestyle intervention – all primary health care professionals (general 
practitioners, practice and district nurses, health visitors) in the practice will be invited to an 
initial one hour session to introduce the programme and the patient pack.  Practice or district 
nurses involved in delivering the intervention to patients will be invited to take part in two further 
45 minute sessions on the delivery of a personalised pack and motivational interviewing 
techniques.  
The choice of number and duration of training sessions is based on experience in other similar 
studies, and represents a balance between minimising the demands on busy health professionals’ 
resources, whilst having sufficient time to motivate doctors and nurses and to equip them with the 
knowledge and skills required to deliver the interventions to patients. Our personal experience, 
reinforced by the literature20, suggests that in-practice delivery of training of this nature is more 
cost-effective than delivery at a single, central location.  
1.3.4 Target population 
People aged 55 or over with chronic constipation living in private households. The choice of an age 
cut-off of people aged 55 or over has been made after due consideration of the morbidity statistics 
from general practice21 which show that general-practitioner consultation rates for constipation take 
off in the 45-64 age group and rise steadily with age. The exclusion of residents in long-term care 
reflects the different morbidity and life-style experience of long-term care residents. We will focus 
on a predominantly ambulant population able to independently attend a primary care clinic. 
1.3.4.1 Inclusion criteria 
The complexity of the revised Rome criteria for functional constipation22 militates against their use 
in screening for chronic constipation. Moreover, newly incident cases of constipation, especially 
amongst older adults, should be investigated to determine the underlying cause of the constipation 
and to eliminate more serious problems23 before laxatives are prescribed.  
This trial will therefore identify and recruit only ‘prevalent’ cases, defined in terms of those 
prescribed laxatives three or more times in the previous 12 months. Participants meeting this 
criterion will be identified from general practice computerised patient records using an electronic 
‘query’ to interrogate repeat prescribing databases.  It is recognised that the relapsing and 
remitting nature of constipation means that not all patients thus identified will be constipated (by 
objective or subjective criteria) at any given time.  Patients identified through the electronic query 
will be invited to attend a recruitment clinic at their general practice, at which current bowel function 
and perceptions of whether constipated will be elicited; these baseline data will be included as co-
variates in our analysis (1.3.7).  
1.3.4.2 Exclusion criteria 
• Patients resident in long-term care. 
• Patients with inflammatory bowel disease, intestinal obstruction/bowel strictures, known colonic 
carcinoma, and conditions contra-indicative to the prescription of laxative preparations24. 
• Inability to read and understand written treatment plans and educational material. 
• Inability to complete outcome assessments, even with assistance (e.g. major cognitive 
impairment, lack of understanding of English). 
 
1.3.5 Assessment of outcomes 
1.3.5.1 Outcome measures 
The primary outcome, and the criterion upon which the sample size calculations have been based, 
is patient-reported condition-specific quality of life at three months post recruitment (1.3.5.2).  Our 
preferred measure of quality of life is the constipation-specific PAC-SYM / PAC-QOL25, which has 
been demonstrated to have good validity and reliability.  However, this measure is not utility-based.  
For the purposes of the economic evaluation (1.3.8), a measure of the utility placed by patients on 
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their health state will be required.  The condition-specific measure of quality of life will therefore be 
supplemented by the generic, utility-based EQ-5D26;27. 
Secondary outcomes will include: bowel movement frequency; the presence/absence of the other 
Rome criteria for constipation; patients’ own perceptions of whether or not they are constipated; 
patient satisfaction with bowel function; adverse effects of treatment; relapse / re-consultation rates; 
fluid and fibre intake (Table 1).   
In addition, the cost implications of the condition and its treatment (e.g. GP consultations, purchase 
of prescribed and over-the-counter medication) will be assessed, as part of the economic 
evaluation (Table 2; section 1.3.8).  
 
Table 1 Outcome measures 
Primary outcome Measurement method When Where 
Health-related quality of life Postal questionnaire At three months 
post recruitment  
Participant’s 
home 
Secondary outcomes Measurement method When Where 
Health-related quality of life Postal questionnaire At six and twelve 
months post 
recruitment  
Participant’s 
home 
Number of bowel movements per 
week 
Self-completed structured 
diary 
+ Postal questionnaire 
Daily for 6 
months 
At 12 months 
Participant’s 
home 
Other Rome criteria: straining at 
defecation, stool consistency, 
perceived incomplete evacuation 
Self-completed structured 
diary 
 
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months 
At 12 months 
Participant’s 
home 
Subjective perception of whether 
constipated; satisfaction with 
bowel function 
Telephone interview 
+ Postal questionnaire 
At 3 months 
At 6 months & 12 
months 
Participant’s 
home 
Adverse events: abdominal pain, 
nausea, bloating, flatulence, 
diarrhoea 
Self-completed structured 
diary 
 
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months 
At 12 months 
Participant’s 
home 
Use of prescribed and OTC 
laxatives  
Self-completed structured 
diary 
 
 
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months 
 
At 12 months 
Participant’s 
home 
Fluid and fibre intake Self-completed structured 
diary 
+ Postal questionnaire 
1 day per month 
for 6 months 
At 12 months 
Participant’s 
home 
Relapse rates: including repeat 
consultations  
Self-completed structured 
diary; GP records 
Daily for 6 
months; Twelve 
months post 
recruitment 
Participant’s 
home (diary); 
General practices 
(GP records) 
Personal measures of success 
with the management of 
constipation 
Telephone interview At 3 months and 
6 months 
Participant’s 
home 
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Table 2 Measuring treatment impact 
Impact Measure When Where 
Costs to participants 
of the condition and 
its management  
Structured health 
diary; telephone 
interview; postal 
questionnaire 
Using different 
methods, for six 
months 
Participant’s home 
Consultation rates 
and laxative 
prescriptions 
GP records At twelve months 
post recruitment 
General practices 
 
1.3.5.2 Follow-up period 
Maximum response to the interventions are expected within 12 weeks of initiation of treatment; this 
dictates that the primary outcome should be assessed at three months post recruitment.  However, 
since a common criticism of behaviour change interventions is the lack of sustained effect, quality 
of life data will be collected again at six and twelve months post recruitment while symptom diaries 
will be completed daily for six months.  Relapse rates (defined in terms of re-consultation and/or 
demand for further prescriptions for laxatives) will be monitored for twelve months post recruitment, 
through interrogation of patients’ medical records.  We believe that intensive follow-up of patients 
for six months coupled with extended monitoring of quality of life, consulting and prescribing data 
represents a reasonable compromise between placing excessive burden on respondents (posing 
threats to recruitment and retention rates) and assessing longer-term consequences of the 
interventions.     
1.3.5.3 Methods of data collection 
1.3.5.3.1 Base-line assessment (W0) 
Patients identified through the electronic query as meeting initial eligibility criteria will be invited to 
attend a nurse-led recruitment clinic.  At this clinic, current bowel function (based on Rome criteria), 
fluid and fibre intake and patients’ self-perceptions of whether they are currently constipated and 
levels of anxiety and depression28 will be elicited.  The study will be explained and a baseline 
questionnaire to assess activities of daily living29, condition-specific quality of life and laxative use 
(both prescribed and over the counter) will be administered. A weekly structured self-completed 
diary will be distributed and explained. Informed consent will be taken at this recruitment clinic. An 
invitation to return to a week later, to initiate treatment per intervention protocol (1.3.5.4) will be 
issued.  Should patients decide to withdraw when they return to collect either their laxative 
prescription or for their diet and lifestyle appointment, baseline interview and questionnaire data 
will be destroyed.    
1.3.5.3.2 Health diary (daily for 6 months from W0) 
To minimise recall bias, data on bowel function (based on the Rome criteria)22, fluid and fibre 
intake, perceptions of whether constipated and use of laxatives will be gathered by a structured 
(tick box format) health diary, completed each day and returned monthly for six months.  
1.3.5.3.3 Follow-up self-completion questionnaires (W13 and W26 and W52) 
Follow-up questionnaires, using up to two reminders, will be sent at W11 (for completion by W13),  
W24 (for completion by W26) and W50 (for completion by W52). Data to be collected will be: 
condition-specific quality of life (1.3.5.1); Rome criteria22; and anxiety and depression28.  
Although structured interviews are the gold standard for collecting a large volume of complex 
data30, the choice of postal questionnaires has been made to contain the cost of data collection. 
The use of postal questionnaires will also allow some blinding of outcome assessment (1.3.5.5). 
Our recent experience in using postal questionnaires to gather information on quality of life and 
costs of treatment from ambulant, cognitively normal, older people with angina, in which we 
achieved response rates of 72%, 83% and 90% at  baseline, 12-month and 24-month follow-up 
respectively, suggests that non-response bias will not be a significant problem.   
1.3.5.3.4 Telephone interviews (W3-4, W13 and W26)  
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Within two weeks of their consultation for diet and lifestyle advice a small sample of patients in the 
standardised and personalised intervention arms of the trial will receive a telephone call to ask 
about the diet and lifestyle advice they were given.  The purpose being to monitor the content of 
the interventions.  Short telephone interviews will be used to collect cost data on medication 
purchase (both prescribed and OTC), and other out of pocket expenses for the economic analysis. 
This interview will also ask patients about their personal levels of success in the management of 
their constipation.  They will be conducted by a research secretary at W13 and W26 and data will be 
recorded directly onto a database by the interviewer. We are currently using this method effectively 
in a study of older people.  Other resource use data will be collected from practice medical records 
(1.3.5.3.5).   
1.3.5.3.5 Medical records (W52) 
Data pertaining to consultation rates and prescription of laxatives for all study participants for the 
twelve months post recruitment will be abstracted from medical records. This will be done practice-
by-practice at the end of the data collection period. Trained research nurses will interrogate paper-
based and computerised records and will enter data directly to a database on lap-top computer.  
The electronic query used to identify patients at the beginning of the trial will be adapted to capture 
data on laxative prescriptions.  We have used these methods of data collection to good effect in 
previous similar studies. 
1.3.5.4 Participants’ pathways through trial 
  Activity 
1  Potential participants identified from computerised practice databases using simple electronic 
query to flag individuals receiving prescriptions for constipation (3 or more in previous 12 
months). 
2  Initial screen by practice to identify clear exclusions. 
3  Written invitation by practice (facilitated by research team) to patient to attend nurse-led clinic 
to discuss constipation.  
4 W0 Nurse-led clinic – eligibility confirmed; consent for data collection obtained; base-line 
assessment; diary issued and explained; follow-up appointment arranged for a week later;  
5 W1 Nurse-led clinic – laxative prescription issued or diet and lifestyle intervention initiated.  
Baseline data destroyed if patient wishes to withdraw. 
6 W2 One week reinforcement phone call from nurse to patients randomised to personalised diet 
and lifestyle advice 
7 W3-4 Intervention fidelity measure – a small sample of patients in the standardised and 
personalised intervention arms of the trial will receive a telephone call to ask about the diet 
and lifestyle advice. 
8 W5 One month reinforcement phone call from nurse to patients randomised to personalised diet 
and lifestyle advice 
9 W12 Three month follow up outcome assessment (postal questionnaire) and collection of cost data 
and personal levels of success (telephone interview) 
10 W26 Six month follow up outcome assessment (postal questionnaire) and collection of cost data 
and personal levels of success (telephone interview) 
11 W52 Twelve month follow up outcome assessment (postal questionnaire & 1-week symptom diary). 
Review of practice notes to abstract data on consultation rates and prescription patterns.   
1.3.5.5 Blinding of outcome assessment 
Health technology assessment is essentially a pragmatic activity conducted in normal clinical 
practice. It follows that blinding doctors, nurses and patients to treatment is not desirable (even if 
practicable – which would not be the case here, since the three interventions are visibly and 
demonstrably different) since it distorts normal clinical practice.  In contrast, blinding of assessors 
is desirable because it minimises subjective bias towards a given treatment.  Where practical 
considerations (e.g. size of research team) preclude concealment of allocation of treatment from 
those collecting data, highly structured data collection instruments can reduce the risk of bias in 
data recording and analysis. In this study, complete concealment of the allocation is likely to be 
impractical.  However, the individuals responsible for the delivery of training in the dietary and life-
style intervention, and for the collection of qualitative data on facilitators of and barriers to 
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adherence to treatment protocol, will not reveal their experiences in respect of individual practices 
to those collecting and analysing patient outcome data.  
 
 
 
 
 
1.3.6 Sampling design and implementation 
1.3.6.1 Practice recruitment and randomisation 
General practices in the Northern England will be invited by letter to participate. Standard sample 
size calculations for a cluster randomised trial31 indicate that we will need to recruit 57 practices in 
total (1.3.6.3).  This estimate is based on the number of patients likely to be available in the 
average-sized practice; if larger practices participate, the number of practices required may be 
slightly reduced. We will initially seek to include practices from local primary care research 
networks but may need to supplement with others, depending on take up. Practices agreeing to 
take part in the study will be randomised by computer to one of the three arms.  We recognise that 
practices may have preferences with respect to allocation of interventions.  We will make it very 
clear to the practices approached to participate in the LIFELAX study that allocation to intervention 
will be completely at random and that practice preferences cannot be taken into account.   
Randomisation will be carried out by an individual not otherwise involved in practice contact, or in 
data analysis.  
1.3.6.2 Patient identification and recruitment 
Two methods of patient identification were considered: incident and prevalent cases. Consultation 
rate data21 indicate that there would be only a small number of incident cases per year in any one 
practice.  Moreover, these incident cases would, at least initially, be subject to more intensive 
medical investigation23, which would militate against inclusion in the trial. Finally, we are aware of 
experiences of differential rates of patient identification across active and control arms of previous 
cluster randomised trials (e.g. the UK BEAM trial) and the potential for selection bias that results 
from such differential rates.  This risk is greater when incident cases are being identified, and when 
responsibility for identification lies with the clinician.  For these reasons, only prevalent cases 
(1.3.4.1),  which will be retrospectively identified through computerised records, will be considered.    
The identification process will be through an independent interrogation of practice prescribing 
databases, and will therefore not be subject to influence by the participating clinicians.  We believe 
that this approach will minimise selection bias. 
To spread practice workload, patient recruitment in each practice will be spread over four months.  
It would not be practicable to identify all (i.e. across all 57 practices) potentially eligible patients 
prior to practice randomisation and patient contact.  The reason for this is that bowel symptoms 
may fluctuate in patients and a patient identified as ‘constipated’ at a given point in time may no 
longer be ‘constipated’ several months later.  We expect that the delivery of the intervention to 
practices will extend over 10 months.  Initial eligibility of patients will be based on receipt of 3 or 
more prescriptions for laxatives in the preceding 12 months (1.3.4.1).  If the patient identification 
query were to be run in all practices at the beginning of this 10 month period and patients thus 
identified were to be ‘banked’ until the intervention was delivered in a specific practice, some of 
those identified might no longer meet eligibility criteria, while others by then meeting eligibility 
criteria would not be considered for inclusion.   
1.3.6.3 Sample size 
Participating practices will be randomised to one of three arms. In calculating sample size for 
cluster randomised trials31, it is necessary to take into account within-cluster variance, measured 
by an intra-class correlation (ICC).  Our experience in previous studies suggests that intra-class 
correlations of 0.05 for quality of life outcome are typical.   
Preliminary analysis of data from the average-sized practices of one of the applicants suggests 
that there will be approximately 40 patients in such a practice meeting eligibility criteria (1.3.4). We 
recognise that patients in practices allocated to the diet and lifestyle arms of the trial may be 
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reluctant to undertake a change to their diet or lifestyle  and may therefore withhold consent to 
participate.  It is in anticipation of this risk that we have made the assumption that only 30 out of 40 
patients identified will agree to participate and that only 25 will provide follow up data for 12 months. 
Our primary outcome is a continuous variable – score on a quality of life (QoL) scale.  In the 
absence of detailed data on the distribution of QoL scores in our population, we can nonetheless 
specify the effect size that we wish to detect.  We arbitrarily set this at 0.3 standard deviations on 
the condition-specific quality of life scale.  Within the literature on quality of life assessment, there 
is a growing consensus32 that an effect size (i.e. change over time divided by standard deviation at 
baseline) of less than 0.2 represents a negligible change, an effect size of 0.2 up to 0.5 represents 
a ‘small’ effect, an effect size of 0.5 up to 0.8 represents a ‘moderate’ change and an effect size of 
in excess of 0.8 represents a ‘large’ change.  These criterion values, which have been shown to be 
stable across a range of settings, have been established by reference to what clinicians and 
patients consider to be an ‘important’ difference – the emphasis is therefore on clinical rather than 
statistical significance. Our proposed effect size of 0.3 therefore represents the difference between 
the threshold values for ‘small’, ‘moderate’ and ‘large’ changes (0.5 – 0.2; 0.8 – 0.5).   
It is important to note that the LIFELAX trial is not a comparison of an intervention with placebo or 
with normal practice.  Instead, there are three active treatment groups.  It is not unreasonable to 
assume that we might observe at least a small change over time in symptom-related and quality of 
life outcomes in all of these treatment groups.  What we are primarily interested in is whether one 
intervention offers a relative advantage over the others.  For example, if the changes over time for 
the laxative and standardised diet and lifestyle interventions were ‘small’ by the established criteria 
set out above, but a ‘moderate’ improvement was observed in the individualised diet and lifestyle 
arms, we might reasonably conclude that this intervention offered a relative advantage. 
For an effect size of 0.3, 90% power, a significance level of 5%, an intra-class correlation of 0.04, 
and the ability to recruit and retain 25 patients per practice, we therefore need a total of 57 
practices (19 per arm).   
1.3.6.4 Strategies for improving compliance 
The commitment of general practitioners and practice staff will be crucial to the success of the 
study. Educational events will be used to introduce the study protocol to health professionals from 
the participating practices. A regular newsletter to practices will report on progress in the study.  
Financial support will be provided to practices to identify and recruit patients.  CPD accreditation 
will be sought for in-practice training. An educational meeting (again accredited) for participating 
practices will be held at the end of the study to disseminate findings and recommended strategies.  
We believe that the availability of “rescue” medication for patients randomised to the diet and 
lifestyle arms will reduce the risk of non-consent or loss to follow-up, due to anxieties about not 
being able to use medication. 
1.3.7 Statistical analysis  
Analysis will be on an intention-to-treat basis. No sub-group analyses are planned. The data will be 
analysed using mixed effects models, accepted practice for the analysis of data from cluster 
randomised trials31.  Variation between practices and variation between patients nested within 
practices will be fitted as random effects.  The difference between treatment strategies (i.e. the 
three arms of the trial will be fitted as fixed effects.  Most of the outcome variables (e.g. quality of 
life scores, number of days with (or without) symptoms are continuous and will be analysed 
assuming a Normal error structure.  The dependent variable in each model will be point of follow-
up (three, six and twelve months outcomes for quality of life, symptoms and perceptions of bowel 
function; twelve months for consultation and prescription rates). For each patient, baseline data will 
be included as a co-variate.  The mixed models will be used to generate interval estimates for the 
differences between alternative treatment strategies. 
1.3.8 Economic evaluation 
1.3.8.1 Perspective of the evaluation 
We will conduct a cost-effectiveness analysis, placing particular emphasis on the subset of costs 
and effects relevant to address the health service perspective at a macro level.  We will 
supplement this by an individual participant perspective.  Our selected outcome measures include 
condition- and treatment-specific quality of life and a generic utility-based measure of health state, 
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measured at the individual level.  We will also record the costs of the condition and its 
management which are met directly by the patients themselves. 
1.3.8.2 Measure of benefits used and type of study 
Considering all the measures of effectiveness estimated within the clinical trial, a cost-
consequence analysis33 will be outlined alongside the cost-effectiveness analysis.  In the cost-
consequence analysis, clinical and QoL profile scores, resources used for the implementation of 
the intervention strategies and related costs will be presented in a disaggregated way. For each 
arm of the trial, the breakdown of costs and outcomes will be listed in a tabular format; no 
summary measures will be presented. This type of evaluation and presentation provides readers 
with a more transparent interpretation of the results and allows them to make a more selective 
application of the findings to specific decision-making contexts. 
Although quality of life is an important indicator of benefit in the treatment of constipation, and is 
the primary outcome measure in this study, none of the currently available condition-specific 
measures yield a unique QoL score.  A comparison/synthesis of costs and outcomes based on 
each of the separate QoL dimensions in our chosen profile measures would be methodologically 
invalid.  For this reason, a utility-based, index measure – the EQ-5D26;27 – will also be used, to 
facilitate calculation of Quality Adjusted Life Years (QALYs). We are, however, aware of the 
concerns about the use of QALYs in devising resource allocation strategies between different age 
cohorts. Therefore, we aim to develop or apply already existing ‘corrective’ measures to the results 
we will obtain, so that our findings will not have unfavourable implications for the funding of health 
technologies for older people.   
Furthermore, we anticipate that the EQ-5D may not be sensitive enough to detect differences in 
the population being studied. Therefore, alongside this utility-based measure, we will calculate 
discomfort-free days (DFDs) as a new measure of outcome. This measure will include the impact 
on patients’ wellbeing of unwanted symptoms due to both constipation and treatment side-effects. 
It will be a crude but meaningful measure of the patients’ perceived effectiveness of treatment. 
DFDs will be derived through the self-completed structured diaries, in which patients will be asked 
to report the overall impact of both the symptoms of constipation and side-effects of the laxatives 
on their wellbeing. Severity of impact will be graded in levels, and the number of days spent in 
each level of discomfort  will be calculated.  This information will be used to assess correlation with 
DFDs responses. We believe that the comparison of DFDs with EQ-5D utilities will represent a 
useful addition to the body of knowledge on the assessment of cost-effectiveness in trials where 
the main impact is expected to be on palliation of symptoms and improvement of the quality of life, 
rather than on extension of life.  
(In the parallel STOOL study, we will also seek to develop scenarios based on symptoms of 
constipation and condition-specific quality of life, and to use standard gamble and time trade-off 
techniques to establish utilities for the defined health states.  The findings from this work could also 
be applied in the LIFELAX trial). 
1.3.8.3 Resources data collected within the trial and costing methods 
Costs to the National Health Service (NHS) will be estimated on the basis of the use of resources 
needed to implement the three proposed treatment strategies as well as those related to the 
subsequent use of services. Relevant costs include prescribed laxatives, consultations with GPs 
and nurses, and services related to the dietary and lifestyle interventions, such as the delivery of 
advice packages. The costs of preparing and delivering information materials and of training health 
care professionals in their use will also be estimated. These latter represent ‘start-up’ sunk costs, 
which would not be recurrent once the intervention is in place. Allowance against future savings 
will be made in the cost-effectiveness analysis for this initial investment. 
Data on consultation rates and drugs prescribed will be collected through extraction of data from 
medical records of trial participants. Use of resources related to case management services and 
start-up costs will be gathered from the protocol, which will describe in detail how the dietary and 
lifestyle intervention will be delivered. Costs related to the use of medication and health services 
will be assigned using national published data for the United Kingdom24;34. 
Costs falling on the NHS will be supplemented with costs falling on patients themselves. These will 
be derived through telephone interviews, and will include information about the patients’ purchase 
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of  over-the-counter laxatives and any  other possible expenditure relating to the management of 
constipation (e.g. use of complementary medicine, travel costs). Where possible, participants will 
be asked to report costs and quantities separately. 
1.3.8.4 Synthesis of costs and outcomes 
If there is not statistically and clinically significant evidence that one treatment strategy is superior 
to another in terms of health utilities or DFDs, a cost-minimisation framework will be used and the 
adoption of the less expensive strategies will be recommended. Similarly, recommendations for 
adoption will be made if one strategy appears to be more effective and less costly than its 
comparator(s). If one strategy appears to be more effective but more expensive than its 
comparator(s), estimates of incremental cost-effectiveness ratios will be generated and compared. 
A judgement will be required in a policy-making context to establish whether the additional benefits 
warrant the additional costs. In any case, results will be presented taking into account the issues of 
the generalisability of the results to other local settings. 
1.3.8.5 Sensitivity analysis 
Issues of uncertainty in assumptions, methods and data, and of the generalisability of the results 
will be addressed in the sensitivity analysis, where the robustness of the results to any variations in 
key data inputs to the study will be tested. Moreover, a sensitivity analysis, taking into account of 
differences in resource use which are practically significant (i.e. potentially costly) but which have 
not been shown to be statistically significant, will be also be undertaken. 
1.3.9 Ethical arrangements 
Approval for this study will be sought from the Northern and Yorkshire Multicentre Reseach Ethics 
Committee (MREC) and subsequently from the relevant Local Research Ethics Committees.  We 
will follow the recommendations of the MREC, the Medical Research Council and Consumers for 
Ethics in Research (CERES) in conducting this trial and in providing participants with appropriate 
information.   
The risks to patients are anticipated to be minimal (particularly since the option of rescue 
medication is available to those allocated to the diet and lifestyle arms).  Conversely, there are 
potential benefits in terms of symptom relief and enhanced quality of life for all participants (since 
all groups get an ‘active’ intervention and are not denied treatment).  Written information leaflets 
will be used to inform those invited to participate about the potential benefits, risks and implications 
of participation, and this written information will be reinforced by the nurse when patients are 
invited to participate. Those invited to participate will have a minimum of a week to consider 
whether they wish to join the study. Affirmation of consent (for participation in the trial and for 
access to medical records) will be requested at the follow-up consultation (1.3.5.4) and baseline 
data from those withholding consent will be destroyed.  We do not anticipate that anyone eligible 
for the study would be incapable of giving fully informed consent. The University of Newcastle 
recommends that original research data be retained for a minimum of ten years and we will follow 
this recommendation.  All data will be held in compliance with the requirements of the Data 
Protection Act. 
Hutton35 has suggested that cluster randomised trials pose unique ethical issues.  In particular, 
since randomisation in this trial is at the level of the practice, patient consent must essentially be 
post-randomisation.  As stated above, we believe that the offer of rescue medication to patients in 
practices allocated to the diet and lifestyle arms will go some way to ameliorating this constraint on 
patient choice.  
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Trial protocol/V5/240706 
LIFELAX – Diet and lifestyle vs. laxatives in the management of chronic constipation 
in older people 
Protocol for a randomised controlled trial 
1 Planned investigation 
1.1 The research brief 
The commissioning brief (HTA 01/10) specifies the key research question: “What is the 
comparative cost-effectiveness of laxatives compared with dietary and lifestyle changes in the 
treatment of elderly patients with chronic constipation”.   Dietary interventions are to be 
differentiated from bulk laxatives, such as bran, and dietary and/or lifestyle changes may be 
compared with single laxative agents. 
1.2 The research questions addressed by this study 
In studies of individual behaviour change strategies, particularly those relating to dietary change 
and exercise1-3, personalised interventions have been shown to be more effective than standard, 
non-customised approaches.  Elements of personalisation variously include: assessment of the 
importance of making a behaviour change and confidence in carrying out the new behaviour, 
where the individual is situated in the ‘stages of change’ model4, motivational interviews5;
discussion of current behaviour and of facilitators of and barriers to change; agreement of 
individualised goals  and provision of personalised information and advice on behaviour 
change2;6;7; and follow-up reinforcement contacts7.  Such personalised interventions, however, are 
typically more resource-intensive than non-individualised approaches5.  For these reasons, it is 
important to ascertain not just the effectiveness but also the cost-effectiveness of these strategies.  
We therefore propose a pragmatic three-armed trial to compare laxative treatment of chronic 
constipation in older people with both standardised, non-personalised dietary and lifestyle advice 
(delivered in a single, short consultation) and personalised dietary and lifestyle advice (delivered in 
a long consultation – or two shorter consultations, with telephone reinforcement).  Through the trial 
we will address the following key questions, derived from the research brief: 
• What is the comparative clinical and cost-effectiveness of laxatives versus a combination of 
dietary and lifestyle advice? 
• What is the comparative clinical and cost-effectiveness of brief, standardised, non-personalised 
dietary and lifestyle advice versus personalised dietary and lifestyle advice, including 
reinforcement?
1.2.1 Objectives 
1. To investigate the clinical and cost-effectiveness of laxatives versus dietary and lifestyle 
advice.
2. To investigate the clinical and cost-effectiveness of standardised versus personalised dietary 
and lifestyle advice. 
1.3 Detailed plan of investigation 
1.3.1 Trial design 
The trial will take the form of a prospective, pragmatic8, three-armed cluster randomised trial with 
an economic evaluation. Analysis will be on an ‘intention to treat’ basis. Participating practices will 
be randomised to one of three arms: (1) prescription of laxatives; (2) provision of standardised, 
non-personalised dietary and lifestyle advice; (3) provision of personalised dietary and lifestyle 
advice, with reinforcement. 
A randomised controlled trial is the optimum design when evaluating behaviour change 
interventions. However, in this study, if the unit of randomisation was to be the individual patient, 
there would be a risk that health care professionals might provide elements of the dietary and 
lifestyle package to patients randomised to laxatives only. A solution to this problem is to ‘cluster 
randomise’ at the level of an entire practice, while collecting data about outcomes of care at the 
individual patient level. As patients within any one cluster are more likely to respond in a similar 
manner, such a design violates the assumption that the outcome for an individual patient is 
completely independent of that for any other patient. Therefore a cluster randomised design is not 
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as statistically efficient as a patient randomised design; it has lower statistical power than a patient-
randomised trial of equivalent size9 and sample sizes need to be inflated to compensate for this 
(1.3.6).
1.3.2 Setting 
General practices in  England and Scotland and the homes of older people (aged 50 years and 
over) from these practices. 
1.3.3 Health technologies being assessed 
1.3.3.1 Treatment strategies at the patient level 
Study participants will be randomised to one of three treatment strategies (1.3.1).   
Within the laxatives arm, free choice of class of laxatives will be allowed.  There is at present 
insufficient evidence10;11 of the relative superiority of one class of laxatives over another, or of 
combination therapies as opposed to single preparations.  Free choice of laxative therapy will more 
closely replicate the situation which will pertain in routine clinical practice; adherence to treatment 
protocol is therefore expected to be better than where a change in drug is required.  For similar 
reasons, leeway in dosage will be permitted, within dose ranges commonly used in clinical 
practice.  To minimise the risk of prescribing sub-therapeutic doses, the intervention protocol will 
remind participating GPs of the therapeutic dose ranges for the available laxative preparations. 
The dietary and lifestyle interventions will be informed by findings from previous trials of diet and 
lifestyle interventions1;2;6;7. They will also draw upon theories of individual behaviour change, 
including the concept of self-efficacy12 and the stages of change model4.
In both the standardised and personalised arms, the ‘information package’ will comprise practical, 
target-based advisory sheets on: diet – increased consumption of non-starch polysaccharides 
(NSP (fibre)) of both cereal and fruit and vegetable origin13 and of bread and bran products14;
hydration15; dentition16; mobility and exercise17;18; abdominal massage18; toilet habits17; what 
constitutes normal bowel function19; the action and potential side-effects of laxative use. Locality-
specific information (e.g. details of local exercise programmes for older adults and of fruit-and-
vegetable buying clubs) will be included in the package for those allocated to the personalised 
dietary and lifestyle intervention. 
In both arms, this package will be delivered by practice or community nurses (according to local 
custom).  Appointments will generally be offered at the surgery, though home visits will be an 
option where appropriate. In the standardised, non-personalised arm, there will be a single short 
(maximum of 10 minutes) appointment, with delivery of a standard pack of information and brief, 
general explanation of these information materials. In the personalised arm, there will be an initial 
long (30-45 minutes)5 appointment (though this may be undertaken in two shorter appointment 
should clinic time so dictate) and the technique of ‘motivational interviewing’ – ‘a directive client-
centred counselling style for eliciting behaviour change by helping clients to explore and resolve 
ambivalence’ 5 – will be employed.  The personalised approach will include a patient-specific 
assessment of barriers to and facilitators of change and delivery of a personalised pack of 
information with individual targets.  Patients in this arm will receive a follow-up motivational 
telephone call from the nurse at one week and one month after initial appointment. 
A potential threat to patient recruitment and retention in this trial is patients’ unwillingness to forego 
medication.  For this reason, although diet and lifestyle will be the first-line treatment for patients 
allocated to those arms, the option of continuing laxative use (either prescribed or over-the-
counter) will be available if required; the need for and use of such medication will be captured in 
patient diaries (1.3.5.1 and 1.3.5.3). 
1.3.3.2 Training strategies for health professionals 
An orientation and training programme will be developed for the practices recruited to the study. All 
practices will have an on-site training visit to discuss aspects of the treatment protocol and how it is 
to be delivered in the practice. In addition, a dietician with experience in health promotion will 
deliver in-practice training on how to deliver the dietary and lifestyle intervention to patients, as 
follows:
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• Standardised dietary and lifestyle intervention – all primary health care professionals (general 
practitioners, practice and district nurses, health visitors) in the practice will be invited to a 
single, one hour session to introduce the programme and the patient pack. 
• Personalised dietary and lifestyle intervention – all primary health care professionals (general 
practitioners, practice and district nurses, health visitors) in the practice will be invited to an 
initial one hour session to introduce the programme and the patient pack.  Practice staff 
involved in delivering the intervention to patients will be invited to take part in two further 45 
minute sessions on the delivery of a personalised pack and motivational interviewing 
techniques.
The choice of number and duration of training sessions is based on experience in other similar 
studies, and represents a balance between minimising the demands on busy health professionals’ 
resources, whilst having sufficient time to motivate doctors and nurses and to equip them with the 
knowledge and skills required to deliver the interventions to patients. Our personal experience, 
reinforced by the literature20, suggests that in-practice delivery of training of this nature is more 
cost-effective than delivery at a single, central location.  
1.3.4 Target population 
People aged 50 or over with chronic constipation living in private households. The choice of an age 
cut-off of people aged 50 or over has been made after due consideration of the morbidity statistics 
from general practice21 which show that general-practitioner consultation rates for constipation take 
off in the 45-64 age group and rise steadily with age. The exclusion of residents in long-term care 
reflects the different morbidity and life-style experience of long-term care residents. We will focus 
on a predominantly ambulant population able to independently attend a primary care clinic. 
1.3.4.1 Inclusion criteria 
The complexity of the revised Rome criteria for functional constipation22 militates against their use 
in screening for chronic constipation. Moreover, newly incident cases of constipation, especially 
amongst older adults, should be investigated to determine the underlying cause of the constipation 
and to eliminate more serious problems23 before laxatives are prescribed.  
This trial will therefore identify and recruit only ‘prevalent’ cases, defined in terms of those 
prescribed laxatives three or more times in the previous 12 months. Participants meeting this 
criterion will be identified from general practice computerised patient records using an electronic 
‘query’ to interrogate repeat prescribing databases.  It is recognised that the relapsing and 
remitting nature of constipation means that not all patients thus identified will be constipated (by 
objective or subjective criteria) at any given time.  Eligible participants who have given informed 
consent will be invited to complete a baseline assessment during which current bowel function and 
perceptions of whether constipated will be elicited; these baseline data will be included as co-
variates in our analysis (1.3.7). 
1.3.4.2 Exclusion criteria 
• Patients resident in long-term care. 
• Patients with inflammatory bowel disease, intestinal obstruction/bowel strictures, known colonic 
carcinoma, and conditions contra-indicative to the prescription of laxative preparations24.
• Inability to read and understand written treatment plans and educational material. 
• Inability to complete outcome assessments, even with assistance (e.g. major cognitive 
impairment, lack of understanding of English). 
1.3.5 Assessment of outcomes 
1.3.5.1 Outcome measures 
The primary outcome, and the criterion upon which the sample size calculations have been based, 
is patient-reported condition-specific quality of life at three months post recruitment (1.3.5.2).  Our 
preferred measure of quality of life is the constipation-specific PAC-SYM / PAC-QOL25, which has 
been demonstrated to have good validity and reliability.  However, this measure is not utility-based.  
For the purposes of the economic evaluation (1.3.8), a measure of the utility placed by patients on 
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their health state will be required.  The condition-specific measure of quality of life will therefore be 
supplemented by the generic, utility-based EQ-5D26;27.
Secondary outcomes will include: bowel movement frequency; the presence/absence of the other 
Rome criteria for constipation; patients’ own perceptions of whether or not they are constipated; 
patient satisfaction with bowel function; adverse effects of treatment; relapse / re-consultation 
rates; fluid and fibre intake (Table 1).   
In addition, the cost implications of the condition and its treatment (e.g. GP consultations, purchase 
of prescribed and over-the-counter medication) will be assessed, as part of the economic 
evaluation (Table 2; section 1.3.8).
Table 1 Outcome measures 
Primary outcome Measurement method When Where 
Health-related quality of life Postal questionnaire At three months 
post recruitment  
Participant’s
home
Secondary outcomes Measurement method When Where
Health-related quality of life Postal questionnaire At six and twelve 
months post 
recruitment
Participant’s
home
Number of bowel movements per 
week 
Self-completed structured 
diary
+ Postal questionnaire 
Daily for 6 
months
At 12 months 
Participant’s
home
Other Rome criteria: straining at 
defecation, stool consistency, 
perceived incomplete evacuation 
Self-completed structured 
diary
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months
At 12 months 
Participant’s
home
Subjective perception of whether 
constipated; satisfaction with 
bowel function 
Telephone interview 
+ Postal questionnaire 
At 3 months 
At 6 months & 12 
months
Participant’s
home
Adverse events: abdominal pain, 
nausea, bloating, flatulence, 
diarrhoea 
Self-completed structured 
diary
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months
At 12 months 
Participant’s
home
Use of prescribed and OTC 
laxatives  
Self-completed structured 
diary
+ Postal questionnaire 
Daily for 6 
months & for 1 
week at 12 
months
At 12 months 
Participant’s
home
Fluid and fibre intake Self-completed structured 
diary
+ Postal questionnaire 
1 day per month 
for 6 months 
At 12 months 
Participant’s
home
Relapse rates: including repeat 
consultations  
Self-completed structured 
diary; GP records 
Daily for 6 
months; Twelve 
months post 
recruitment
Participant’s
home (diary); 
General practices 
(GP records) 
Personal measures of success 
with the management of 
constipation 
Telephone interview At 3 months and 
6 months 
Participant’s
home
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Table 2 Measuring treatment impact 
Impact Measure When Where 
Costs to participants of 
the condition and its 
management  
Structured health diary; 
telephone interview; 
postal questionnaire 
Using different 
methods, for six months
Participant’s home 
Consultation rates and 
laxative prescriptions 
GP records At twelve months post 
recruitment
General practices 
1.3.5.2 Follow-up period 
Maximum response to the interventions are expected within 12 weeks of initiation of treatment; this 
dictates that the primary outcome should be assessed at three months post recruitment.  However, 
since a common criticism of behaviour change interventions is the lack of sustained effect, quality 
of life data will be collected again at six and twelve months post recruitment while symptom diaries 
will be completed daily for six months.  Relapse rates (defined in terms of re-consultation and/or 
demand for further prescriptions for laxatives) will be monitored for twelve months post recruitment, 
through interrogation of patients’ medical records.  We believe that intensive follow-up of patients 
for six months coupled with extended monitoring of quality of life, consulting and prescribing data 
represents a reasonable compromise between placing excessive burden on respondents (posing 
threats to recruitment and retention rates) and assessing longer-term consequences of the 
interventions.
1.3.5.3 Methods of data collection 
1.3.5.3.1 Base-line assessment (W0)
Prior to any assessments being conducted, each participant will speak on the telephone with a 
member of the research team and be invited to discuss any aspect of participation in the study they 
wish. Once informed consent has been obtained the baseline assessment will be conducted. This 
assessment will include a short  telephone structured interview and a short self completion 
questionnaire. Current bowel function (based on Rome criteria), fluid and fibre intake and patients’ 
self-perceptions of whether they are currently constipated and levels of anxiety and depression28
will be elicited and data on  activities of daily living29, condition-specific quality of life and laxative 
use (both prescribed and over the counter) will be collected. A weekly structured self-completed 
diary will be distributed and explained. The person conducting the baseline assessment will notify 
practices that patients are ready to begin the intervention (as per protocol) and practices will make 
an appointment to see participants to start the intervention. In following this approach we minimise 
the risk of patients who have not given informed consent receiving the intervention as the 
intervention will only be delivered once a signed copy of the consent form is sent to the practice 
with the instruction to begin the intervention. At this first appointment, treatment per intervention 
protocol (1.3.5.4) will be initiated.  Should patients decide to withdraw when they return to collect 
either their laxative prescription or for their diet and lifestyle appointment, the practice will notify the 
research team and all baseline assessment data and patient identification data will be destroyed or 
deleted from the study database.
1.3.5.3.2 Health diary (daily for 6 months from W0)
To minimise recall bias, data on bowel function (based on the Rome criteria)22, fluid and fibre 
intake, perceptions of whether constipated and use of laxatives will be gathered by a structured 
(tick box format) health diary, completed each day and returned monthly for six months.  
1.3.5.3.3 Follow-up self-completion questionnaires (W13 and W26 and W52)
Follow-up questionnaires, using up to two reminders, will be sent at W11 (for completion by W13),
W24 (for completion by W26) and W50 (for completion by W52). Data to be collected will be: 
condition-specific quality of life (1.3.5.1); Rome criteria22; and anxiety and depression28.
Although structured interviews are the gold standard for collecting a large volume of complex 
data30, the choice of postal questionnaires has been made to contain the cost of data collection. 
The use of postal questionnaires will also allow some blinding of outcome assessment (1.3.5.5). 
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Our recent experience in using postal questionnaires to gather information on quality of life and 
costs of treatment from ambulant, cognitively normal, older people with angina, in which we 
achieved response rates of 72%, 83% and 90% at  baseline, 12-month and 24-month follow-up 
respectively, suggests that non-response bias will not be a significant problem.  
1.3.5.3.4 Telephone interviews (W3-4, W13 and W26)
Within two weeks of their consultation for diet and lifestyle advice a small sample of patients in the 
standardised and personalised intervention arms of the trial will receive a short postal 
questionnaire to ask about the diet and lifestyle advice they were given.  The purpose being to 
monitor the content of the interventions.  Short telephone interviews will be used to collect cost 
data on medication purchase (both prescribed and OTC), and other out of pocket expenses for the 
economic analysis. This interview will also ask patients about their personal levels of success in 
the management of their constipation.  They will be conducted by a research secretary at W13 and 
W26 and data will be recorded directly onto a database by the interviewer. We are currently using 
this method effectively in a study of older people.  Other resource use data will be collected from 
practice medical records (1.3.5.3.5).   
1.3.5.3.5 Medical records (W52)
Data pertaining to consultation rates and prescription of laxatives for all study participants for the 
twelve months post recruitment will be abstracted from medical records. This will be done practice-
by-practice at the end of the data collection period. Trained research nurses will interrogate paper-
based and computerised records and will enter data directly to a database on lap-top computer.  
The electronic query used to identify patients at the beginning of the trial will be adapted to capture 
data on laxative prescriptions.  We have used these methods of data collection to good effect in 
previous similar studies. 
1.3.5.4 Participants’ pathways through trial 
Activity 
1 Potential participants identified from computerised practice databases using simple electronic 
query to flag individuals receiving prescriptions for constipation (3 or more in previous 12 
months).
2 Initial screen by practice to identify clear exclusions. 
3 Written invitation sent by practice (facilitated by research team) to patient to participate in 
study. Contact details form and pre-paid envelope included for patients wishing to join the 
study included. Research team to contact patient to answer questions and explain about 
process for informed consent. Consent form posted to patient with pre-paid envelope.  Self 
completion questionnaire and pre-paid envelope also sent. Control patients will receive their 
diary (including pre-paid envelope) at this point. 
4 W0 When consent form is returned the telephone baseline interview will be conducted.   patient 
advised to expect contact from practice to arrange ‘intervention start’ appointment. 
5 W1 Appointment at practice – laxative prescription issued or diet and lifestyle intervention initiated. 
All patient information and baseline data destroyed by research team if patient notifies 
practice of their wish to withdraw from study. 
6 W2 One week reinforcement phone call from nurse to patients randomised to personalised diet 
and lifestyle advice 
7 W3-4 Intervention fidelity measure – a small sample of patients in the standardised and 
personalised intervention arms of the trial will receive a short postal questionnaire to ask 
about the diet and lifestyle advice. 
8 W5 One month reinforcement phone call from nurse to patients randomised to personalised diet 
and lifestyle advice 
9 W12 Three month follow up outcome assessment (postal questionnaire) and collection of cost data 
and personal levels of success (telephone interview) 
10 W26 Six month follow up outcome assessment (postal questionnaire) and collection of cost data 
and personal levels of success (telephone interview) 
11 W52 Twelve month follow up outcome assessment (postal questionnaire & 1-week symptom diary). 
Review of practice notes to abstract data on consultation rates and prescription patterns.   
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1.3.5.5 Blinding of outcome assessment 
Health technology assessment is essentially a pragmatic activity conducted in normal clinical 
practice. It follows that blinding doctors, nurses and patients to treatment is not desirable (even if 
practicable – which would not be the case here, since the three interventions are visibly and 
demonstrably different) since it distorts normal clinical practice.  In contrast, blinding of assessors 
is desirable because it minimises subjective bias towards a given treatment.  Where practical 
considerations (e.g. size of research team) preclude concealment of allocation of treatment from 
those collecting data, highly structured data collection instruments can reduce the risk of bias in 
data recording and analysis. In this study, complete concealment of the allocation is likely to be 
impractical.  However, the individuals responsible for the delivery of training in the dietary and life-
style intervention, and for the collection of qualitative data on facilitators of and barriers to 
adherence to treatment protocol, will not reveal their experiences in respect of individual practices 
to those collecting and analysing patient outcome data.  
1.3.6 Sampling design and implementation 
1.3.6.1 Practice recruitment and randomisation 
General practices in England and Scotland will be invited by letter to participate. Standard sample 
size calculations for a cluster randomised trial31 indicate that we will need to recruit 57 practices in 
total (1.3.6.3).  This estimate is based on the number of patients likely to be available in the 
average-sized practice; if larger practices participate, the number of practices required may be 
slightly reduced. We will initially seek to include practices from local primary care research 
networks but may need to supplement with others, depending on take up. Practices agreeing to 
take part in the study will be randomised by computer to one of the three arms.  We recognise that 
practices may have preferences with respect to allocation of interventions.  We will make it very 
clear to the practices approached to participate in the LIFELAX study that allocation to intervention 
will be completely at random and that practice preferences cannot be taken into account.   
Randomisation will be carried out by an individual not otherwise involved in practice contact, or in 
data analysis.
1.3.6.2 Patient identification and recruitment 
Two methods of patient identification were considered: incident and prevalent cases. Consultation 
rate data21 indicate that there would be only a small number of incident cases per year in any one 
practice.  Moreover, these incident cases would, at least initially, be subject to more intensive 
medical investigation23, which would militate against inclusion in the trial. Finally, we are aware of 
experiences of differential rates of patient identification across active and control arms of previous 
cluster randomised trials (e.g. the UK BEAM trial) and the potential for selection bias that results 
from such differential rates.  This risk is greater when incident cases are being identified, and when 
responsibility for identification lies with the clinician.  For these reasons, only prevalent cases 
(1.3.4.1),  which will be retrospectively identified through computerised records, will be considered.    
The identification process will be through an independent interrogation of practice prescribing 
databases, and will therefore not be subject to influence by the participating clinicians.  We believe 
that this approach will minimise selection bias. 
To spread practice workload, patient recruitment in each practice will be spread over four months.  
It would not be practicable to identify all (i.e. across all 57 practices) potentially eligible patients 
prior to practice randomisation and patient contact.  The reason for this is that bowel symptoms 
may fluctuate in patients and a patient identified as ‘constipated’ at a given point in time may no 
longer be ‘constipated’ several months later.  We expect that the delivery of the intervention to 
practices will extend over 10 months.  Initial eligibility of patients will be based on receipt of 3 or 
more prescriptions for laxatives in the preceding 12 months (1.3.4.1).  If the patient identification 
query were to be run in all practices at the beginning of this 10 month period and patients thus 
identified were to be ‘banked’ until the intervention was delivered in a specific practice, some of 
those identified might no longer meet eligibility criteria, while others by then meeting eligibility 
criteria would not be considered for inclusion.   
1.3.6.3 Sample size 
Participating practices will be randomised to one of three arms. In calculating sample size for 
cluster randomised trials31, it is necessary to take into account within-cluster variance, measured 
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by an intra-class correlation (ICC).  Our experience in previous studies suggests that intra-class 
correlations of 0.05 for quality of life outcome are typical.   
Preliminary analysis of data from the average-sized practices of one of the applicants suggests 
that there will be approximately 40 patients in such a practice meeting eligibilty criteria (1.3.4). We 
recognise that patients in practices allocated to the diet and lifestyle arms of the trial may be 
reluctant to undertake a change to their diet or lifestyle and may therefore withhold consent to 
participate.  It is in anticipation of this risk that we have made the assumption that only 30 out of 40 
patients identified will agree to participate and that only 25 will provide follow up data for 12 
months.
Our primary outcome is a continuous variable – score on a quality of life (QoL) scale.  In the 
absence of detailed data on the distribution of QoL scores in our population, we can nonetheless 
specify the effect size that we wish to detect.  We arbitrarily set this at 0.3 standard deviations on 
the condition-specific quality of life scale.  Within the literature on quality of life assessment, there 
is a growing consensus32 that an effect size (i.e. change over time divided by standard deviation at 
baseline) of less than 0.2 represents a negligible change, an effect size of 0.2 up to 0.5 represents 
a ‘small’ effect, an effect size of 0.5 up to 0.8 represents a ‘moderate’ change and an effect size of 
in excess of 0.8 represents a ‘large’ change.  These criterion values, which have been shown to be 
stable across a range of settings, have been established by reference to what clinicians and 
patients consider to be an ‘important’ difference – the emphasis is therefore on clinical rather than 
statistical significance. Our proposed effect size of 0.3 therefore represents the difference between 
the threshold values for ‘small’, ‘moderate’ and ‘large’ changes (0.5 – 0.2; 0.8 – 0.5).   
It is important to note that the LIFELAX trial is not a comparison of an intervention with placebo or 
with normal practice.  Instead, there are three active treatment groups.  It is not unreasonable to 
assume that we might observe at least a small change over time in symptom-related and quality of 
life outcomes in all of these treatment groups.  What we are primarily interested in is whether one 
intervention offers a relative advantage over the others.  For example, if the changes over time for 
the laxative and standardised diet and lifestyle interventions were ‘small’ by the established criteria 
set out above, but a ‘moderate’ improvement was observed in the individualised diet and lifestyle 
arms, we might reasonably conclude that this intervention offered a relative advantage. 
For an effect size of 0.3, 90% power, a significance level of 5%, an intra-class correlation of 0.04, 
and the ability to recruit and retain 25 patients per practice, we therefore need a total of 57 
practices (19 per arm).   
1.3.6.4 Strategies for improving compliance 
The commitment of general practitioners and practice staff will be crucial to the success of the 
study. Educational events will be used to introduce the study protocol to health professionals from 
the participating practices. A regular newsletter to practices will report on progress in the study.  
Financial support will be provided to practices to identify and recruit patients.  CPD accreditation 
will be sought for in-practice training. An educational meeting (again accredited) for participating 
practices will be held at the end of the study to disseminate findings and recommended strategies.  
We believe that the availability of “rescue” medication for patients randomised to the diet and 
lifestyle arms will reduce the risk of non-consent or loss to follow-up, due to anxieties about not 
being able to use medication. 
1.3.7 Statistical analysis  
Analysis will be on an intention-to-treat basis. No sub-group analyses are planned. The data will be 
analysed using mixed effects models, accepted practice for the analysis of data from cluster 
randomised trials31.  Variation between practices and variation between patients nested within 
practices will be fitted as random effects.  The difference between treatment strategies (i.e. the 
three arms of the trial will be fitted as fixed effects.  Most of the outcome variables (e.g. quality of 
life scores, number of days with (or without) symptoms are continuous and will be analysed 
assuming a Normal error structure.  The dependent variable in each model will be point of follow-
up (three, six and twelve months outcomes for quality of life, symptoms and perceptions of bowel 
function; twelve months for consultation and prescription rates). For each patient, baseline data will 
be included as a co-variate.  The mixed models will be used to generate interval estimates for the 
differences between alternative treatment strategies. 
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1.3.8 Economic evaluation 
1.3.8.1 Perspective of the evaluation 
We will conduct a cost-effectiveness analysis, placing particular emphasis on the subset of costs 
and effects relevant to address the health service perspective at a macro level.  We will 
supplement this by an individual participant perspective.  Our selected outcome measures include 
condition- and treatment-specific quality of life and a generic utility-based measure of health state, 
measured at the individual level.  We will also record the costs of the condition and its 
management which are met directly by the patients themselves. 
1.3.8.2 Measure of benefits used and type of study 
Considering all the measures of effectiveness estimated within the clinical trial, a cost-
consequence analysis33 will be outlined alongside the cost-effectiveness analysis.  In the cost-
consequence analysis, clinical and QoL profile scores, resources used for the implementation of 
the intervention strategies and related costs will be presented in a disaggregated way. For each 
arm of the trial, the breakdown of costs and outcomes will be listed in a tabular format; no 
summary measures will be presented. This type of evaluation and presentation provides readers 
with a more transparent interpretation of the results and allows them to make a more selective 
application of the findings to specific decision-making contexts. 
Although quality of life is an important indicator of benefit in the treatment of constipation, and is 
the primary outcome measure in this study, none of the currently available condition-specific 
measures yield a unique QoL score.  A comparison/synthesis of costs and outcomes based on 
each of the separate QoL dimensions in our chosen profile measures would be methodologically 
invalid.  For this reason, a utility-based, index measure – the EQ-5D26;27 – will also be used, to 
facilitate calculation of Quality Adjusted Life Years (QALYs). We are, however, aware of the 
concerns about the use of QALYs in devising resource allocation strategies between different age 
cohorts. Therefore, we aim to develop or apply already existing ‘corrective’ measures to the results 
we will obtain, so that our findings will not have unfavourable implications for the funding of health 
technologies for older people.   
Furthermore, we anticipate that the EQ-5D may not be sensitive enough to detect differences in 
the population being studied. Therefore, alongside this utility-based measure, we will calculate 
discomfort-free days (DFDs) as a new measure of outcome. This measure will include the impact 
on patients’ wellbeing of unwanted symptoms due to both constipation and treatment side-effects. 
It will be a crude but meaningful measure of the patients’ perceived effectiveness of treatment. 
DFDs will be derived through the self-completed structured diaries, in which patients will be asked 
to report the overall impact of both the symptoms of constipation and side-effects of the laxatives 
on their wellbeing. Severity of impact will be graded in levels, and the number of days spent in 
each level of discomfort  will be calculated.  This information will be used to assess correlation with 
DFDs responses. We believe that the comparison of DFDs with EQ-5D utilities will represent a 
useful addition to the body of knowledge on the assessment of cost-effectiveness in trials where 
the main impact is expected to be on palliation of symptoms and improvement of the quality of life, 
rather than on extension of life.
1.3.8.3 Resources data collected within the trial and costing methods 
Costs to the National Health Service (NHS) will be estimated on the basis of the use of resources 
needed to implement the three proposed treatment strategies as well as those related to the 
subsequent use of services. Relevant costs include prescribed laxatives, consultations with GPs 
and nurses, and services related to the dietary and lifestyle interventions, such as the delivery of 
advice packages. The costs of preparing and delivering information materials and of training health 
care professionals in their use will also be estimated. These latter represent ‘start-up’ sunk costs, 
which would not be recurrent once the intervention is in place. Allowance against future savings 
will be made in the cost-effectiveness analysis for this initial investment. 
Data on consultation rates and drugs prescribed will be collected through extraction of data from 
medical records of trial participants. Use of resources related to case management services and 
start-up costs will be gathered from the protocol, which will describe in detail how the dietary and 
lifestyle intervention will be delivered. Costs related to the use of medication and health services 
will be assigned using national published data for the United Kingdom24;34.
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Costs falling on the NHS will be supplemented with costs falling on patients themselves. These will 
be derived through telephone interviews, and will include information about the patients’ purchase 
of  over-the-counter laxatives and any  other possible expenditure relating to the management of 
constipation (e.g. use of complementary medicine, travel costs). Where possible, participants will 
be asked to report costs and quantities separately. 
1.3.8.4 Synthesis of costs and outcomes 
If there is not statistically and clinically significant evidence that one treatment strategy is superior 
to another in terms of health utilities or DFDs, a cost-minimisation framework will be used and the 
adoption of the less expensive strategies will be recommended. Similarly, recommendations for 
adoption will be made if one strategy appears to be more effective and less costly than its 
comparator(s). If one strategy appears to be more effective but more expensive than its 
comparator(s), estimates of incremental cost-effectiveness ratios will be generated and compared. 
A judgement will be required in a policy-making context to establish whether the additional benefits 
warrant the additional costs. In any case, results will be presented taking into account the issues of 
the generalisability of the results to other local settings. 
1.3.8.5 Sensitivity analysis 
Issues of uncertainty in assumptions, methods and data, and of the generalisability of the results 
will be addressed in the sensitivity analysis, where the robustness of the results to any variations in 
key data inputs to the study will be tested. Moreover, a sensitivity analysis, taking into account of 
differences in resource use which are practically significant (i.e. potentially costly) but which have 
not been shown to be statistically significant, will be also be undertaken. 
1.3.9 Ethical arrangements 
Approval for this study will be sought from Scotland A Multicentre Reseach Ethics Committee 
(MREC) and subsequently from the relevant Local Research Ethics Committees.  We will follow 
the recommendations of the MREC (the Medical Research Council and Consumers for Ethics in 
Research (CERES) in conducting this trial and in providing participants with appropriate 
information.
The risks to patients are anticipated to be minimal (particularly since the option of rescue 
medication is available to those allocated to the diet and lifestyle arms).  Conversely, there are 
potential benefits in terms of symptom relief and enhanced quality of life for all participants (since 
all groups get an ‘active’ intervention and are not denied treatment).  Written information leaflets 
will be used to inform those invited to participate about the potential benefits, risks and implications 
of participation, and this written information will be reinforced by the nurse when patients are 
invited to participate. Those invited to participate will have a minimum of a week to consider 
whether they wish to join the study. Affirmation of consent (for participation in the trial and for 
access to medical records) will be requested at the follow-up consultation (1.3.5.4) and baseline 
data from those withholding consent will be destroyed.  We do not anticipate that anyone eligible 
for the study would be incapable of giving fully informed consent. The University of Newcastle 
recommends that original research data be retained for a minimum of ten years and we will follow 
this recommendation.  All data will be held in compliance with the requirements of the Data 
Protection Act. 
Hutton35 has suggested that cluster randomised trials pose unique ethical issues.  In particular, 
since randomisation in this trial is at the level of the practice, patient consent must essentially be 
post-randomisation.  As stated above, we believe that the offer of rescue medication to patients in 
practices allocated to the diet and lifestyle arms will go some way to ameliorating this constraint on 
patient choice.
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LIFELAX brief patient info sheet (PIS), version 5 (26 May 2006)
ISRCTN7388134 
 
 
 
 
 
 
“What are 
you going to 
ask me to 
do?”
“What does it 
mean for me if I 
agree to take part 
in the study?”  
 
 
 
 
 
 
 
 
 
 
A study about different ways of treating constipation in older 
people 
 Diet and lifestyle versus laxatives in the management of chronic constipation in 
older people. 
Some important questions answered 
Welcome to LIFELAX.  We would like to invite you to take part in our research study.  This study 
looks at the way that constipation in older people is treated by doctors and nurses.  
Before you decide if you want to take part, it is important for you to know why the research is 
being carried out and what it will involve for you should you decide to join in. This short 
information sheet will give you a brief outline of the study, and explains why we need your help, 
and what we will ask you to do.   
The Full Information Sheet that accompanies this one is more detailed and answers lots of 
questions about the whole study. It would be helpful for you to read it too.  You can call us 
anonymously if you have any further questions about taking part.
Thank you for your time and the interest you have shown in our research. 
 Centre for Health Services Research,  
 University of Newcastle upon Tyne,  
 Newcastle upon Tyne NE2 4AA 
LIFELAX brief patient information sheet – version  5 260506 
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The LIFELAX research team is based in the University of Newcastle. We 
work with GPs across England and Scotland. 
Who is doing this study? 
Constipation is a common and often bothersome problem for older 
adults. There are different ways of treating it. We are trying to find out the 
best way of doing this. 
Why are you doing the 
study?
We are trying three different approaches. One uses laxative treatment, 
two look at changing your diet and lifestyle.  
How are you going to do 
the study? 
Your GP believes our research to be worthwhile and is supporting us. 
According to your medical notes, you have been prescribed laxatives 
often enough to take part in the study. 
Why ask me to help in the 
study?
No. It is voluntary. If you do agree to join then change your mind you can 
leave at any time. We will need you to sign a consent form to say you are 
happy to join, but even then you can drop out. 
Do I have to take part in 
the study? 
A member of the research team will contact you and answer any 
questions you might have.  You will be asked to sign a consent form.  A 
convenient time will be arranged with you for you to  talk to a member of 
the research team on the telephone  They will ask you some questions 
about your constipation. We ask everyone to fill in a daily diary about 
your bowel habits to monitor any changes during the study. We also ask 
you to fill in  4 postal questionnaires during the 12 months of the study. 
Some people may be asked about what it was like to take part in the 
study or get a telephone call to ask about the diet and lifestyle advice 
they were given.  Just like before, this is voluntary and you don’t need to 
take part.  
What will I be asked to do 
in the study? 
The treatment your surgery is asked to provide in the study was randomly 
chosen. This makes the study fair and equal. However, if you do not wish 
to continue in the study because you are not happy with the group your 
surgery is in, you should tell your doctor. They will then treat your 
constipation in whatever way you and your doctor think is best for you. 
Can I choose my 
treatment?
No, not as part of our study.  Do I need to have any 
medical tests or 
examinations?
Yes. This is because we need to see just how often you have been to 
see your GP during the study and what prescriptions you have had. This 
helps us to work out the cost of treating constipation. 
Will you need to see my 
medical records? 
Yes. We have to make every bit of information anonymous. Nothing you 
say can be traced directly back to you. 
Will my records, diary and 
questionnaire answers
stay private? 
Yes. We have had it checked out by and approved by a Research Ethics 
Committee. It is sponsored by the NHS. We are not using any new or 
untried drugs. We have very strict rules to follow to make sure everything 
we do in the study is safe as it possibly can be. 
Has anyone checked to 
see whether this study is 
safe?
The accompanying Full Patient Information Leaflet does tell you more 
about the whole study. If you can’t find an answer to any of your 
questions in it, then please telephone Chris Speed. 
I want to know more. What 
should I do? 
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ISRCTN7388134
A study about different ways of treating 
constipation in older people 
Diet and lifestyle versus laxatives in the management of 
chronic constipation in older people.
We would like to invite you to take part in our research study.  This study looks at the way 
that constipation in older people is treated by nurses and doctors.
Before you decide if you want to take part, it is important for you to know why the research 
is being carried out and what it will involve for you should you decide to join in please take
time to read this sheet carefully - it answers many of the questions you may have.  If you 
wish, you can show the leaflet to your family or friends and discuss it with them.  If there is 
anything at all you are not clear about, or if you would like any more information, please 
ask one of the research team - our contact details can be found at the end of this sheet. 
Please take your time to decide whether or not you wish to join this study - you don’t need
to make up your mind ‘on the spot’.
Thank you for taking the time to consider the study. 
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Who is doing this study? 
We are a team of researchers based at 
the Centre for Health Services Research 
at the University of Newcastle upon Tyne.
This study is funded by the National 
Health Service.  We will be working with 
GPs across England and Scotland. 
Why is this study being done? 
Constipation is a common and often 
bothersome problem in adults in the 
United Kingdom, particularly amongst 
those aged 50 and over.  There are 
different ways in which doctors can treat 
it.  Constipation can be treated by 
prescribing laxatives.  It can also be 
treated by altering diet and lifestyle.
What do you want to find out? 
We are carrying out the study because 
we need to know the best way to manage 
constipation in older people.  To do this 
we need to compare the different types of 
treatment to see which one is best.   
How is this study being done?
• First – we have recruited practices to 
the study (because you have this 
information sheet your surgery is 
taking part).  Your practice will have 
been randomly selected to be in one 
of three groups.  We will tell you more 
about these groups later in this leaflet.
• Second – we have helped 
practices to identify people, like 
yourself who can take part in our 
study.
• Third – doctors are inviting eligible 
patients to take part.
How and why have I been 
picked?
You have been chosen to take part 
because, according to your medical 
records, you have experienced 
constipation often enough and are in the 
correct age group for the study.
We need about 1500 people with 
constipation, both men and women, aged
50 and over and will be selecting patients 
from a number of general practices in 
England  and Scotland
What are the benefits to me for 
taking part? 
We hope that all the treatments on offer 
in the study will be of benefit to patients.
However, there is no guarantee that an 
individual patient will get an immediate, 
direct benefit.  We do hope that in the 
longer term our research will allow us to 
treat chronic constipation in a better way.
Do I have to take part?
No, it is entirely up to you whether you 
take part.  We would like you to take your 
time, to read this information sheet and to 
think about the study.  We would very 
much like you to help us, but if you decide 
not to take part, the care that you get 
from your GP’s surgery will not be 
affected by your decision and no one will 
put pressure on you to take part.  If you 
decide that you don’t want to be part of 
the study you do not need to give us a 
reason.
Can I say ‘Yes’ now, and change 
my mind later? 
Yes, you can. Even if you say ‘yes’ now 
you can leave the study at any time.  You 
are not committing yourself to the study 
forever, and if you decide to leave you will 
not be asked for a reason.
What are the three groups you 
mentioned before? 
As we said before, your practice will have 
been randomly selected to be in one of 
three groups.  The three groups are:-
1) Your doctor will prescribe laxatives 
for your constipation.
2) Your surgery will give you 
standard, non-personalised dietary 
and lifestyle advice to help with 
your constipation. 
3)  Your surgery will give you 
personalised dietary and lifestyle 
advice, and you will be given 
ongoing help and advice to help 
with your constipation. 
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Can I or my surgery choose the 
group we are in? 
No, it is not possible for you or your 
doctor to choose the group that you go 
into.  This is because we have to make it 
as fair as possible for all practices and 
patients.  Because none of the doctors 
can choose their favourite group there is 
an equal chance for all practices to go 
into each group. The group that a 
surgery is in is decided randomly (like the 
Lotto).  Because there are three groups 
the surgery has an equal chance of one 
in three (33%) of being in a group.  If you 
do not wish to be included in the study, 
you should tell your doctor.  He or she will 
then treat your constipation in whatever 
way you and the doctor think is best for 
you.
Will there be any lifestyle 
restrictions for me? 
There will not be any lifestyle restrictions 
as such for anyone taking part in the 
study.  If you happen to be chosen for the 
Diet and Lifestyle group you will be 
offered advice on your lifestyle but 
whether you take it is entirely up to you.
As with any treatment, please feel free to 
discuss any aspects of it with your doctor 
at any time.  
What about any side effects from 
the treatment? 
Because we are not trying out any new 
laxatives in the study, your doctor will be 
able to tell you of any known side effects 
for any of the laxatives they may 
prescribe.  However, like any medicines, 
laxatives can have unwanted side-effects 
in some patients such as abdominal 
discomfort, bloating, flatulence etc.  The 
likelihood and nature of these side-effects 
varies with the type of laxative but in 
general they are mild to moderate in 
intensity.
In the diet and lifestyle groups, you may 
notice a slight change in your bowel 
habits in the short term as it takes a while 
for any changes you make to take effect.
Again, if you have any concerns about 
any aspect of your treatment or 
constipation you can talk to your doctor.
Is there another part to the study 
that I should know about? 
We will be asking some people to talk to 
us about their experiences of their time in 
the study.  If we ask you to be interviewed 
for that part of the study, we will ask you 
to sign a consent form to say that you 
agree to be interviewed.  Again, this does 
not tie you down.  You will still be free to 
change your mind at any time and leave 
this part or the whole study.  
If I’m picked for the interviews, 
what will they be like? 
The meeting will take place wherever 
feels most comfortable to you (e.g. at 
home or in your GP’s surgery..  If you 
have to travel from your home for the 
interview, we will pay your travel 
expenses.  The interview will take about 
an hour and will be conducted by an 
experienced researcher.  It will be taped 
so that the researcher can talk with you 
without having to make too many notes.  
This allows the interview to flow like a 
conversation and to be quite informal.
Anything you say at any stage or any 
information you give us will be strictly in 
confidence.  You can ask to have the 
tape turned off at any stage during the 
interview and you won’t have to give a 
reason. Only people in the research team 
will ever hear the tape.
What will happen next if I decide 
to take part in the study? 
If you would like to join the study, you will 
need to send the research team your 
contact details using the enclosed form 
and envelope. A member of the research 
team will contact you and answer any 
questions that you might have about the 
study.  They will send you a copy of a 
consent form to sign.  When you have 
signed and returned it to the study team 
they will arrange  a convenient time to  
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call you on the telephone to ask you 
some questions about your general bowel 
health, constipation and medication.   The 
research team will also tell you about 
your special study diary and how to 
complete it We will ask everyone taking 
part in the research to fill in a diary to help 
us see which treatments are best.
After you have returned your consent 
form to the research team they will send a 
copy back to you along with a postal 
questionnaire.  A copy of your consent 
form will be sent to your GP.  We will also 
let your surgery know you are taking part 
in the study and need an appointment so 
your study treatment can begin. As we 
explained earlier, the treatment you 
receive at this appointment depends on 
the group your surgery is in.
Some people who were given diet and 
lifestyle advice will get a telephone call to 
ask about the diet and lifestyle advice 
they were given. 
About three months after you join the 
study we will send you a questionnaire 
through the post.  All we ask is that you 
would fill in the questionnaire and send it 
back to us.  We will provide you with a 
stamped addressed envelope.  We will 
ask you to fill in another questionnaire 
after six months and again after twelve 
months.  Some patients will also receive 
a telephone interview to help in our 
economic evaluation in the study.  You 
will be asked some simple questions 
about any costs you have had in 
connection with your constipation.  
If when you start your study treatment, 
you decide that you don’t want to take 
part in the research please tell the 
practice staff. They will let the study team 
know and we will destroy all of your study 
documents and paperwork including your 
consent form.  No one will know what you 
said.  Remember you don’t need to give a 
reason why you don’t want to take part. 
Will you need to see my medical 
records?
In order to get all of the information about 
your constipation that we need, we will 
need to look at your notes at the end of 
the study.  Again, all of this information 
will be kept private.
Will I get paid for taking part?
No, we are not paying anyone to take part 
in the study.  Your doctors and nurses do 
not get paid  for including you in this 
study.  If you have to travel from your 
home for an interview at a later stage in 
the study, we will pay your travel 
expenses.
Has anyone checked out this 
study to see if it is all right? 
When we applied to the NHS for money 
to do this research, our plans for the 
study were examined by other 
researchers to confirm that they are 
scientifically sound.  The Multi-Centre 
Research Ethics Committee has reviewed 
the study.  This committee is responsible 
for ensuring that all medical research 
going on in the area is ethical and fair to 
study participants like you.
I have private health insurance. 
Do I need to tell my insurer if I 
decide to take part in the study?
If you decide to take part in the study, it is 
most unlikely that it will affect any private 
health insurance that you may have.
However, you should let your insurer 
know that you are taking part in the study.
Will anyone else know I am in 
this study? 
Local GPs know that this study is going 
on.  We have written to all practices to tell 
them of our work.  Only your own GP’s 
surgery will know that you personally are 
in the study.  One issue that we need to 
draw to your attention at this stage is that 
the people who wrote some of the 
questions we will use in our research 
(Jansen Pharmaceuticals Ltd.) ask for our 
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data to be sent to them so that they can 
further refine their questionnaire.  At this 
stage we make sure that no information 
that can identify any patient or doctor is 
sent.  These data will be made 
completely anonymous and no individual 
or practice will be identifiable at any time. 
Will what I tell you be kept 
private?
Other than staff in your practice, only the 
research team who will be running the 
study, and collecting and analysing 
information from study participants, will 
know who is in this study.  We are all 
bound by a written code of confidentiality.
This means that we must take great care 
to prevent anyone from outside the 
research team seeing any personal 
information about you, and we must not 
tell anyone else what you say.  So all the 
information the research team has about 
you (e.g. from the interviews, 
questionnaires and examining your 
medical records) will be kept private.  Any 
information about you which leaves the 
surgery will have your name removed so 
that you cannot be recognised from it.
On your questionnaire, you are only 
identified by a number.  Only people in 
our office will know who the questionnaire 
came from.  Anything you tell us will be 
kept secret.  We will not tell anyone what 
you have said unless you ask us to.  If 
you decide to withdraw from the study at 
any point all data and personal 
information collected will be destroyed. 
What will happen to the results 
from the study? 
At the end of the study, in 2006, the 
research team will write a report of the 
results for the NHS.  After that, we will 
write articles about the findings for 
publication in the magazines that other 
health workers and carers read.  In all the 
reports that we write, we will take great 
care that no individual patient can be 
identified.  All the information the 
research team have about you will be 
kept private.  If you would like a copy of 
the findings of the study, we will send 
them to you.  
How can I get more information 
about the study? 
Please feel free to contact a member of 
the research team if you would like some 
more information about the study, or if 
you have any questions you want 
answered.  Our phone numbers are 
shown on the next page.  You may 
contact us right through the study.  It’s 
best to call during office hours (9.00-
12.30, 1.30-5.00) but we do have an 
answer machine switched on when we 
are out of the office. If you prefer to write 
to us, our addresses are also shown on 
the next page. 
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Contents pages from the intervention 
manuals and patient information leaflets
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Standardised intervention arm
Contents of the training manual
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Personalised intervention arm
Contents of the training manual
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Personalised PILs 
Constipation
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Bowel health
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Fruit and vegetables
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Fibre and constipation
DOI: 10.3310/hta14520 Health Technology Assessment 2010; Vol. 14: No. 52
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
185
Appendix 3
186
DOI: 10.3310/hta14520 Health Technology Assessment 2010; Vol. 14: No. 52
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
187
Appendix 3
188
Fibre
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Alternative therapies
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Laxatives
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EQ-5D – This is Euro Qual – 5D for completion by the patient.   
 
The next few questions are how you are at present.  For each of the five sets of statements 
below please circle the number that best describes your own health state today. 
 
1. Mobility 
 I have no problems in walking about ............................................................1 
 I have some problems in walking about .......................................................2 
 I am confined to bed.....................................................................................3 
 
2. Self-Care 
 I have no problems with self-care.................................................................1 
 I have some problems washing or dressing myself ......................................2 
 I am unable to wash or dress myself ............................................................3 
 
3. Usual Activities 
 I have no problems with performing my usual  activities 
   (eg work, study, housework, family or leisure activities) .........................1 
 I have some problems with performing my usual activities...........................2 
 I am unable to perform my usual activities ...................................................3 
 
4. Pain/Discomfort 
 I have no pain or discomfort .........................................................................1 
 I have moderate pain or discomfort ..............................................................2 
 I have extreme pain or discomfort ................................................................3 
 
5. Anxiety/Depression 
 I am not anxious or depressed .....................................................................1 
 I am moderately anxious or depressed ........................................................2 
 I am extremely anxious or depressed...........................................................3 
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2 
 
100 
9   0 
8   0 
7   0 
6   0 
5   0 
4   0 
3   0 
2   0 
1   0 
0 
Best 
imaginable 
health state 
Worst 
imaginable 
health state 
Your own health 
state today 
6. Now we would like you to tell us how good or bad 
is your own health today, in your opinion. 
To help you say how good or bad your own health  
state is, we have drawn a scale (rather like a thermometer) 
on which the best state you can imagine is marked by 100 
and the worst state you can imagine is marked by 0. 
Please draw a line from the box below 
to whichever point on the scale indicates how good or  
bad you feel your health state is  today.  
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Appendix 5  
Adapted CONSORT e-flowchart 
for process evaluation
Approached for inclusion in the process evaluation:
Trial team (n = 10)
Patients (n = 53)
aPractice nurses (n = 10 )
aGP/practice managers (n = 8) 
bTrial team (n = 11)
Patients (n = 23)
Nurses (n = 9)
GP/practice managers (n = 6)
Trial team (n = 11)
Patients (n = 23)
Nurses (n = 9)
GP/practice managers (n = 6)
Refused to participate:
Trial team (n = 0)
Patients (n = 30)
Nurses (n = 1)
GP/practice managers (n = 2)  
Enrolment
Analysis 
FIGURE 12  Adapted CONSORT e-flowchart for process evaluation. a, additional practice staff were approached, but refusal was 
only recorded if actually given. Contact with key practice staff was sometimes never established, the researcher stopped attempts 
after 3–4 repeat calls. b, iterative interview with one member.
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Feedback
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your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.
